Connecting via Winsock to STN

Welcome to STN International! Enter x:x

L* * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:48:00 ON 08 SEP 2008

=> file reg
ww.cas.org/support/stngen/stndoc/properties.html

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10584208.str



chain nodes :
17 18 19 20 21 22 23 24 28 29 30 31 32 33 34 35 36 37 38 39 40
41 42 43 44 45 46 47
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26 27
chain bonds :
1-35 2-34 3-33 4-32 7-11 8-18 9-25 12-36 13-37 14-17 15-38 16-39 18-19
18-40 19-20 19-41 20-21 20-28 20-42 21-22 21-43 21-44 22-23 22-29 22-45
23-24 23-46 23-47 24-30 24-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16 25-26 25-27 26-27

```
exact/norm bonds :
20-28  22-29  24-30  24-31  25-26  25-27  26-27
exact bonds :
1-35  2-34  3-33  4-32  7-11  8-18  9-25  12-36  13-37  14-17  15-38  16-39  18-19
18-40  19-20  19-41  20-21  20-42  21-22  21-43  21-44  22-23  22-45  23-24  23-46
23-47
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  11-12  11-16  12-13  13-14
 14-15  15-16


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:Atom  26:Atom  27:Atom
28:CLASS  29:CLASS  30:CLASS  31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS
36:CLASS  37:CLASS  38:CLASS  39:CLASS  40:CLASS  41:CLASS  42:CLASS  43:CLASS
44:CLASS  45:CLASS  46:CLASS  47:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
L3           73 SEA SSS FUL L1

=> file ca


=> s l3
L4          720 L3

=> s crystal and l4
       1335748 CRYSTAL
L5            8 CRYSTAL AND L4

=> d ibib abs fhitstr 1-8

L5   ANSWER 1 OF 8  CA  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         149:128752  CA
TITLE:                    Preparation of novel crystals of pitavastatin calcium
                          for treatment of hypercholesterolemia, familial
                          hypercholesterolemia, and atherosclerosis
INVENTOR(S):              Huang, Yuming; Yang, Shengxi; Li, Yang; Luo, Jie; Lin,
                          Meng; Dan, Chunyan; Zhang, Daolin
PATENT ASSIGNEE(S):       Chongqing Pharmaceutical Research Institute Co., Ltd.,
                          Peop. Rep. China
```

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 8pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101195603	A	20080611	CN 2007-10093011	20071121

PRIORITY APPLN. INFO.: CN 2007-10093011 20071121

AB This invention relates to novel crystals of pitavastatin calcium, whose corresponding 2θ value of characteristic diffraction line in powder X-ray diffraction patterns is 4.3 and 5.2. The preparation process comprises crystallizing from pitavastatin calcium-containing water solution or mixed solution containing pitavastatin calcium and organic solvent, then drying at 20-150°C to water content 0.5-3%. A medical composition containing pitavastatin calcium novel crystals and medical adjuvants can be prepared as tablets and capsules, and can be used for treating hypercholesterolemia, familial hypercholesterolemia, and/or atherosclerosis (no data).

IT 147526-32-7P, Pitavastatin calcium
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel crystals of pitavastatin calcium for treatment of hypercholesterolemia, familial hypercholesterolemia, and atherosclerosis)

RN 147526-32-7 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L5 ANSWER 2 OF 8 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 147:365510 CA
TITLE: Dibenzyl amine compounds and derivatives as CETP inhibitors and their preparation, pharmaceutical compositions and use in the treatment of atherosclerosis and cardiovascular diseases
INVENTOR(S): Chang, George; Garigipati, Ravi S.; Lefker, Bruce; Perry, David A.
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 124pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070213314	A1	20070913	US 2007-619299	20070103
WO 2007105049	A1	20070920	WO 2007-IB524	20070228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
NL 2000527	A1	20070911	NL 2007-2000527	20070307
NL 2000527	C2	20080206		

PRIORITY APPLN. INFO.:	US 2006-781488P	P	20060310
	US 2007-619299	A	20070103

OTHER SOURCE(S): MARPAT 147:365510
GI



I



II

AB Dibenzyl amine compds. and derivs. of formula I, pharmaceutical compns. containing such compds. and the use of such compds. to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans. Compds. of formula I wherein A is CO2-C1-4 alkyl, CN, CHO, CONH2, etc.; B is NH2 and derivs., and (un)substituted 3- to 8-membered heterocyclic ring; X is X and N, wherein if X is N, R4 is absent; R1, R2, R3, R4, R5, R6 and R7 are independently H, halo, CN, OH, NO2, (un)substituted C1-6 alkyl, etc.; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by reductive amination of 2-[[(3,5-bis(trifluoromethyl)benzyl)(2-methyl-2H-tetrazol-5-yl)amino]methyl]-4-trifluoromethylbenzaldehyde with dimethylamine. All the invention compds. were evaluated for their CETP inhibitory activity (no data).

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of dibenzyl amine compds. and derivs. as CETP inhibitors and their use in the treatment of atherosclerosis and cardiovascular diseases)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L5 ANSWER 3 OF 8 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 147:173649 CA
TITLE: Combination of triazine derivatives and HMG-CoA reductase inhibitors
INVENTOR(S): Moinet, Gerard; Cravo, Daniel; Mesangeau, Didier
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: PCT Int. Appl., 34pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007079916	A2	20070719	WO 2006-EP12184	20061218
WO 2007079916	A3	20071206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
FR 2896158	A1	20070720	FR 2006-343	20060113
PRIORITY APPLN. INFO.:			FR 2006-343 A	20060113
OTHER SOURCE(S):	MARPAT 147:173649			

AB The present patent application relates to combinations of a triazine derivative with an HMG-CoA reductase inhibitor. Thus, a formulation contained pravastatin 10, and (+)-2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine-HCl 750 mg in addition to conventional excipients.

IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination of triazine derivs. and HMG-CoA reductase inhibitors)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L5 ANSWER 4 OF 8 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 143:393062 CA
TITLE: Combinations comprising (S)-amlodipine and an HMG-CoA reductase inhibitor and/or cholesterol absorption inhibitor for reducing hypertension
INVENTOR(S): Barberich, Timothy J.
PATENT ASSIGNEE(S): Sepracor Inc., USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097191	A2	20051020	WO 2005-US9910	20050325
WO 2005097191	A3	20051208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-559612P P 20040404
AB The present invention relates to pharmaceutical compns. comprising optically pure (S)-amlodipine and a HMG-CoA reductase inhibitor,

preferably lovastatin. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine and a cholesterol absorption inhibitor, preferably ezetimibe, or optically pure (S)-amlodipine, a HMG-CoA reductase inhibitor, and a cholesterol absorption inhibitor. The aforementioned pharmaceutical compns. further comprises niacin. The invention also relates to methods for treating a patient suffering from hypertension, hyperlipidemia, or a cardiac disorder. The invention also relates to methods for the treatment of hypertension and hyperlipidemia. For example, a solution of L-malic acid (6.68 kg, 49.82 mol) in isopropanol-water was added to a solution of (S)-amlodipine (19.5 kg, 47.69 mol) in isopropanol-MTBE and the reaction mixture was held with agitation for about one hour at about 50°C to form a slurry. The slurry was cooled with agitation to about 0° over 2.5 to 3 h and held with agitation at about 0° for about one hour. The solid product was isolated by filtration at about 0° and the wet cake obtained was dried at about 60° in vacuo to provide (S)-amlodipine L-malate (Form A) (25.41 kg, 46.79 mol, 98.1% yield). Tablets were prepared containing (S)-amlodipine L-malate (Form A) 3.32%, Avicel PH 101 70.7%, Starch 1500 20.75%, Explotab 5.0%, and magnesium stearate 0.25%.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising amlodipine and HMG-CoA reductase inhibitor and/or cholesterol absorption inhibitor for treatment of cardiovascular disorders)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L5 ANSWER 5 OF 8 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	143:139169 CA
TITLE:	Preparation of crystal form of pitavastatin calcium
INVENTOR(S):	Ohara, Yoshio; Takada, Yasutaka; Matsumoto, Hiroo; Yoshida, Akihiro
PATENT ASSIGNEE(S):	Nissan Chemical Industries, Ltd., Japan
SOURCE:	PCT Int. Appl., 21 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063711	A1	20050714	WO 2004-JP19451	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309241	A1	20050714	AU 2004-309241	20041217
CA 2551050	A1	20050714	CA 2004-2551050	20041217
EP 1697326	A1	20060906	EP 2004-807807	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1898211	A	20070117	CN 2004-80038955	20041217
JP 2007516952	T	20070628	JP 2006-520594	20041217
KR 2007001910	A	20070104	KR 2006-711877	20060616
IN 2006KN01757	A	20070511	IN 2006-KN1757	20060623
US 20070112024	A1	20070517	US 2006-584208	20060623
MX 2006PA07435	A	20061208	MX 2006-PA7435	20060626
PRIORITY APPLN. INFO.:			JP 2003-431788 A	20031226
			WO 2004-JP19451 W	20041217

AB A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) the water content is adjusted to a level of 5-15%, and the crystal form is controlled to be crystal form A, thereby to obtain the drug excellent in stability.

IT 147526-32-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystal form of pitavastatin calcium)

RN 147526-32-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 8 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 141:230683 CA
TITLE: Crystalline forms of pitavastatin calcium
INVENTOR(S): Van Der Schaaf, Paul Adriaan; Blatter, Fritz; Szelagiewicz, Martin; Schoening, Kai-Uwe
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072040	A1	20040826	WO 2004-EP50066	20040202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212160	A1	20040826	AU 2004-212160	20040202
CA 2513837	A1	20040826	CA 2004-2513837	20040202
EP 1592668	A1	20051109	EP 2004-707232	20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006518354	T	20060810	JP 2006-501997	20040202
DE 202004021379	U1	20080327	DE 2004-202004021379	20040202
CN 101219992	A	20080716	CN 2008-10001291	20040202
US 20060142582	A1	20060629	US 2005-544752	20050808

IN 2005CN02219 A 20070406 IN 2005-CN2219 20050912
PRIORITY APPLN. INFO.: EP 2003-405080 A 20030212
CN 2004-80003952 A3 20040202
EP 2004-707232 A 20040202
WO 2004-EP50066 W 20040202

AB The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compns. comprising these crystalline forms or the amorphous form. The hemicalcium salt was prepared from pitavastatin tert-Bu ester in tert-Bu ether and MeOH, NaOH added, and aqueous phase extracted with Me tert-Bu ether. Then $CaCl_2$ was added to give a form A.

IT 147526-32-7P
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(crystalline forms of pitavastatin calcium)

RN 147526-32-7 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L5 ANSWER 7 OF 8 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:311199 CA
TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes
INVENTOR(S): Gougoutas, Jack Z.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083066	A2	20021024	WO 2002-US11066	20020408
WO 2002083066	A3	20030306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2444481	A1	20021024	CA 2002-2444481	20020408
AU 2002254567	A1	20021028	AU 2002-254567	20020408
AU 2002254567	B2	20071011		
US 20030064935	A1	20030403	US 2002-117914	20020408
US 6774112	B2	20040810		
EP 1385856	A2	20040204	EP 2002-723801	20020408
EP 1385856	B1	20060222		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004536047	T	20041202	JP 2002-580871	20020408
AT 318272	T	20060315	AT 2002-723801	20020408
ES 2258141	T3	20060816	ES 2002-723801	20020408
HU 2006000232	A2	20060828	HU 2006-232	20020408
AU 2008200159	A1	20080207	AU 2008-200159	20080111
PRIORITY APPLN. INFO.:			US 2001-283097P	P 20010411
			AU 2002-254567	A3 20020408
			WO 2002-US11066	W 20020408

OTHER SOURCE(S): MARPAT 137:311199
GI



I

AB Crystalline complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R1, R2, R2a = H, OH, OR5, alkyl, OCHF2, OCF3, SR5a, halogen; R3, R4 = H, OH, OR5b, alkyl, cycloalkyl, CF3, OCHF2, OCF3, halogen, CONR6R6a, CO2R5c, CO2H, COR6b, CH(OH)R6c, CH(OR5d)R6d, CN, NHCOR5e, NHSO2R5f, NHSO2-aryl, SR5g, SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO2), or R3 and R4 together with the carbons to which they are attached form an annelated

five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney) inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF2, R2, R2a, R3 = H) was prepared by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone, and CHF2Cl and treated with L-phenylalanine to form the crystalline 1:1 complex.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L5 ANSWER 8 OF 8 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:140435 CA
TITLE: Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use
INVENTOR(S): Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020103242	A1	20020801	US 2001-21667	20011029
US 6713508	B2	20040330		
CA 2427610	A1	20020808	CA 2001-2427610	20011026
WO 2002060434	A2	20020808	WO 2001-US49501	20011026
WO 2002060434	A3	20030619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248221	A1	20020812	AU 2002-248221	20011026
AU 2002248221	B2	20060817		
EP 1347755	A2	20031001	EP 2001-997102	20011026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517938	T	20040617	JP 2002-560626	20011026
PRIORITY APPLN. INFO.:			US 2000-244698P	P 20001031
			WO 2001-US49501	W 20011026

OTHER SOURCE(S): MARPAT 137:140435

GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and

their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH2, CO; R1 = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R1 forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO2, CH2, (un)substituted NH; n = 1-6; R4 = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their preparation is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH2O(CH2)3Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alkaline hydrolysis (100%), to give title compound II. PPAR binding assays using human recombinant PPAR are described without data. Co-administration of compds. I with a variety of other drug categories, including a number of specific drugs, is claimed.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also containing; preparation of benzopyrancarboxylic acid
derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 10:48:00 ON 08 SEP 2008)

FILE 'REGISTRY' ENTERED AT 10:48:22 ON 08 SEP 2008

FILE 'REGISTRY' ENTERED AT 10:48:39 ON 08 SEP 2008

```
L1              STRUCTURE UPLOADED
L2            5 S L1 SAM
L3           73 S L1 FULL

     FILE 'CA' ENTERED AT 10:50:20 ON 08 SEP 2008
L4          720 S L3
L5            8 S CRYSTAL AND L4

=> s l4 and py<2004
     22793959 PY<2004
L6          215 L4 AND PY<2004

=> s l6 and (solid or cryst?)
       1101551 SOLID
       2223251 CRYST?
L7            6 L6 AND (SOLID OR CRYST?)

=> d :ibib abs fhitstr kwic

L7   ANSWER 1 OF 6  CA  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         139:117344  CA
TITLE:                    Process for producing optically active oxoheptenoic
                          acid ester
INVENTOR(S):              Horiuchi, Takashi; Shimizu, Masamichi; Kondo, Shoichi;
                          Soejima, Tadashi; Umeo, Kazuhiro
PATENT ASSIGNEE(S):       Nissan Chemical Industries, Ltd., Japan; Sankyo
                          Chemical Industries, Ltd.
SOURCE:                   PCT Int. Appl., 20 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
     WO 2003042180        A1    20030522    WO 2002-JP11870        20021114 <--
     WO 2003042180        A9    20030731
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2485580           A1    20030522    CA 2002-2485580        20021114 <--
     AU 2002343787        A1    20030526    AU 2002-343787         20021114 <--
     EP 1466905           A1    20041013    EP 2002-780087         20021114
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     CN 1589263           A     20050302    CN 2002-822734         20021114
     TW 243165            B     20051111    TW 2002-91133400       20021114
     ZA 2004003722        A     20050516    ZA 2004-3722           20040514
     IN 2004DN01342       A     20070316    IN 2004-DN1342         20040518
```

US 20050054853 A1 20050310 US 2004-495268 20040604
US 7064209 B2 20060620
PRIORITY APPLN. INFO.: JP 2001-348569 A 20011114
WO 2002-JP11870 W 20021114
OTHER SOURCE(S): CASREACT 139:117344; MARPAT 139:117344

GI



AB Disclosed is a novel process for producing an optically active (5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoic acid alkyl ester represented by the formula (I; R = C1-4 alkyl), which is an important intermediate for (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid salt as a medicine for treating hyperlipidemia and arteriosclerosis. It comprises reacting a 1,3-bis(trimethylsilyloxy)-1-alkoxybuta-1,3-diene represented by the formula (II; R = C1-4 alkyl) with (E)-3-[2-cyclopropyl-4-(4-fluorphenyl)quinolin-3-yl]prop-2-en-1-al, which is represented by the formula (III), in the presence of an optically active binaphthol-titanium complex obtained from 1,1'-bi-2-naphthol and titanium tetraisopropoxide and of a metal salt and an amine and then subjecting the reaction product to desilylation. The use of metal salt and various amines in the above addition reaction markedly improves optical purity (≥99% ee) and yields (≥85%). Thus, 25.0 g III was dissolved in 305.0 g THF under N atmospheric and treated with a toluene solution (6.35 g) of (S)-(-)-1,1'-bi-2-naphthol and titanium tetraisopropoxide (0.0016 mol) and then with 1.10 g LiCl and N,N,N',N'-tetramethylethylenediamine, followed by adding dropwise

51.34 g II (R = Et), and the resulting mixture was stirred at 27-30° for 4 h, quenched by adding 32.5 mL ion-exchanged water and 32.5 mL aqueous saturated NaHCO3 solution THF was removed by distillation under reduced pressure and the organic layer was extracted with 675 mL EtOAc. The extract was washed with 125 mL ion-exchanged water and 125 mL aqueous saturated NaHCO3 solution, dried over 20 g anhydrous MgSO4, and filtered. The filtrate was cooled to 0°, treated dropwise with 23.9 g 50 weight% aqueous H2SO4 solution, stirred at 0-5° for 2 h, and filtered to collect the precipitated sulfate salt which was washed twice with 25 mL EtOAc, dispersed in a mixture of 250 mL EtOAc and 100 mL ion-exchanged water, treated with 150 mL 10 weight% aqueous Na2CO3 solution, stirred at 26-28° for 30 min to give, after further workup and crystallization from ethylcyclohexane, 30.06 g I (R = Et) (85.2% yield, 99% ee).

IT 147511-69-1DP, (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid, salt
RL: PNU (Preparation, unclassified); PREP (Preparation)
(preparation of optically active alkyl [cyclopropyl(fluorophenyl)quinolinyl] hydroxyoxoheptenoate by addition of bis(trimethylsilyloxy)alkoxybutadiene with [cyclopropyl(fluorphenyl)quinolinyl]propenal in presence of (S)-binaphthol-titanium complex)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003042180 A1 20030522

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003042180	A1	20030522	WO 2002-JP11870	20021114 <--
WO 2003042180	A9	20030731		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2485580	A1	20030522	CA 2002-2485580	20021114 <--
AU 2002343787	A1	20030526	AU 2002-343787	20021114 <--
EP 1466905	A1	20041013	EP 2002-780087	20021114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1589263	A	20050302	CN 2002-822734	20021114
TW 243165	B	20051111	TW 2002-91133400	20021114
ZA 2004003722	A	20050516	ZA 2004-3722	20040514
IN 2004DN01342	A	20070316	IN 2004-DN1342	20040518
US 20050054853	A1	20050310	US 2004-495268	20040604
US 7064209	B2	20060620		

AB . . . with 150 mL 10 weight% aqueous Na2CO3 solution, stirred at 26-28° for 30 min to give, after further workup and crystallization from ethylcyclohexane, 30.06 g I (R = Et) (85.2% yield, 99% ee).

IT 147511-69-1DP, (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid, salt
RL: PNU (Preparation, unclassified); PREP (Preparation)
(preparation of optically active alkyl [cyclopropyl(fluorophenyl)quinolinyl] hydroxyoxoheptenoate by addition of bis(trimethylsilyloxy)alkoxybutadiene with [cyclopropyl(fluorphenyl)quinolinyl]propenal in presence of (S)-binaphthol-titanium complex)

L7 ANSWER 2 OF 6 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	138:287535 CA
TITLE:	Process for preparation of optically active 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester
INVENTOR(S):	Nishino, Shigeyoshi; Matsushita, Akio; Yokoyama, Shuji; Kawachi, Yasuhiro; Sasaki, Hiroshi
PATENT ASSIGNEE(S):	UBE Industries, Ltd., Japan
SOURCE:	PCT Int. Appl., 26 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027073	A1	20030403	WO 2002-JP9638	20020919 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2005255522	A	20050922	JP 2001-284633		20010919
JP 2005255523	A	20050922	JP 2001-284634		20010919
AU 2002332184	A1	20030407	AU 2002-332184		20020919 <--
PRIORITY APPLN. INFO.:			JP 2001-284633	A	20010919
			JP 2001-284634	A	20010919
			WO 2002-JP9638	W	20020919

AB This invention pertains to prepn method of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester useful as an intermediate for an HMG-CoA reductase inhibitor (cholesterol-lowering agent) in high yield by reacting an amine salt of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid with an alc. in a solvent in the presence of an acid, or by a method comprising reacting the salt with an esterifying agent in a solvent in the presence of a base. For example, 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid was reacted with $PhCH_2NH_2$ in AcOEt to obtain 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid benzylamine salt (94.9%). The above salt was resolved with THF to give (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid benzylamine salt (60.0%, 99.1% ee, 99.8% de). The above optically active salt was reacted with EtOH in the presence of concentrated aqueous HCl to afford (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester (100%), which was crystallized from $(i\text{-}Pr)_2O$ and heptane to produce crystalline sample (91.0%, 99.9% ee, 99.8% de).

IT 503818-48-2P
RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of optically active 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester)

RN 503818-48-2 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, compd. with benzenemethanamine (1:1), (3R,5S)- (CA INDEX NAME)

CM 1

CRN 503818-47-1
CMF C25 H24 F N O4

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 100-46-9
CMF C7 H9 N

H_2N-CH_2-Ph

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003027073 A1 20030403

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003027073	A1	20030403	WO 2002-JP9638	20020919	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	JP 2005255522	A	20050922	JP 2001-284633	20010919	
	JP 2005255523	A	20050922	JP 2001-284634	20010919	
	AU 2002332184	A1	20030407	AU 2002-332184	20020919	<--

AB . . . was reacted with EtOH in the presence of concentrated aqueous HCl to afford (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester (100%), which was crystallized from (i-Pr)2O and heptane to produce crystalline sample (91.0%, 99.9% ee, 99.8% de).

IT 503818-48-2P
RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of optically active 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-

enoic acid Et ester)
IT 475645-79-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of optically active 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester)
IT 172336-32-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of optically active 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester)
IT 64-17-5, Ethanol, reactions 74-96-4, Bromoethane 100-46-9, Benzylamine, reactions 121659-03-8, 7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparation of optically active 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid Et ester)

L7 ANSWER 3 OF 6 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:24649 CA
TITLE: Process for preparation of 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde by ozonolysis of ethyl (6E)-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoate
INVENTOR(S): Matsumoto, Hiroo; Shimizu, Takanori
PATENT ASSIGNEE(S): Daicel Chemical Industries, Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098859	A1	20021212	WO 2002-JP4712	20020515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448421	A1	20021212	CA 2002-2448421	20020515 <--
AU 2002308986	A1	20021216	AU 2002-308986	20020515 <--
AU 2002308986	B2	20070531		
EP 1391455	A1	20040225	EP 2002-776535	20020515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1512984	A	20040714	CN 2002-810769	20020515
IN 2003KN01537	A	20060210	IN 2003-KN1537	20031125
KR 834326	B1	20080602	KR 2003-715406	20031125
US 20040147750	A1	20040729	US 2003-479226	20031201

US 7193086 B2 20070320
PRIORITY APPLN. INFO.: JP 2001-162986 A 20010530
JP 2001-208501 A 20010709
WO 2002-JP4712 W 20020515
OTHER SOURCE(S): CASREACT 138:24649; MARPAT 138:24649
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Described is a process for preparing 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde (I) which is important as an intermediate for the synthesis of drugs, i.e. HMG-CoA reductase inhibitor for cholesterol-lowering agent, efficiently from an unnecessary antipode, characterized by treating a compound represented by formula (II) or (III) (wherein A is -CHOH- or CO; and R is hydrogen, optionally branched C1-4 alkyl, Ph, an alkali metal ion, or an alkaline earth metal ion) with ozone and then conducting either reduction of the resulting compound with an inorg. sulfur compound or hydrogenolysis of the resulting compound Thus, a solution of 5.0 g Et (6E)-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoate in 50 g MeOH was cooled to 0°, followed by introducing 1 g ozone(g) to the solution at 0-5° over 1 h and removing excess ozone with N. To the resulting solution was added dropwise a solution of 0.85 g thiourea in 14.1 g H2O at 0-5° over 10 min, stirred at the same temperature for 1 h, treated with 26 g H2O, and stirred at 5° for 1 h to give, after filtering off precipitated crystals ad washing them with 6 g 50% aqueous MeOH, and drying them, 2.81 g I (86.7% yield and 99.2% purity).

IT 477950-34-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparation of 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde as intermediate for HMG-CoA reductase inhibitor for cholesterol-lowering agent)

RN 477950-34-8 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, ethyl ester, (6E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2002098859 A1 20021212

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002098859	A1	20021212	WO 2002-JP4712	20020515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448421	A1	20021212	CA 2002-2448421	20020515 <--
AU 2002308986	A1	20021216	AU 2002-308986	20020515 <--
AU 2002308986	B2	20070531		
EP 1391455	A1	20040225	EP 2002-776535	20020515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1512984	A	20040714	CN 2002-810769	20020515
IN 2003KN01537	A	20060210	IN 2003-KN1537	20031125
KR 834326	B1	20080602	KR 2003-715406	20031125
US 20040147750	A1	20040729	US 2003-479226	20031201
US 7193086	B2	20070320		

AB . . . 1 h, treated with 26 g H_2O, and stirred at 5° for 1 h to give, after filtering off precipitated crystals ad washing them with 6 g 50% aqueous MeOH, and drying them, 2.81 g I (86.7% yield and 99.2% purity).

IT 10028-15-6, Ozone, reactions 222306-13-0 477950-34-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for preparation of 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde as intermediate for HMG-CoA reductase inhibitor for cholesterol-lowering agent)

L7 ANSWER 4 OF 6 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:384764 CA
TITLE: Process for producing (3R,5S)-7-substituted-3,5-dihydroxyhept-6-enoic acid
INVENTOR(S): Nishino, Shigeyoshi; Yokoyama, Shuji; Kawachi,

Yasuhiro; Sasaki, Hiroshi
PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092570	A1	20021121	WO 2002-JP4710	20020515 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005047803	A	20050224	JP 2001-145358	20010515
AU 2002308984	A1	20021125	AU 2002-308984	20020515 <--
PRIORITY APPLN. INFO.:			JP 2001-145358 A	20010515
			WO 2002-JP4710 W	20020515

OTHER SOURCE(S): MARPAT 137:384764
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed is a process for producing a (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid represented by the formula (I) which comprises optically resolving with an achiral amine compound a mixture of optical isomers of a 7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid represented by the formula (II). The optical resolution involves contacting II with an achiral amine to form II achiral amine salt, recrystg. the salt to form I achiral amine salt, and contacting the I achiral recrystn. amine salt with an acid to give I. This process does not use expensive chiral amines and is suitable for industrial preparation of I which is an intermediate for an anticholesteremic agent (HMG-CoA reductase inhibitor). Thus, 4.21 g II (preparation given), 1.07 g benzylamine, and 30 mL EtOAc were added to a 50 mL flask and cooled to 0° with stirring, upon which crystals precipitated The precipitated crystals were filtered, washed with EtOAc cooled at 0°, and dried under reduced pressure to give 94.9% II benzylamine salt. II benzylamine salt (4.22 g) and 84 mL THF were added to a 100 mL flask, warmed to 50° with stirring to give a homogeneous solution, and cooled to 0°, upon which crystals precipitated The precipitated crystals were filtered and washed with 42 mL THF cooled at 0°. This procedure was repeated twice to give 2.52 g I benzyl amine salt (60.0%) which (2.11 g) and 10 mL MeOH were added to a 50 mL flask, adjusted to pH 3.5 by adding 1 M aqueous HCl, and extracted with 10 mL EtOAc twice, followed by drying the EtOAc extract over anhydrous MgSO4 and

concentration to give 1.66 g I (99.0%).

IT 475645-80-8P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid by optical resolution using achiral amine via formation of achiral amine salt, recrystn., and treatment with acid)

RN 475645-80-8 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, compd. with benzenemethanamine (1:1), (3R,5S,6E)- (CA INDEX NAME)

CM 1

CRN 147511-69-1
CMF C25 H24 F N O4

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



CM 2

CRN 100-46-9
CMF C7 H9 N

H_2N-CH_2-Ph

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002092570 A1	20021121			
PI WO 2002092570	A1	20021121	WO 2002-JP4710	20020515 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2005047803	A	20050224	JP 2001-145358	20010515	
AU 2002308984	A1	20021125	AU 2002-308984	20020515	<--

AB . . . benzylamine, and 30 mL EtOAc were added to a 50 mL flask and cooled to 0° with stirring, upon which crystals precipitated The precipitated crystals were filtered, washed with EtOAc cooled at 0°, and dried under reduced pressure to give 94.9% II benzylamine salt. II. . . a 100 mL flask, warmed to 50° with stirring to give a homogeneous solution, and cooled to 0°, upon which crystals precipitated The precipitated crystals were filtered and washed with 42 mL THF cooled at 0°. This procedure was repeated twice to give 2.52 g. . .

IT 475645-80-8P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid by optical resolution using achiral amine via formation of achiral amine salt, recrystn., and treatment with acid)

IT 121659-03-8P, 7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid 147511-69-1P 475645-77-3P, 7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoic acid isopropyl ester 475645-78-4P, 7-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid isopropyl ester 475645-79-5P 475645-81-9P 475645-82-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid by optical resolution using achiral amine via formation of achiral amine salt, recrystn., and treatment with acid)

L7 ANSWER 5 OF 6 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:311199 CA
TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes
INVENTOR(S): Gougoutas, Jack Z.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002083066	A2	20021024	WO 2002-US11066	20020408	<--
WO 2002083066	A3	20030306			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2444481	A1	20021024	CA 2002-2444481	20020408	<--
AU 2002254567	A1	20021028	AU 2002-254567	20020408	<--
AU 2002254567	B2	20071011			
US 20030064935	A1	20030403	US 2002-117914	20020408	<--
US 6774112	B2	20040810			
EP 1385856	A2	20040204	EP 2002-723801	20020408	
EP 1385856	B1	20060222			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004536047	T	20041202	JP 2002-580871	20020408	
AT 318272	T	20060315	AT 2002-723801	20020408	
ES 2258141	T3	20060816	ES 2002-723801	20020408	
HU 2006000232	A2	20060828	HU 2006-232	20020408	
AU 2008200159	A1	20080207	AU 2008-200159	20080111	
PRIORITY APPLN. INFO.:			US 2001-283097P	P 20010411	
			AU 2002-254567	A3 20020408	
			WO 2002-US11066	W 20020408	

OTHER SOURCE(S): MARPAT 137:311199
GI



I

AB Crystalline complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R1, R2, R2a = H, OH, OR5, alkyl, OCHF2, OCF3, SR5a, halogen; R3, R4 = H, OH, OR5b, alkyl, cycloalkyl, CF3, OCHF2, OCF3, halogen, CONR6R6a, CO2R5c, CO2H, COR6b, CH(OH)R6c, CH(OR5d)R6d, CN, NHCOR5e, NHSO2R5f, NHSO2-aryl, SR5g, SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO2), or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney) inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF2, R2, R2a, R3 = H) was prepared by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone, and CHF2Cl and treated with L-phenylalanine to form the crystalline

1:1 complex.

IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



PI WO 2002083066 A2 20021024

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002083066	A2	20021024	WO 2002-US11066	20020408 <--
WO 2002083066	A3	20030306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2444481	A1	20021024	CA 2002-2444481	20020408 <--
AU 2002254567	A1	20021028	AU 2002-254567	20020408 <--
AU 2002254567	B2	20071011		
US 20030064935	A1	20030403	US 2002-117914	20020408 <--
US 6774112	B2	20040810		
EP 1385856	A2	20040204	EP 2002-723801	20020408
EP 1385856	B1	20060222		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004536047	T	20041202	JP 2002-580871	20020408
AT 318272	T	20060315	AT 2002-723801	20020408
ES 2258141	T3	20060816	ES 2002-723801	20020408
HU 2006000232	A2	20060828	HU 2006-232	20020408
AU 2008200159	A1	20080207	AU 2008-200159	20080111

AB Crystalline complexes are obtained from 1:1 or 2:1 mixts. of either

the (D) or (L) enantiomer of natural amino acids and. . . prepared by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone, and CHF2Cl and treated with L-phenylalanine to form the crystalline 1:1 complex.
ST crystal structure amino acid complex aryl glucoside; amino acid complex aryl glucoside prepn antidiabetic
IT Antidiabetic agents
Antiobesity agents
Atherosclerosis
Crystal structure
Diabetes mellitus
Human
Hyperglycemia
Hypertension
Hypertriglyceridemia
Hypolipemic agents
Obesity
(preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)
IT 51-64-9, Dexamphetamine 94-20-2, Chlorpropamide 122-09-8, Phentermine 637-07-0, Clofibrate 657-24-9, Metformin 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 21187-98-4, Gliclazide 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 49562-28-9, Fenofibrate 56180-94-0, Acarbose 72432-03-2, Miglitol 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 141750-63-2, Nisvastatin 141758-74-9, AC2993 144288-97-1, TS 962 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 152755-31-2, LY295427 159183-92-3, L750355 161600-01-7, Isaglitazone 166518-60-1, Avasimibe 170861-63-9, JTT-501 176435-10-2, LY315902 178759-95-0, MD 700 196808-45-4 199113-98-9, NN-2344 199914-96-0, YM-440 213252-19-8, KRP297 244081-42-3, AJ9677 258345-41-4, GW-409544 282526-98-1, ATL-962 287714-41-4, Rosuvastatin 335149-08-1, L895645 335149-14-9, R-119702 335149-15-0, KAD1129 335149-17-2, ARHO39242 335149-23-0, NVPDPP-728A 335149-25-2, CP331648 430433-17-3, Glipyride 444069-80-1, Axokine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

L7 ANSWER 6 OF 6 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:140435 CA
TITLE: Benzopyrancarboxylic acid derivatives with PPAR agonist activity for the treatment of diabetes and lipid disorders, and their preparation, pharmaceutical compositions, and use
INVENTOR(S): Sahoo, Soumya P.; Koyama, Hiroo; Miller, Daniel J.; Boueres, Julia K.; Desai, Ranjit C.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020103242	A1	20020801	US 2001-21667	20011029 <--
US 6713508	B2	20040330		
CA 2427610	A1	20020808	CA 2001-2427610	20011026 <--
WO 2002060434	A2	20020808	WO 2001-US49501	20011026 <--
WO 2002060434	A3	20030619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248221	A1	20020812	AU 2002-248221	20011026 <--
AU 2002248221	B2	20060817		
EP 1347755	A2	20031001	EP 2001-997102	20011026 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517938	T	20040617	JP 2002-560626	20011026
PRIORITY APPLN. INFO.:			US 2000-244698P	P 20001031
			WO 2001-US49501	W 20011026
OTHER SOURCE(S):	MARPAT 137:140435			

GI



I



II

AB A class of benzopyrancarboxylic acid derivs. is disclosed, which comprises compds. that are potent agonists (no data) of peroxisome proliferator activated receptors (PPAR) alpha and/or gamma, and are therefore useful in the treatment, control, or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia,

hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions. In particular, compds. I and their pharmaceutically acceptable salts and/or prodrugs are disclosed [wherein: Z = CH2, CO; R1 = H, OH, halo, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, or aryl; or R1 forms (un)substituted cyclopropane fusion to adjacent C atom; X, Y = O, S, SO, SO2, CH2, (un)substituted NH; n = 1-6; R4 = (un)substituted benzoheterocyclyl, cycloalkyl, heterocyclyl, cycloalkyloxy, halo, OH or derivs., alk(en/yn)yl, alk(en/yn)yloxy, or aryl, etc.; other R groups = H, halo, OH, (un)substituted alk(en/yn)yl, alk(en/yn)yloxy, aryl, aryloxy, aroyl, etc.; or R3R4 or R4R5 = (un)substituted 5- or 6-membered heterocyclic ring]. A list of 29 compds. is claimed, and their preparation is described. For example, Et 7-hydroxy-4-oxo-4H-chromene-2-carboxylate underwent a sequence of: (1) complete hydrogenation of the enone (98%), (2) etherification of the alc. with PhCH2O(CH2)3Br (66%), (3) alpha ethylation of the ester (70%), (4) hydrogenolytic debenzylation (100%), (5) conversion of the resultant alc. to a bromide (96%), (6) etherification of the bromide with 3-(trifluoromethyl)-7-propyl-6-hydroxybenz[4,5]isoxazole (85%), and (7) alkaline hydrolysis (100%), to give title compound II. PPAR binding assays using human recombinant PPAR are described without data. Co-administration of compds. I with a variety of other drug categories, including a number of specific drugs, is claimed.

IT 147511-69-1, Itavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also containing; preparation of benzopyrancarboxylic acid
derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

RN 147511-69-1 CA

CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



PI US 20020103242 A1 20020801

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20020103242	A1	20020801	US 2001-21667	20011029 <--
US 6713508	B2	20040330		
CA 2427610	A1	20020808	CA 2001-2427610	20011026 <--

WO 2002060434 A2 20020808 WO 2001-US49501 20011026 <--
WO 2002060434 A3 20030619
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002248221 A1 20020812 AU 2002-248221 20011026 <--
AU 2002248221 B2 20060817
EP 1347755 A2 20031001 EP 2001-997102 20011026 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004517938 T 20040617 JP 2002-560626 20011026

IT Crystal structure
Molecular structure
(of enantiomeric (benzyloxy)alkylchromanecarboxylic acid esters with pantolactone; preparation of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

IT 406488-88-8P, (R)-Benzyloxy-2-ethylchromane-2-carboxylic acid ester with (S)-pantolactone
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate, crystal structure of; preparation of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

IT 444341-94-0P, (S)-7-Benzyloxy-2-methylchromane-2-carboxylic acid ester with (R)-pantolactone
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate, x-ray crystal structure of; preparation of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

IT 50-78-2, Aspirin 59-67-6, Nicotinic acid, biological studies 59-67-6D, Nicotinic acid, salts 64-77-7, Tolbutamide 100-55-0, Nicotinyl alcohol 114-86-3, Phenformin 122-09-8, Phentermine 458-24-2, Fenfluramine 599-79-1, Azulfidine 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 3239-44-9, Dexfenfluramine 9004-10-8D, Insulin, mimetics 9004-54-0D, Dextran, crosslinked dialkylaminoalkyl derivs. 11041-12-6, Cholestyramine 22232-71-9, Mazindol 23288-49-5, Probucol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 41859-67-0, Bezafibrate 49562-28-9, Fenofibrate 50925-79-6, Colestipol 56180-94-0, Acarbose 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97322-87-7, Troglitazone 106650-56-0, Sibutramine 109229-58-5, Englitazone 111025-46-8, Pioglitazone 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 143201-11-0, Rivastatin 147098-20-2, ZD-4522 147511-69-1, Itavastatin 161600-01-7, MCC-555 163222-33-1, Ezetimibe 166518-60-1, Avasimibe 213252-19-8, KRP-297
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also containing; preparation of benzopyrancarboxylic acid derivs. as PPAR agonists for treatment of diabetes and lipid disorders)

```
=> d his

     (FILE 'HOME' ENTERED AT 10:48:00 ON 08 SEP 2008)

     FILE 'REGISTRY' ENTERED AT 10:48:22 ON 08 SEP 2008

     FILE 'REGISTRY' ENTERED AT 10:48:39 ON 08 SEP 2008
L1             STRUCTURE UPLOADED
L2               5 S L1 SAM
L3              73 S L1 FULL

     FILE 'CA' ENTERED AT 10:50:20 ON 08 SEP 2008
L4             720 S L3
L5               8 S CRYSTAL AND L4
L6             215 S L4 AND PY<2004
L7               6 S L6 AND (SOLID OR CRYST?)

=> s l6 not l7
L8             209 L6 NOT L7

=> s l8 and (ca or calcium)
           777397 CA
           870969 CALCIUM
L9             38 L8 AND (CA OR CALCIUM)

=> d ibib abs kwic 1-38

L9   ANSWER 1 OF 38  CA  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         147:528186  CA
TITLE:                    Nanoparticulate fibrate formulations
INVENTOR(S):              Ryde, Tuula; Gustow, Evan E.; Jain, Rajeev; Patel,
                          Rakesh; Wilkins, Michael John
PATENT ASSIGNEE(S):       Elan Pharma International, Ltd., Ire.
SOURCE:                   U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S.
                          Ser. No. 522,528.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
     US 20070264348       A1    20071115    US 2007-710607          20070226
     US 20030224058       A1    20031204    US 2003-370277          20030221 <--
     US 20050276974       A1    20051215    US 2003-444066          20030523
     US 7276249           B2    20071002
PRIORITY APPLN. INFO.:                      US 2002-383294P     P   20020524
                                            US 2003-370277      B2  20030221
                                            US 2003-444066      A2  20030523
                                            US 2005-275278      B1  20051221
                                            US 2006-522528      B2  20060918
AB   The present invention is directed to fibrate compns. having improved
     pharmacokinetic profiles and reduced fed/fasted variability.  The fibrate
     particles of the composition have an effective average particle size of less
than
```

about 2000 nm. Thus, formulation was prepared containing fenofibrate 5%, hydroxypropyl cellulose 1%, and dioctyl sodium sulfosuccinate 0.05%.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070264348	A1	20071115	US 2007-710607	20070226
	US 20030224058	A1	20031204	US 2003-370277	20030221 <--
	US 20050276974	A1	20051215	US 2003-444066	20030523
	US 7276249	B2	20071002		

IT Angiotensin receptor antagonists
Antidiabetic agents
Antihypertensives
Buccal drug delivery systems
Calcium channel blockers
Cardiovascular system, disease
Controlled-release drug delivery systems
Coronary artery disease
Diuretics
Drug bioavailability
Drug bioequivalence
Dyslipidemia
HMG-CoA reductase inhibitors
Hypercholesterolemia
Hyperlipidemia
Hypertriglyceridemia
Inhalation drug delivery systems
Nasal drug delivery systems
Ophthalmic drug delivery systems
Oral drug delivery systems
Pharmaceutical aerosols
Pharmaceutical capsules
Pharmaceutical gels
Pharmaceutical nanoparticles
Pharmaceutical ointments
Pharmaceutical suspensions
Pharmaceutical tablets
Rectal drug delivery systems
Topical drug delivery systems
Vaginal drug delivery systems
α-Adrenoceptor antagonists
β-Adrenoceptor antagonists
(nanoparticulate fibrate formulations)

IT 56-81-5, Glycerol, biological studies 57-09-0, Hexadecyltrimethylammonium bromide 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 57-88-5, Cholesterol, biological studies 62-49-7D, Choline, esters 75-50-3D, Trimethylamine, halide salts 79-43-6, biological studies 102-71-6, Triethanolamine, biological studies 109-97-7D, Pyrrole, 2,3-disubstituted derivs. 110-00-9D, Furan, 2,3-disubstituted derivs. 110-02-1D, Thiophene, 2,3-disubstituted derivs. 110-94-1D, Pentanedioic acid, derivs. 112-00-5, Lauryl trimethylammonium chloride 122-19-0D, Stearalkonium chloride, compound 123-03-5, Cetylpyridinium chloride 124-40-3D, Dimethylamine, dialkys derivs., salts 139-07-1, Lauryl dimethyl benzylammonium chloride 140-72-7, Cetylpyridinium bromide 151-21-3, Sodium lauryl sulfate, biological studies 504-31-4D, 2-Pyranone, pyrrol-1-ylalkyl derivs. 506-59-2, Dimethylammonium chloride 577-11-7, Dioctyl sodium sulfosuccinate 593-81-7D, Trimethylammonium chloride, coconut derivs. 657-24-9, Metformin 674-26-0D, Mevalonolactone,

analogs 1119-94-4 1119-97-7, Tetradecyltrimethylammonium bromide 1327-43-1, Magnesium aluminum silicate 1592-23-0, Calcium stearate 1643-19-2, Tetrabutylammonium bromide 1875-92-9D, Dimethylbenzylammonium chloride, alkylated 2082-84-0, Decyltrimethylammonium bromide 2498-25-1D, C12-15-alkyl derivs. 2840-24-6, Trimethylammonium bromide 2840-24-6D, Trimethylammonium bromide, coconut derivs. 5137-55-3, Methyltrioctylammonium chloride 5350-41-4, Benzyltrimethylammonium bromide 6303-21-5D, Phosphinic acid, compds. 7173-51-5, Dimethyl didecyl ammonium chloride 7281-04-1, Lauryl dimethyl benzylammonium bromide 9000-01-5, Gum acacia 9000-30-0, Guar 9000-65-1, Tragacanth 9001-63-2, Lysozyme 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethylcellulose sodium 9004-34-6, Cellulose, biological studies 9004-54-0, Dextran, biological studies 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hypromellose 9004-67-5, Methylcellulose 9004-99-3, Polyoxyethylene stearate 9005-32-7, Alginic acid 9011-14-7, Polymethyl methacrylate 9050-04-8 9050-31-1, Hypromellose phthalate 10041-19-7, Dioctyl sulfosuccinate 12441-09-7D, Sorbitan, esters 16749-13-6D, Phosphonium, compound 16969-45-2D, Pyridinium, salts, alkylated 18155-21-0D, Sulfonium, compound 18186-71-5, Dodecyltriethylammonium bromide 21424-22-6 21424-24-8 25086-89-9, Vinyl acetate-vinylpyrrolidone copolymer 25301-02-4 25322-68-3 25322-68-3D, PEG, phospholipid derivs. 25377-46-2D, Heptenoic acid, pyridyl dihydroxy derivs. 26062-79-3, Poly-diallyldimethylammonium chloride 27195-16-0, Sucrose distearate 27321-96-6D, PEG-cholesterol, derivative 28228-56-0 28299-33-4D, quaternized, salt 28679-24-5, Dodecylbenzyl triethyl ammonium chloride 29454-16-8D, Sodium sulfosuccinate, dialkylester 29836-26-8, n-Octyl-β-D-glucopyranoside 31244-58-3, Octahydronaphthalene 31566-31-1, Glycerol monostearate 37318-31-3, Sucrose stearate 38443-60-6, Decyl triethylammonium chloride 39995-55-6 52467-63-7, Tricetyl methylammonium chloride 52539-48-7 54060-15-0D, coconut derivs. 58846-77-8, n-Decylβ-D-glucopyranoside 59080-45-4, n-Hexyl-β-D-glucopyranoside 59122-55-3, n-Dodecylβ-D-glucopyranoside 63722-04-3D, C12-14-alkyl derivs. 65059-43-0 69227-93-6, n-Dodecylβ-D-maltoside 69984-73-2 75330-75-5, Lovastatin 75330-75-5D, Mevinolin, analogs 78617-12-6, n-Heptyl-β-D-glucopyranoside 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81859-24-7, PolyQUAT 10 82494-09-5, n-Decylβ-D-maltopyranoside 85261-19-4, Nonanoyl-N-methylglucamide 85261-20-7 85316-98-9 85618-20-8, n-Heptylβ-D-thioglucoside 85618-21-9, Octyl-β-D-thioglucopyranoside 93957-54-1, Fluvastatin 93957-55-2, Fluindostatin 101397-87-9, Heptanoyl-N-methylglucamide 106392-12-5, Poloxamer 113079-72-4D, derivs. 134523-00-5, Atorvastatin 135241-51-9D, coconut derivs. 137360-57-7D, C12-15-alkyl derivs. 143201-11-0, Rivastatin 147511-69-1, Pitavastatin 283158-20-3 287714-41-4, Rosuvastatin 329326-68-3, p-Isononylphenoxypoly-(glycidol) 503178-50-5 608094-65-1, PEG-vitamin A 630400-66-7 630400-67-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate fibrate formulations)

L9 ANSWER 2 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 146:330827 CA
TITLE: Bile preparations for colorectal disorders
INVENTOR(S): Yoo, Seo Hong
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S.

Ser. No. 996,945.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070072828	A1	20070329	US 2006-522162	20060915
US 6251428	B1	20010626	US 1999-357549	19990720 <--
US 20020031558	A1	20020314	US 2001-778154	20010205 <--
US 7303768	B2	20071204		
US 20050158408	A1	20050721	US 2004-996945	20041124
AU 2004325203	A1	20060601	AU 2004-325203	20041124
CA 2588168	A1	20060601	CA 2004-2588168	20041124
EP 1819318	A1	20070822	EP 2004-812094	20041124
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101065110	A	20071031	CN 2004-80044467	20041124
BR 2004019213	A	20071218	BR 2004-19213	20041124
JP 2008521800	T	20080626	JP 2007-543006	20041124
AU 2006203315	A1	20060824	AU 2006-203315	20060803
IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
KR 2007098821	A	20071005	KR 2007-714361	20070622

PRIORITY APPLN. INFO.:

US 1998-94069P	P	19980724
US 1999-357549	A2	19990720
US 2000-180268P	P	20000204
US 2001-778154	A2	20010205
US 2004-996945	A2	20041124
AU 2001-36685	A3	20010205
WO 2004-US39507	A	20041124

AB The present disclosure relates to methods and compns. to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compns. may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of ppts. or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070072828	A1	20070329	US 2006-522162	20060915
	US 6251428	B1	20010626	US 1999-357549	19990720 <--
	US 20020031558	A1	20020314	US 2001-778154	20010205 <--
	US 7303768	B2	20071204		
	US 20050158408	A1	20050721	US 2004-996945	20041124
	AU 2004325203	A1	20060601	AU 2004-325203	20041124
	CA 2588168	A1	20060601	CA 2004-2588168	20041124
	EP 1819318	A1	20070822	EP 2004-812094	20041124
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 101065110	A	20071031	CN 2004-80044467	20041124
BR 2004019213	A	20071218	BR 2004-19213	20041124
JP 2008521800	T	20080626	JP 2007-543006	20041124
AU 2006203315	A1	20060824	AU 2006-203315	20060803
IN 2007CN02532	A	20070907	IN 2007-CN2532	20070612
KR 2007098821	A	20071005	KR 2007-714361	20070622

IT 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 584-08-7, Potassium carbonate 1305-62-0, Calcium hydroxide, biological studies 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 7664-41-7, Ammonia, biological studies 8027-56-3, Liquid glucose 9004-32-4, Carboxymethylcellulose 9004-34-6D, Cellulose, derivs. 9004-53-9, Fibersol-2 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropylcellulose 9004-65-3, Hydroxypropylmethylcellulose 9005-25-8, Starch, biological studies 9050-36-6, Maltodextrin 11138-66-2, Xanthan gum
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bile prepns. for colorectal disorders)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-78-2, Aspirin 51-21-8, 5-Fluorouracil 51-48-9, Levothyroxine, biological studies 53-86-1, Indomethacin 55-86-7, Mechlorethamine hydrochloride 55-98-1, Busulfan 58-05-9, Leucovorin 61-68-7, Mefenamic acid 69-72-7, Salicylic acid, biological studies 83-43-2, Methylprednisolone 83-49-8, Hyodeoxycholic acid 83-79-4, Rotenone 89-57-6, Mesalamine 119-36-8, Methyl salicylate 128-13-2, Ursodeoxycholic acid 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 302-79-4, Tretinoin 305-03-3, Chlorambucil 315-30-0, Allopurinol 326-91-0, Thenoyltrifluoroacetone 446-86-6, Azathioprine 644-62-2, Meclofenamic acid 645-05-6, Altretamine 671-16-9, Procarbazine 1327-53-3, Arsenic trioxide 1397-94-0, Antimycin A 1404-19-9, Oligomycin 1972-08-3, Dronabinol 2898-95-5, Ursodeoxycholic acid sodium salt 2998-57-4, Estramustine 4291-63-8, Cladribine 4651-67-6, 7-Ketolithocholic acid 5003-48-5, Benorylate 5104-49-4, Flurbiprofen 8065-29-0, Liotrix 9000-01-5, Acacia gum 13311-84-7, Flutamide 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 20537-88-6, Amifostine 21256-18-8, Oxaprozin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 23214-92-8, Doxorubicin 24280-93-1, Mycophenolic acid 24584-09-6, Dexrazoxane 29679-58-1, Fenoprofen 33005-95-7, Tiaprofenic acid 33069-62-4, Paclitaxel 36322-90-4, Piroxicam 38194-50-2, Sulindac 40391-99-9 41340-25-4, Etodolac 42924-53-8, Nabumetone 51481-61-9, Cimetidine 51803-78-2, Nimesulide 53123-88-9, Sirolimus 53714-56-0, Leuprolide 53716-49-7, Carprofen 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 59865-13-3, Cyclosporine 61825-94-3, Oxaliplatin 65271-80-9, Mitoxantrone 65807-02-5, Goserelin 68767-14-6, Loxoprofen 71125-38-7, Meloxicam 71486-22-1, Vinorelbine 73573-88-3, Mevastatin 74103-06-3, Ketorolac 75330-75-5, Lovastatin 76706-55-3, Myxothiazol 76712-82-8, Histrelin 79902-63-9, Simvastatin 80573-04-2, Balsalazide 81093-37-0, Pravastatin 83150-76-9, Octreotide 85622-93-1, Temozolomide 87806-31-3, Porfimer 90357-06-5, Bicalutamide 93957-54-1, Fluvastatin 95058-81-4, Gemcitabine 97682-44-5, Irinotecan 98530-12-2, Interferon alfa-2b 99614-02-5, Ondansetron 104987-11-3, Tacrolimus 107868-30-4, Exemestane 109889-09-0, Granisetron 110942-02-4, Aldesleukin 112809-51-5, Letrozole 115956-12-2, Dolasetron 118072-93-8, Zoledronic acid 120511-73-1, Anastrozole

121181-53-1, Filgrastim 123318-82-1, Clofarabine 123774-72-1, Sargramostim 123948-87-8, Topotecan 124508-66-3, Triptorelin pamoate 128794-94-5, Mycophenolate mofetil 129453-61-8, Fulvestrant 134523-00-5, Atorvastatin 134774-45-1, Rasburicase 135729-61-2, Palonosetron 137281-23-3, Pemetrexed 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 152459-95-5, Imatinib 152923-56-3, Daclizumab 153559-49-0, Bexarotene 154361-50-9, Capecitabine 162011-90-7, Rofecoxib 162394-19-6, Palifermin 169590-42-5, Celecoxib 170729-80-3, Aprepitant 173146-27-5, Denileukin diftitox 174722-31-7, Rituximab 179045-86-4, Basiliximab 179324-69-7, Bortezomib 180288-69-1, Trastuzumab 181695-72-7, Valdecoxib 183321-74-6, Erlotinib 184475-35-2, Gefitinib 198470-84-7, Parecoxib 202409-33-4, Etoricoxib 205923-56-4, Cetuximab 206181-63-7, Ibritumomab tiuxetan 208265-92-3, Pegfilgrastim 208921-02-2, Tositumomab 216503-57-0, Alemtuzumab 216974-75-3, Bevacizumab 220578-59-6, Gemtuzumab ozogamicin 226256-56-0, Cinacalcet 287714-41-4, Rosuvastatin 777076-34-3, 2,2-Bis-(4-(4-amino-3-hydroxyphenoxy)phenyl) adamantane
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bile prepns. for colorectal disorders)

L9 ANSWER 3 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 145:342445 CA
TITLE: Dual controlled release osmotic device comprising two different active agents
INVENTOR(S): Vergez, Juan A.; Ricci, Marcelo A.
PATENT ASSIGNEE(S): Argent.
SOURCE: U.S. Pat. Appl. Publ., 29pp., Cont.-in-part of U.S. Ser. No. 321,736.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060204578	A1	20060914	US 2006-355315	20060215
US 20030185882	A1	20031002	US 2001-992488	20011106 <--
US 20060177510	A1	20060810	US 2005-321736	20051229
PRIORITY APPLN. INFO.:			US 2001-992488	B3 20011106
			US 2005-321736	A2 20051229

AB A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bilayered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement. For example, bilayered controlled release tablet was prepared containing first layer comprised of oxybutynin hydrochloride 5.15 mg, Myvacet 5-07 10.80 mg, Povidone K25 5.40 mg, microcryst. cellulose spheres 68.68 mg, cellulose acetophtalate 4.10 mg, colloidal silicon dioxide 0.60 mg, and magnesium stearate 10.80 mg; second layer comprised of tolterodine L-tartrate 2.92 mg, Myvaplex 600P NF 82.07 mg, red iron oxide 0.15 mg, microcryst. cellulose spheres 67.76 mg, cellulose acetophtalate 4.10 mg, colloidal silicon dioxide 1.80 mg,

croscarmellose sodium 1.80 mg, and magnesium stearate 0.75 mg.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20060204578	A1	20060914	US 2006-355315	20060215	
	US 20030185882	A1	20031002	US 2001-992488	20011106	<--
	US 20060177510	A1	20060810	US 2005-321736	20051229	

IT Adrenoceptor agonists
Amebicides
Analgesics
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antibiotics
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antimalarials
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antiulcer agents
Antiviral agents
Anxiolytics
Calcium channel blockers
Cardiovascular agents
Contraceptives
Decongestants
Diagnostic agents
Dissolution
Diuretics
Fungicides
Hypnotics and Sedatives
Hypolipemic agents
Muscle relaxants
Parasiticides
Prokinetic agents
Tranquilizers
β-Adrenoceptor antagonists
(dual controlled-release osmotic device comprising two different active agents)

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, biological studies 50-99-7, Dextrose, biological studies 51-71-8, Phenelzine 52-86-8, Haloperidol 58-00-4, Apomorphine 58-38-8 58-39-9, Perphenazine 59-67-6, Nicotinic acid, biological studies 59-92-7, Levodopa, biological studies 64-77-7, Tolbutamide 69-09-0, Chloropromazine hydrochloride 69-23-8, Fluphenazine 69-65-8, Mannitol 72-69-5, Nortriptyline 77-37-2, Procyclidine 87-69-4, Tartaric acid, biological studies 94-20-2, Chloropropamide 102-76-1, Triacetin 117-89-5, Trifluoperazine 132-17-2, Benztropine mesylate 137-53-1, Dextrothyroxine sodium 144-11-6 155-09-9, Tranylcypromine 298-46-4, Carbamazepine 303-49-1, Clomipramine 321-64-2, Tacrine 322-35-0 339-43-5, Carbutamide 339-44-6, Glymidine 357-70-0, Galantamine 438-60-8, Protriptyline

451-71-8, Glyhexamide 511-45-5, Pridinol 514-65-8, Biperiden 535-65-9, Glybuthiazole 557-04-0, Magnesium stearate 637-07-0, Clofibrate 657-24-9, Metformin 664-95-9, Tolcyclamide 739-71-9, Trimipramine 768-94-5, Amantadine 968-81-0, Acetohexamide 1156-19-0, Tolazamide 1228-19-9, Glypinamide 1309-37-1, Iron oxide (Fe2O3), biological studies 1492-02-0, Glybuzole 1668-19-5, Doxepin 1977-10-2, Loxapine 2062-78-4, Pimozide 2295-31-0, Thiazolidinedione 3149-00-6, Phenbutamide 3313-26-6, Thiothixene 4618-41-1, 1-Butyl-3-metanilylurea 5588-33-0, Mesoridazine 5786-21-0, Clozapine 6882-47-9, Biguanidine 7416-34-4, Molindone 7631-86-9, Silica, biological studies 7647-14-5, Sodium chloride (NaCl), biological studies 9003-39-8, Povidone 9004-34-6, Cellulose, biological studies 9004-35-7 9004-38-0, Cellulose acetophthalate 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-65-6, Polysorbate 80 10238-21-8, Glibenclamide 10262-69-8, Maprotiline 11041-12-6, Cholestyramine 13463-67-7, Titanium oxide (TiO2), biological studies 14028-44-5, Amoxapine 14611-51-9, Selegiline 18016-80-3, Lisuride 19794-93-5, Trazodone 19982-08-2, Memantine 21187-98-4, Gliclazide 23288-49-5, Probucol 25046-79-1, Glisoxepid 25086-89-9 25322-68-3, Polyethylene glycol 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26944-48-9, Glibornuride 28721-07-5, Oxcarbazepine 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29094-61-9, Glipizide 31566-31-1 33342-05-1, Gliquidone 34911-55-2, Bupropion 36282-47-0, Tramadol hydrochloride 50925-79-6, Cholestipol 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 59729-33-8, Citalopram 61036-40-6, Myvacet 5-07 61869-08-7, Paroxetine 62571-86-2, Captopril 63675-72-9, Nisoldipine 66104-22-1, Pergolide 68291-97-4, Zonisamide 73573-88-3, Mevastatin 74811-65-7, Croscarmellose sodium 75330-75-5, Lovastatin 79617-96-2, Sertraline 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81409-90-7, Cabergoline 83366-66-9, Nefazodone 84057-84-1, Lamotrigine 85650-52-8, Mirtazapine 91374-21-9, Ropinirole 93413-69-5, Venlafaxine 93957-54-1, Fluvastatin 97240-79-4, Topiramate 97322-87-7, Troglitazone 102767-28-2, Levetiracetam 104632-26-0, Pramipexole 105816-04-4, Nateglinide 106266-06-2, Risperidone 111025-46-8, Pioglitazone 111974-69-7, Quetiapine 112529-15-4, Pioglitazone hydrochloride 120014-06-4, Donepezil 122320-73-4, Rosiglitazone 123441-03-2, Rivastigmine 130929-57-6, Entacapone 132539-06-1, Olanzapine 133099-07-7, Darifenacin hydrobromide 134308-13-7, Tolcapone 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin calcium 135062-02-1, Repa-glinide 136434-34-9, Duloxetine hydrochloride 146939-27-7, Ziprasidone 147511-69-1, Pitavastatin 149202-17-5, Cellactose 156897-06-2, Licofelone 162011-90-7, Rofecoxib 163222-33-1, Ezetimibe 909710-69-6, Opadry Y 1-18-128A White

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual controlled-release osmotic device comprising two different active agents)

L9 ANSWER 4 OF 38 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 142:49262 CA

TITLE: Orally administered small peptides synergize statin activity, and therapeutic uses

INVENTOR(S): Fogelman, Alan M.; Anantharamaiah, Gattadahalli M.; Navab, Mohamad

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: U.S. Pat. Appl. Publ., 159 pp., Cont.-in-part of U.S. Ser. No. 423,830.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20040254120	A1	20041216	US 2003-649378	20030826	
US 7148197	B2	20061212			
US 6664230	B1	20031216	US 2000-645454	20000824	<--
US 20030045460	A1	20030306	US 2001-896841	20010629	<--
US 6933279	B2	20050823			
CN 1375299	A	20021023	CN 2001-103876	20010823	<--
CN 1739787	A	20060301	CN 2005-10103876	20010823	
CN 1911439	A	20070214	CN 2006-10100670	20010823	
CN 1931358	A	20070321	CN 2006-10100667	20010823	
CN 1931359	A	20070321	CN 2006-10100669	20010823	
CN 1943781	A	20070411	CN 2006-10100668	20010823	
EP 1864675	A1	20071212	EP 2007-7775	20010823	
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR					
US 20030171277	A1	20030911	US 2002-187215	20020628	<--
US 7144862	B2	20061205			
US 20030229015	A1	20031211	US 2002-273386	20021016	<--
US 7166578	B2	20070123			
US 20040266671	A1	20041230	US 2003-423830	20030425	
US 7199102	B2	20070403			
US 20050164950	A1	20050728	US 2004-913800	20040806	
AU 2004264944	A1	20050224	AU 2004-264944	20040810	
CA 2534676	A1	20050224	CA 2004-2534676	20040810	
WO 2005016280	A2	20050224	WO 2004-US26288	20040810	
WO 2005016280	A3	20060105			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1660112	A2	20060531	EP 2004-786504	20040810	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
CN 1867348	A	20061122	CN 2004-80029870	20040810	
JP 2007512228	T	20070517	JP 2006-523396	20040810	
HU 2007000157	A2	20070529	HU 2007-157	20040810	
JP 2006056899	A	20060302	JP 2005-304531	20051019	
MX 2006PA01743	A	20060512	MX 2006-PA1743	20060213	
NO 2006001139	A	20060508	NO 2006-1139	20060309	
IN 2006KN00576	A	20070803	IN 2006-KN576	20060310	
US 20070060527	A1	20070315	US 2006-485620	20060711	
JP 2006312650	A	20061116	JP 2006-220831	20060814	
JP 2007277250	A	20071025	JP 2007-118451	20070427	

JP 2008150358	A	20080703	JP 2007-250264		20070926
AU 2007237157	A1	20071213	AU 2007-237157		20071126
PRIORITY APPLN. INFO.:			US 2000-645454	A2	20000824
			US 2001-896841	A2	20010629
			US 2002-187215	A2	20020628
			US 2002-273386	A2	20021016
			US 2003-423830	A2	20030425
			US 2003-494449P	P	20030811
			CN 2001-103876	A3	20010823
			CN 2001-817280	A3	20010823
			CN 2005-10103876	A3	20010823
			EP 2001-966198	A3	20010823
			JP 2002-520844	A3	20010823
			WO 2001-US26497	A2	20010823
			US 2003-649378	A1	20030826
			WO 2004-US26288	W	20040810
			JP 2005-304531	A3	20051019
			AU 2006-200035	A3	20060106
			JP 2006-220831	A3	20060814

OTHER SOURCE(S): MARPAT 142:49262

AB The invention provides peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-β high d. lipoprotein-like particles and/or to promote lipid transport and detoxification. The invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more antiinflammatory at any given dose.

REFERENCE COUNT: 301 THERE ARE 301 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20040254120	A1	20041216	US 2003-649378	20030826	
	US 7148197	B2	20061212			
	US 6664230	B1	20031216	US 2000-645454	20000824	<--
	US 20030045460	A1	20030306	US 2001-896841	20010629	<--
	US 6933279	B2	20050823			
	CN 1375299	A	20021023	CN 2001-103876	20010823	<--
	CN 1739787	A	20060301	CN 2005-10103876	20010823	
	CN 1911439	A	20070214	CN 2006-10100670	20010823	
	CN 1931358	A	20070321	CN 2006-10100667	20010823	
	CN 1931359	A	20070321	CN 2006-10100669	20010823	
	CN 1943781	A	20070411	CN 2006-10100668	20010823	
	EP 1864675	A1	20071212	EP 2007-7775	20010823	
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR					
	US 20030171277	A1	20030911	US 2002-187215	20020628	<--
	US 7144862	B2	20061205			
	US 20030229015	A1	20031211	US 2002-273386	20021016	<--
	US 7166578	B2	20070123			
	US 20040266671	A1	20041230	US 2003-423830	20030425	
	US 7199102	B2	20070403			
	US 20050164950	A1	20050728	US 2004-913800	20040806	
	AU 2004264944	A1	20050224	AU 2004-264944	20040810	

CA 2534676 A1 20050224 CA 2004-2534676 20040810
WO 2005016280 A2 20050224 WO 2004-US26288 20040810
WO 2005016280 A3 20060105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1660112 A2 20060531 EP 2004-786504 20040810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
CN 1867348 A 20061122 CN 2004-80029870 20040810
JP 2007512228 T 20070517 JP 2006-523396 20040810
HU 2007000157 A2 20070529 HU 2007-157 20040810
JP 2006056899 A 20060302 JP 2005-304531 20051019
MX 2006PA01743 A 20060512 MX 2006-PA1743 20060213
NO 2006001139 A 20060508 NO 2006-1139 20060309
IN 2006KN00576 A 20070803 IN 2006-KN576 20060310
US 20070060527 A1 20070315 US 2006-485620 20060711
JP 2006312650 A 20061116 JP 2006-220831 20060814
JP 2007277250 A 20071025 JP 2007-118451 20070427
JP 2008150358 A 20080703 JP 2007-250264 20070926
AU 2007237157 A1 20071213 AU 2007-237157 20071126

IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bone decalcification/recalcification; orally administered small peptides synergize statin activity, and therapeutic uses)

IT 58-85-5D, Biotin, peptide conjugates 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 163222-33-1, Ezetimibe 287714-41-4, Rosuvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orally administered small peptides synergize statin activity, and therapeutic uses)

L9 ANSWER 5 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:406798 CA
TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 875,155, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040092573	A1	20040513	US 2003-602752	20030624
US 6812345	B2	20041102		
US 20020013334	A1	20020131	US 2001-875155	20010606 <--
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	B2 20010606
OTHER SOURCE(S):	MARPAT 140:406798			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040092573	A1	20040513	US 2003-602752	20030624
	US 6812345	B2	20041102		
	US 20020013334	A1	20020131	US 2001-875155	20010606 <--

IT Calcium channel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(T-type, antagonists, coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT Calcium channel blockers
(T-type, coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium, antagonists, coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT 5-HT reuptake inhibitors
Angiotensin receptor antagonists
Anti-Alzheimer's agents
Anti-infective agents
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics

Antiarthritics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antiosteoporotic agents
Antioxidants
Antitumor agents
Appetite depressants
Calcium channel blockers
Cardiovascular agents
Diuretics
Hormone replacement therapy
Hypolipemic agents
Immunomodulators
α-Adrenoceptor antagonists
β-Adrenoceptor antagonists
β3-Adrenoceptor agonists
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-01-7, Spironolactone 52-53-9, Verapamil 54-31-9, Furosemide 58-32-2, Dipyridamole 58-93-5, Hydrochlorothiazide 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 564-25-0, Doxycycline 637-07-0, Clofibrate 657-24-9, Metformin 1684-40-8, Tacrine hydrochloride 3416-24-8, Glucosamine 4205-91-8, Clonidine hydrochloride 9004-61-9, Hyaluronic acid 9007-28-7, Chondroitin sulfate 10118-90-8, Minocycline 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 29094-61-9, Glipizide 29122-68-7, Atenolol 42200-33-9, Nadolol 49562-28-9, Fenofibrate 55142-85-3, Ticlopidine 56180-94-0, Acarbose 56211-40-6, Torasemide 62571-86-2, Captopril 68475-42-3, Anagrelide 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89750-14-1, Glucagon-like peptide I 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 113665-84-2, Clopidogrel 114798-26-4, Losartan 120014-06-4, Donepezil 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC2993 143443-90-7, Ifetroban 143653-53-6, Abciximab 144288-97-1, TS 962 144494-65-5, Tirofiban 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 152755-31-2, LY 295427 159183-92-3, L 750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 162011-90-7, Vioxx 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS 30440 169590-42-5, Celebrex 170861-63-9, JTT-501 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 188627-80-7, Eptifibatide 196808-45-4, GI-262570 199113-98-9, NN-2344 199914-96-0, YM-440 213252-19-8, KRP297 244081-42-3, AJ9677 246852-12-0, Amlodipine mesylate 251572-86-8, P32/98 258345-41-4, GW-409544 282526-98-1, ATL-962 287714-41-4, Rosuvastatin 335149-08-1, L895645 335149-14-9,

R-119702 335149-15-0, KAD1129 335149-17-2, AR-HO39242 335149-23-0, NVP-DPP-728A 335149-25-2, CP 331648 430433-17-3, Glipyride 430433-43-5, CP 644673 444069-80-1, Axokine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological activity); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

L9 ANSWER 6 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:31532 CA
TITLE: Controlled-release drug composition containing pitavastatin
INVENTOR(S): Tanizawa, Yoshio; Shimokawa, Tatsuharu; Ogawa, Hirotada; Watanabe, Mayumi; Ohashi, Chihiro; Kawashima, Hiroyuki; Shinoda, Yasuo; Inagi, Toshio
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105848	A1	20031224	WO 2003-JP7605	20030616 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003241671	A1	20031231	AU 2003-241671	20030616 <--
US 20040018235	A1	20040129	US 2003-461432	20030616
EP 1514547	A1	20050316	EP 2003-733434	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
CN 1662237	A	20050831	CN 2003-814053	20030616
HK 1082909	A1	20071026	HK 2006-102664	20060228
PRIORITY APPLN. INFO.:			US 2002-388740P	P 20020617
			WO 2003-JP7605	W 20030616

AB Disclosed is a controlled-release drug composition characterized by comprising a composition (A) that contains pitavastatin or its salt or ester and initiates release thereof at least in the stomach and an enteric composition (B) that contains pitavastatin or its salt or ester. The use of this controlled-release drug composition leads to prolonged appropriate maintenance, starting just after administration, of the blood level of pitavastatin, so that safe and highly effective reduction of the blood cholesterol level can be realized. Enteric-coated granules containing pitavastatin calcium and methacrylic acid-Me methacrylate copolymer (Eudragit L), etc., were

prepared, and then further coated with pitavastatin calcium-containing layers to obtain controlled-release granules.
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003105848 A1 20031224

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003105848	A1	20031224	WO 2003-JP7605	20030616 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003241671	A1	20031231	AU 2003-241671	20030616 <--
US 20040018235	A1	20040129	US 2003-461432	20030616
EP 1514547	A1	20050316	EP 2003-733434	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
CN 1662237	A	20050831	CN 2003-814053	20030616
HK 1082909	A1	20071026	HK 2006-102664	20060228

AB . . . pitavastatin, so that safe and highly effective reduction of the blood cholesterol level can be realized. Enteric-coated granules containing pitavastatin calcium and methacrylic acid-Me methacrylate copolymer (Eudragit L), etc., were prepared, and then further coated with pitavastatin calcium-containing layers to obtain controlled-release granules.
IT 147511-69-1, Pitavastatin 147526-32-7
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release pitavastatin compns. containing enteric layers)

L9 ANSWER 7 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:399770 CA
TITLE: Medical goods comprising heparin or chitosan-based hemocompatible coating
INVENTOR(S): Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato
PATENT ASSIGNEE(S): Hemoteq G.m.b.H., Germany
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094990	A1	20031120	WO 2003-DE1253	20030415 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE	10221055	A1	20031127	DE 2002-10221055	20020510 <--
DE	10221055	B4	20071025		
DE	10261986	A1	20040318	DE 2002-10261986	20020510
DE	10261986	B4	20080131		
AU	2003240391	A1	20031111	AU 2003-240391	20030415 <--
AU	2003240391	B2	20070517		
CA	2484269	A1	20031120	CA 2003-2484269	20030415 <--
CN	1543362	A	20041103	CN 2003-800770	20030415
EP	1501565	A1	20050202	EP 2003-729829	20030415
EP	1501565	B1	20061102		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR	2003011446	A	20050315	BR 2003-11446	20030415
CN	1665554	A	20050907	CN 2003-815926	20030415
JP	2005534724	T	20051117	JP 2004-503070	20030415
AT	344064	T	20061115	AT 2003-729829	20030415
ES	2276065	T3	20070616	ES 2003-729829	20030415
NZ	536331	A	20070831	NZ 2003-536331	20030415
IN	2004MN00606	A	20050218	IN 2004-MN606	20041028
ZA	2004008791	A	20050527	ZA 2004-8791	20041028
ZA	2004008757	A	20050531	ZA 2004-8757	20041028
US	20050176678	A1	20050811	US 2004-513982	20041108
MX	2004PA11112	A	20050714	MX 2004-PA11112	20041109
IN	2005MN01451	A	20070706	IN 2005-MN1451	20051230

PRIORITY APPLN. INFO.:

US 2002-378676P	P	20020509
DE 2002-10221055	A	20020510
WO 2003-DE1253	W	20030415
IN 2004-MN606	A3	20041028

AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003094990 A1 20031120

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2003094990	A1	20031120	WO 2003-DE1253	20030415 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10221055	A1	20031127	DE 2002-10221055	20020510 <--
	DE 10221055	B4	20071025		
	DE 10261986	A1	20040318	DE 2002-10261986	20020510
	DE 10261986	B4	20080131		
	AU 2003240391	A1	20031111	AU 2003-240391	20030415 <--
	AU 2003240391	B2	20070517		
	CA 2484269	A1	20031120	CA 2003-2484269	20030415 <--
	CN 1543362	A	20041103	CN 2003-800770	20030415
	EP 1501565	A1	20050202	EP 2003-729829	20030415
	EP 1501565	B1	20061102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003011446	A	20050315	BR 2003-11446	20030415
	CN 1665554	A	20050907	CN 2003-815926	20030415
	JP 2005534724	T	20051117	JP 2004-503070	20030415
	AT 344064	T	20061115	AT 2003-729829	20030415
	ES 2276065	T3	20070616	ES 2003-729829	20030415
	NZ 536331	A	20070831	NZ 2003-536331	20030415
	IN 2004MN00606	A	20050218	IN 2004-MN606	20041028
	ZA 2004008791	A	20050527	ZA 2004-8791	20041028
	ZA 2004008757	A	20050531	ZA 2004-8757	20041028
	US 20050176678	A1	20050811	US 2004-513982	20041108
	MX 2004PA11112	A	20050714	MX 2004-PA11112	20041109
	IN 2005MN01451	A	20070706	IN 2005-MN1451	20051230

IT Calcium-binding proteins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(S-100; medical goods comprising a heparin-based hemocompatible coating)

IT 65277-42-1, Ketoconazole 65807-02-5, Goserelin 66107-60-6, Baccatin 67763-96-6, IGF-1 69306-88-3, Strychnophylline 69521-94-4, Thymosin α-1 70322-87-1, Vismione B 70322-88-2, Vismione A 71125-38-7, Meloxicam 71142-71-7, PPACK 71486-22-1, Vinorelbine 71610-00-9, Cephalomannine 71695-69-7, Baccharinoid B 1 71718-23-5, Baccharinoid B 7 71748-64-6, Baccharinoid B 2 72074-16-9, Baccharinoid B 3 73211-35-5 73981-34-7, Kamebakaurin 74045-97-9D, Psorospermin, derivs. 74863-84-6, Argatroban 75207-66-8, Longikaurin B 75330-75-5, Lovastatin 75607-67-9 75706-12-6, Leflunomide 78536-36-4, Excisanin B 78536-37-5, Excisanin A 79439-84-2, Yadanzioside P 79498-26-3, Leukamenin A 79498-27-4, Leukamenin B 79902-63-9, Simvastatin 80214-83-1, Roxithromycin 80890-47-7, Concanamycin 81093-37-0, Pravastatin 81103-11-9, Clarithromycin 82151-95-9D, derivs. 82410-32-0, Ganciclovir 82657-92-9, Prourokinase 83905-01-5, Azithromycin 84316-84-7, Maytenfoliol 85287-59-8, Sculponeatin C 85505-64-2, Vapiprost 85622-93-1, Temozolomide 85721-33-1, Ciprofloxacin 86293-25-6, Iso-iridogermanal 88418-46-6, Marchantin A

91161-71-6, Terbinafine 93957-54-1, Fluvastatin 94450-14-3
95058-81-4, Gemcitabine 96203-70-2, Pancratistatine 97682-44-5,
Irinotecan 97915-43-0, 1-Hydroxy-11-Methoxycanthin-6-one 98932-70-8,
Folimycin 99283-10-0, Molgramostim 99331-25-6, Triazolopyrimidine
101391-05-3, Bruceanol B 101391-06-4, Bruceanol A 101560-00-3,
Yadanzioside N 101809-47-6, Mansonine 102904-16-5, Mallotochromanol
102904-17-6, Mallotolerin 103839-24-3, 1,11-Dimethoxycanthin-6-one
104987-11-3, Tacrolimus 104987-12-4, Ascomycin 105608-32-0,
Bryophyllin A 105661-18-5, Hippocaesculin 107868-30-4, Exemestane
108736-35-2, Angiopeptin 108864-22-8, Tomenphantopin A 108864-23-9,
Tomenphantopin B 109237-00-5, Stizophyllin 109351-36-2, Sinococuline
110024-07-2, Agrostistachin 110024-07-2D, Agrostistachin, derivs.
110187-24-1, Maquiroside A 110300-76-0, Taxamairin A 110300-77-1,
Taxamairin B 110942-02-4, Aldesleukin 112078-76-9, Bisparthenolidine
112809-51-5, Letrozole 112965-21-6, Calcipotriol 114076-69-6,
Agroskerin 114076-70-9 114586-21-9, Bruceanol C 114727-97-8,
Cudraisoflavone A 114828-46-5, Periplocoside A 114977-28-5, Docetaxel
116963-87-2, Manwuweizic acid 118711-55-0, Hyptatic acid A
119188-33-9, Coronarin A 119188-35-1, Coronarin C 119188-37-3,
Coronarin D 119188-38-4, Coronarin B 119459-76-6, Ghalakinoside
120511-73-1, Anastrozole 121181-53-1, Filgrastim 123948-87-8,
Topotecan 128270-60-0, Bivalirudin 129399-53-7,
Isobutyrylmallotochromanol 130062-03-2, Larreatricin 130167-69-0,
Pegaspargase 134523-00-5, Atorvastatin 135968-09-1, Lenograstim
137071-32-0, Pimecrolimus 138068-37-8, r-Hirudin 139639-23-9, Tissue
plasminogen activator 140208-23-7, Plasminogen activator inhibitor-1
143090-92-0, Anakinra 143653-53-6, Abciximab 145599-86-6, Cerivastatin
147511-69-1, Pitavastatin 151499-39-7, Bafilomycin
152044-53-6, Epothilone A 152044-54-7, Epothilone B 152923-56-3,
Daclizumab 153212-75-0, 6α-Hydroxy-Paclitaxel 154361-50-9,
Capecitabine 159351-69-6, Everolimus 169590-42-5, Celecoxib
179045-86-4, Basiliximab 180288-69-1, Trastuzumab 185077-23-0, PI 88
185243-69-0, Etanercept 204205-90-3, D-24851 215647-85-1,
Peginterferon alfa-2b 265646-19-3, Indanocine 287714-41-4,
Rosuvastatin 625456-01-1, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical goods comprising a heparin-based hemocompatible coating)

L9 ANSWER 8 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:391031 CA
TITLE: Pitavastatin Inhibits Upregulation of Intermediate Conductance Calcium-Activated Potassium Channels and Coronary Arteriolar Remodeling Induced by Long-Term Blockade of Nitric Oxide Synthesis
AUTHOR(S): Terata, Yutaka; Saito, Takashi; Fujiwara, Yoshimasa; Hasegawa, Hitoshi; Miura, Hiroto; Watanabe, Hiroyuki; Chiba, Yoshikatsu; Kibira, Satoshi; Miura, Mamoru
CORPORATE SOURCE: Second Department of Internal Medicine, Akita University, Akita, Japan
SOURCE: Pharmacology (2003), 68(4), 169-176
CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We have reported that intermediate conductance Ca2+-activated K+ channels (ImK) showed augmented expression in angiotensin II (AII) type 1 receptor-dependent manner in post-ischemic rat heart. ImK has tyrosine

phosphorylation sequence in the C-terminus and motifs for NFκB and AP1 in the promoter. While statin inhibits AII-mediated vascular remodeling via anti-inflammatory effect independent of cholesterol lowering. To test the possible effect of statin on expression of ImK, Wistar-Kyoto rats received L-nitro-arginine Me ester (LNAME: 1 mg/mL in drinking water) for 4 wk in group L. While in L+P group, rats received both LNAME and pitavastatin (PTV: 1 mg/kg/day in drinking water). Temporal profile of ImK mRNA was examined by RT-PCR using specific primers for ImK. Long-term LNAME administration produced significant hypertension and resulted in marked microvascular remodeling characterized by medial thickening and perivascular fibrosis of coronary arterioles (100-200 μm in diameter). RT-PCR revealed significant up-regulation of ImK mRNA with two distinct peaks in L group in the early phase (days 3-7) and the late phase (4 wk). PTV partially inhibited a rise in systolic blood pressure, but completely abolished the first peak of ImK upregulation (0.76±0.04 vs. 3.96±1.43 folds at day 7, $p < 0.001$). Co-treatments with PTV also significantly inhibited medial thickening and perivascular fibrosis. These findings indicate that statin inhibits microvascular remodeling induced by chronic inhibition of NO synthesis through the action independent of cholesterol lowering.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Pitavastatin Inhibits Upregulation of Intermediate Conductance Calcium-Activated Potassium Channels and Coronary Arteriolar Remodeling Induced by Long-Term Blockade of Nitric Oxide Synthesis

SO Pharmacology (2003), 68(4), 169-176
CODEN: PHMGBN; ISSN: 0031-7012

ST pitavastatin statin calcium activated potassium channel NO coronary remodeling

IT Electric conductivity
(biol.; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Potassium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium-activated; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Fibrosis
(cardiac, coronary arteriole fibrosis; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Cardiovascular agents
Cytoprotective agents
(cardioprotective agents; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Artery
(coronary, arteriole; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Heart, disease
(fibrosis, coronary arteriole fibrosis; pitavastatin inhibits

upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Blood vessel
(microvessel; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT Anti-inflammatory agents
Remodeling
(pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT 9028-35-7, NADPH-hydroxymethylglutaryl-CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, statins; pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT 10102-43-9, Nitric oxide, biological studies 125978-95-2, NO synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)

L9 ANSWER 9 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:375605 CA
TITLE: Synthesis and uses of 4-azasteroid derivatives as selective androgen receptor modulators (SARMs)
INVENTOR(S): Wang, Jiabing; McVean, Carol A.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092588	A2	20031113	WO 2003-US13120	20030425 <--
WO 2003092588	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2484173	A1	20031113	CA 2003-2484173		20030425 <--
AU 2003223754	A1	20031117	AU 2003-223754		20030425 <--
AU 2003223754	B2	20070816			
EP 1501512	A2	20050202	EP 2003-719957		20030425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005529897	T	20051006	JP 2004-500773		20030425
US 20050131005	A1	20050616	US 2004-512800		20041027
US 20060281761	A1	20061214	US 2006-504325		20060814
PRIORITY APPLN. INFO.:			US 2002-376779P	P	20020430
			WO 2003-US13120	W	20030425
			US 2004-512800	A1	20041027

OTHER SOURCE(S): MARPAT 139:375605

GI



AB Compds. of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compds. are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

PI WO 2003092588 A2 20031113

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003092588	A2	20031113	WO 2003-US13120	20030425 <--
WO 2003092588	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2484173	A1	20031113	CA 2003-2484173	20030425	<--
AU 2003223754	A1	20031117	AU 2003-223754	20030425	<--
AU 2003223754	B2	20070816			
EP 1501512	A2	20050202	EP 2003-719957	20030425	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005529897	T	20051006	JP 2004-500773	20030425	
US 20050131005	A1	20050616	US 2004-512800	20041027	
US 20060281761	A1	20061214	US 2006-504325	20060814	

IT Receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium, antagonist, in addition to SARMs treatment; synthesis and uses of 4-azasteroid derivs. as selective androgen receptor modulators (SARMs) in the treatment of androgen deficiency-related diseases)

IT 7440-70-2, Calcium, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplements, in addition to SARMs treatment; synthesis and uses of 4-azasteroid derivs. as selective androgen receptor modulators (SARMs) in the treatment of androgen deficiency-related diseases)

IT 50-28-2, 17β-Estradiol, biological studies 53-16-7, Estrone, biological studies 64-96-0 67-96-9, Dihydrotachysterol 67-98-1, Mer-25 68-22-4, Norethindrone 71-58-9, Medroxyprogesterone acetate 471-34-1, Calcium carbonate, biological studies 911-45-5, Clomiphene 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, derivs. 1845-11-0, Nafoxidine 2809-21-4 4717-38-8, 17β-Ethynyl estradiol 5863-35-4, CI-628 7440-70-2D, Calcium, salts 7681-49-4, Sodium fluoride, biological studies 7693-13-2, Calcium citrate 9002-64-6, Parathyroid hormone 9002-64-6D, Parathyroid hormone, analog 9002-72-6, Somatotropin 9007-12-9, Calcitonin 10540-29-1, Tamoxifen 10596-23-3 12001-79-5, Vitamin K 12001-79-5D, Vitamin K, derivs. 15690-55-8, Zuclomiphene 15690-57-0, Enclomiphene 16984-48-8D, Fluoride, salts 19356-17-3 20859-36-3, Monosodium fluorophosphate 32222-06-3 35212-22-7, Ipriflavone 40391-99-9 41294-56-8 47931-85-1, Salmon calcitonin 52232-67-4, Human PTH (1-34) 54573-75-0 56287-31-1, CI-680 57333-95-6 57333-96-7 61912-98-9, Insulin-like growth factor 66376-36-1, Alendronate 67763-96-6, IGF I 67763-97-7, IGF II 75330-75-5, Lovastatin 75755-07-6 78994-23-7, Levormeloxifene 79778-41-9, Neridronate 79902-63-9, Simvastatin 81093-37-0, Pravastatin 82413-20-5, Droloxifene 83805-11-2 84449-90-1, Raloxifene 89778-26-7, Toremifene 89987-06-4, Tiludronate 93957-54-1, Fluvastatin 103909-75-7, 22-Oxacalcitriol 104121-92-8, ED71 105462-24-6 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 112965-21-6, Calcipotriol 114084-78-5, Ibandronate 116057-75-1, Idoxifene 118072-93-8, Zoledronate 118694-43-2, Ro 23-7553 121009-77-6 121268-17-5, Alendronate monosodium trihydrate 121368-58-9, Olpadronate 130447-37-9 131875-08-6, KH1060 134404-52-7, EB1089 134523-00-5, Atorvastatin 134523-84-5 138330-18-4, Incadronate 141750-63-2, Nisvastatin 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin

180064-38-4 180916-16-9, Lasofoxifene 182133-25-1, Arzoxifene 182167-02-8, EM-652 182167-03-9, EM-800 187483-31-4, U-100A 193830-08-9, GDF5 198481-33-3, TSE 424 205944-50-9, Osteoprotegerin 260055-05-8, Alendronate monosodium monohydrate 287714-41-4, Rosuvastatin 304853-26-7, Growth hormone secretagogue 583063-07-4, 1-84-Parathormone (human)
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in addition to SARMs treatment; synthesis and uses of 4-azasteroid derivs. as selective androgen receptor modulators (SARMs) in the treatment of androgen deficiency-related diseases)

L9 ANSWER 10 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:297028 CA
TITLE: Remedies for glomerular diseases containing antiplatelet agents and HMG-CoA reductase inhibitors
INVENTOR(S): Nakagawa, Takashi; Toyoizumi, Sayaka; Isuge, Masako
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082338	A1	20031009	WO 2003-JP3995	20030328 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 290833	B	20071211	TW 2003-92106940	20030327
CA 2478017	A1	20031009	CA 2003-2478017	20030328 <--
AU 2003220958	A1	20031013	AU 2003-220958	20030328 <--
EP 1488808	A1	20041222	EP 2003-715612	20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642574	A	20050720	CN 2003-807203	20030328
US 20050256141	A1	20051117	US 2004-504851	20040826
US 20060257474	A1	20061116	US 2006-434061	20060516

PRIORITY APPLN. INFO.:		
JP 2002-92238	A	20020328
WO 2003-JP3995	W	20030328
US 2004-504851	B1	20040826

AB Preventives or remedies for glomerular diseases comprising as the active ingredients an antiplatelet agent and an HMG-CoA reductase inhibitor. The above drugs are useful in preventing or treating various glomerular diseases such as chronic glomerular nephritis. The effect of administration of pitavastatin calcium in combination with dilazep hydrochloride in nephritis rats was examined A tablet containing

pitavastatin calcium 2, dilazep hydrochloride 100, lactose 70, low-substituted hydroxypropyl cellulose 20, hydroxypropyl cellulose 6, and magnesium stearate 2 mg was formulated.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003082338 A1 20031009

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003082338	A1	20031009	WO 2003-JP3995	20030328	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	TW 290833	B	20071211	TW 2003-92106940	20030327	
	CA 2478017	A1	20031009	CA 2003-2478017	20030328	<--
	AU 2003220958	A1	20031013	AU 2003-220958	20030328	<--
	EP 1488808	A1	20041222	EP 2003-715612	20030328	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	CN 1642574	A	20050720	CN 2003-807203	20030328	
	US 20050256141	A1	20051117	US 2004-504851	20040826	
	US 20060257474	A1	20061116	US 2006-434061	20060516	

AB . . . are useful in preventing or treating various glomerular diseases such as chronic glomerular nephritis. The effect of administration of pitavastatin calcium in combination with dilazep hydrochloride in nephritis rats was examined A tablet containing pitavastatin calcium 2, dilazep hydrochloride 100, lactose 70, low-substituted hydroxypropyl cellulose 20, hydroxypropyl cellulose 6, and magnesium stearate 2 mg was formulated.

IT 20153-98-4 147526-32-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedies for glomerular diseases containing antiplatelet agents and HMG-CoA reductase inhibitors)

IT 58-32-2, Dipyridamol 5011-34-7, Trimetazidine 15421-84-8, Trapidil 35898-87-4, Dilazep 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 287714-41-4, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedies for glomerular diseases containing antiplatelet agents and HMG-CoA reductase inhibitors)

L9 ANSWER 11 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:277056 CA
TITLE: Preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivatives as androgen receptor modulators
INVENTOR(S): Meissner, Robert S.; Perkins, James J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077919	A1	20030925	WO 2003-US8277	20030307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478186	A1	20030925	CA 2003-2478186	20030307 <--
AU 2003218235	A1	20030929	AU 2003-218235	20030307 <--
AU 2003218235	B2	20080515		
EP 1485095	A1	20041215	EP 2003-714228	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
BR 2003008355	A	20050125	BR 2003-8355	20030307
CN 1652786	A	20050810	CN 2003-810485	20030307
JP 2005526082	T	20050902	JP 2003-575972	20030307
NZ 534946	A	20070531	NZ 2003-534946	20030307
RU 2320670	C2	20080327	RU 2004-130452	20030307
IN 2004CN02007	A	20060224	IN 2004-CN2007	20040908
US 20050165039	A1	20050728	US 2004-507239	20040909
US 7186838	B2	20070306		
MX 2004PA08800	A	20041126	MX 2004-PA8800	20040910
NO 2004004312	A	20041012	NO 2004-4312	20041012
US 20070088042	A1	20070419	US 2006-605090	20061128

PRIORITY APPLN. INFO.:	US 2002-363822P	P	20020313
	WO 2003-US8277	W	20030307
	US 2004-507239	A1	20040909

OTHER SOURCE(S): MARPAT 139:277056
GI



I II

AB Fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs., such as I [a-b = CF:CH, CHFCH2, CF2CH2; R1 = H, CH2OH, (un)substituted alkyl; R2 = H, alkyl; R3 = alkyl, cycloheteroalkyl, aryl, heteroaryl; R2R3 = 5 or 6-membered ring fused with a 5- or 6-membered aromatic ring system having 0-2 heteroatoms], or a pharmaceutically acceptable salt or an enantiomer thereof, were prepared for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, 4-aza-androstan-3-one-17β-carboxamide derivative II, was prepared via a multiple step reaction sequence starting from 4-methyl-4-aza-androstan-3-one-17-carboxylic acid Me ester and 2-fluoro-benzylamine. The prepared compds. are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. I are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003077919 A1 20030925

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003077919	A1	20030925	WO 2003-US8277	20030307 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2478186	A1	20030925	CA 2003-2478186	20030307	<--
AU 2003218235	A1	20030929	AU 2003-218235	20030307	<--
AU 2003218235	B2	20080515			
EP 1485095	A1	20041215	EP 2003-714228	20030307	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, SK					
BR 2003008355	A	20050125	BR 2003-8355	20030307	
CN 1652786	A	20050810	CN 2003-810485	20030307	
JP 2005526082	T	20050902	JP 2003-575972	20030307	
NZ 534946	A	20070531	NZ 2003-534946	20030307	
RU 2320670	C2	20080327	RU 2004-130452	20030307	
IN 2004CN02007	A	20060224	IN 2004-CN2007	20040908	
US 20050165039	A1	20050728	US 2004-507239	20040909	
US 7186838	B2	20070306			
MX 2004PA08800	A	20041126	MX 2004-PA8800	20040910	
NO 2004004312	A	20041012	NO 2004-4312	20041012	
US 20070088042	A1	20070419	US 2006-605090	20061128	

IT Receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium, antagonist, bone strengthening agents as adjuvant therapeutics; preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs. as androgen receptor modulators and their therapeutic uses)

IT Dietary supplements
(calcium, bone strengthening agents as adjuvant therapeutics; preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs. as androgen receptor modulators and their therapeutic uses)

IT 50-28-2, 17β-Estradiol, biological studies 53-16-7, Estrone, biological studies 67-96-9, Dihydrotachysterol 67-98-1, Mer-25 68-22-4, Norethindrone 71-58-9, Medroxyprogesterone acetate 911-45-5, Clomiphene 1845-11-0, Nafoxidene 2809-21-4 4717-38-8, 17β-Ethynyl estradiol 5863-35-4, CI-628 7681-49-4, Sodium fluoride, biological studies 9007-12-9, Calcitonin 10540-29-1, TAMOXIFEN 10596-23-3 13598-36-2D, Phosphonic acid, alkylidene-bis-derivs. 15690-55-8, Zuclomiphene 15690-57-0, Enclomiphene 19356-17-3 20859-36-3, Monosodium fluorophosphate 32222-06-3 35212-22-7, Ipriflavone 40391-99-9 41294-56-8 50948-44-2, U-11, biological studies 54573-75-0 56287-31-1, CI-680 57333-95-6 57333-96-7 61912-98-9, Insulin-like growth factor 62031-54-3, Fibroblast growth factor 66376-36-1, Alendronate 75330-75-5, Lovastatin 75755-07-6 78994-23-7, Levormeloxifene 79778-41-9, Neridronate 79902-63-9, Simvastatin 81093-37-0, Pravastatin 82413-20-5, Droloxifene 83805-11-2 84449-90-1, Raloxifene 89778-26-7, Toremifene 89987-06-4, Tiludronate 93957-54-1, Fluvastatin 103909-75-7, 22-Oxacalcitriol 104121-92-8, ED71 105462-24-6 112965-21-6, Calcipotriol 114084-78-5, Ibandronate 116057-75-1, Idoxifene 118072-93-8, Zoledronate 118694-43-2 121268-17-5, Alendronate monosodium trihydrate 121368-58-9, Olpadronate 130447-37-9 131875-08-6, KH1060 134404-52-7, EB1089 134523-00-5, Atorvastatin 134523-84-5 138330-18-4, Incadronate 141750-63-2, Nisvastatin 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 180064-38-4 180916-16-9, Lasofoxifene 182167-02-8, EM-652 182167-03-9, EM-800 187483-31-4, U-100A 198481-33-3, Tse-424 205944-50-9, Osteoprotegerin 260055-05-8, Alendronate monosodium monohydrate 287714-41-4, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of

fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs. as androgen receptor modulators and their therapeutic uses)
IT 471-34-1, Calcium carbonate, biological studies 7693-13-2, Calcium citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary calcium supplement as adjuvant bone strengthening agents; preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs. as androgen receptor modulators and their therapeutic uses)

L9 ANSWER 12 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:214343 CA
TITLE: Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives
INVENTOR(S): Sedelmeier, Gottfried; Mathes, Christian
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070717	A1	20030828	WO 2003-EP1738	20030220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
CA 2473075	A1	20030823	CA 2003-2473075	20030220 <--
AU 2003218994	A1	20030909	AU 2003-218994	20030220 <--
AU 2003218994	B2	20070809		
EP 1478640	A1	20041124	EP 2003-714750	20030220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007801	A	20041221	BR 2003-7801	20030220
CN 1636004	A	20050706	CN 2003-804288	20030220
JP 2005520818	T	20050714	JP 2003-569624	20030220
NZ 534394	A	20061027	NZ 2003-534394	20030220
ZA 2004005436	A	20050617	ZA 2004-5436	20040708
US 20050159480	A1	20050721	US 2004-504655	20040813
US 7208623	B2	20070424		
IN 2004CN01834	A	20070921	IN 2004-CN1834	20040817
MX 2004PA08110	A	20041126	MX 2004-PA8110	20040820
NO 2004003919	A	20040920	NO 2004-3919	20040920
US 20070155970	A1	20070705	US 2007-684134	20070309
PRIORITY APPLN. INFO.:			GB 2002-4129 A	20020221
			WO 2003-EP1738 W	20030220
			US 2004-504655 A3	20040813

OTHER SOURCE(S): MARPAT 139:214343
GI



AB Mevalonic acid derivs. I [R = cyclic residue; X = CH2CH2, CH:CH] are prepared by treating R1R2R3P:CHCOCH2CO2R4 [R1-R3 = (un)substituted Ph; R4 = aliphatic, cycloaliph., aromatic] with RCHO, reducing the resulting RCH:CHCOCH2CO2R4 in presence of a chiral metal BINAP or TsDPEN catalyst, treating the resulting alc. with an ester enolate, reducing the second oxo group, and hydrolyzing the ester group. Thus, ClCH2COCH2CO2Et was treated with PPh3 to give Ph3P:CHCOCH2CO2Et which was treated with 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde to give (E)-5-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3-oxopent-4-enoic acid Et ester. This ester was reduced with Ru[(1R,2R)-p-TsNCHPhCHPhNH](η-p-cymene) and treated with Me3COAc to give (E)-(S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-4-enoic acid tert.-Bu ester which was reduced with MeOBEt2 and hydrolyzed to give (E)-(3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-4-enoic acid calcium salt.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003070717 A1 20030828

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003070717	A1	20030828	WO 2003-EP1738	20030220	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR					
	CA 2473075	A1	20030823	CA 2003-2473075	20030220	<--
	AU 2003218994	A1	20030909	AU 2003-218994	20030220	<--
	AU 2003218994	B2	20070809			
	EP 1478640	A1	20041124	EP 2003-714750	20030220	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	BR 2003007801	A	20041221	BR 2003-7801	20030220	
	CN 1636004	A	20050706	CN 2003-804288	20030220	
	JP 2005520818	T	20050714	JP 2003-569624	20030220	
	NZ 534394	A	20061027	NZ 2003-534394	20030220	
	ZA 2004005436	A	20050617	ZA 2004-5436	20040708	
	US 20050159480	A1	20050721	US 2004-504655	20040813	
	US 7208623	B2	20070424			
	IN 2004CN01834	A	20070921	IN 2004-CN1834	20040817	
	MX 2004PA08110	A	20041126	MX 2004-PA8110	20040820	
	NO 2004003919	A	20040920	NO 2004-3919	20040920	
	US 20070155970	A1	20070705	US 2007-684134	20070309	

AB . . . treated with Me3COAc to give (E)-(S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-4-enoic acid tert.-Bu

ester which was reduced with MeOBEt2 and hydrolyzed to give (E)-(3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-4-enoic acid calcium salt.

IT 13148-05-5P 106302-03-8P 194934-95-7P 194934-96-8P 194935-00-7P 375846-20-1P 562099-44-9P 586966-50-9P 586966-51-0P 586966-52-1P 586966-53-2P 586966-54-3P 586966-55-4P 586966-56-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivs.)

IT 94061-80-0P 587840-28-6P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivs.)

L9 ANSWER 13 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:191440 CA
TITLE: Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
INVENTOR(S): Krul, Elaine S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20030162824	A1	20030828	US 2002-292255		20021112 <--
PRIORITY APPLN. INFO.:			US 2001-331346P	P	20011112
			US 2001-338291P	P	20011113

OTHER SOURCE(S): MARPAT 139:191440

AB Methods for treating or preventing one or more cardiovascular conditions in a subject comprises treating the subject with a therapeutically effective amount of a selective cyclooxygenase-1 inhibitor or a pharmaceutically-acceptable salt, tautomer or prodrug thereof alone or in combination with either a drug used in the treatment or prevention of a cardiovascular condition or a non-drug therapy used in the treatment of a cardiovascular condition. Cyclooxygenase-1 inhibitor, 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole (I), was prepared from 4'-chloroacetophenone and (4-methoxyphenyl)hydrazine hydrochloride. I inhibited development of atherosclerosis in cholesterol-fed apoE knockout mice.

PI US 20030162824 A1 20030828

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030162824	A1	20030828	US 2002-292255	20021112 <--

IT Aneurysm
Angiotensin receptor antagonists
Angiotensin receptor antagonists
Anti-inflammatory agents
Antiarteriosclerotics
Antioxidants
Arteriosclerosis

Atherosclerosis
Calcium channel blockers
Diuretics
Drug delivery systems
Embolism
Human
Kidney, disease
Mammalia
Radiotherapy
Thrombosis
Vasodilators
α-Adrenoceptor antagonists
β-Adrenoceptor antagonists
(cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

IT 66085-59-4, Nimodipine 101477-55-8, Lomerizine
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel blocker, cerebral vasodilator; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

IT 90-54-0, Etafenone 13042-18-7, Fendiline
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel blocker, coronary vasodilator; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

IT 298-57-7, Cinnarizine 2179-37-5, Bencyclane 52468-60-7, Flunarizine
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel blocker, vasodilator; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

IT 52-53-9, Verapamil 390-64-7, Prenylamine 3416-26-0, Lidoflazine 6621-47-2, Perhexiline 15793-40-5, Terodiline 16662-47-8, Gallopamil 21829-25-4, Nifedipine 31309-39-4, Medipine 39562-70-4, Nitrendipine 42399-41-7, Diltiazem 55985-32-5, Nicardipine 63675-72-9, Nisoldipine 64706-54-3, Bepridil 72509-76-3, Felodipine 75530-68-6, Nilvadipine 75695-93-1, Isradipine 86780-90-7, Aranidipine 88150-42-9, Amlodipine 96125-53-0, Clentiazem 100427-26-7, Lercanidipine 103890-78-4, Lacidipine 104713-75-9, Barnidipine 105979-17-7, Benidipine 111011-63-3, Efonidipine 116476-13-2, Semotiadil 116644-53-2, Mibefradil 119413-55-7, Elgodipine 132203-70-4, Cilnidipine
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium channel blocker; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

IT 73573-88-3, Mevastatin 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 147511-69-1, Pitavastatin 287714-41-4, Rosuvastatin
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid-lowering drug; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)

L9 ANSWER 14 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:164712 CA

TITLE: Asymmetric titanium mediated disilyloxydiene/aldehyde addition process for the preparation of δ-hydroxy-β-ketoesters.

INVENTOR(S): Chen, Guang-Pei; Kapa, Prasad Koteswara; Loeser, Eric M.; Beutler, Ulrich; Zaugg, Werner; Girgis, Michael J.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2003064382	A2	20030807	WO 2003-EP804	20030127	<--
WO 2003064382	A3	20031211			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR					
US 20030208072	A1	20031106	US 2003-350615	20030124	<--
US 6835838	B2	20041228			
CA 2472340	A1	20030807	CA 2003-2472340	20030127	<--
EP 1472227	A2	20041103	EP 2003-734696	20030127	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003007236	A	20041207	BR 2003-7236	20030127	
JP 2005516064	T	20050602	JP 2003-564005	20030127	
CN 1625550	A	20050608	CN 2003-802877	20030127	
AU 2003239294	B2	20061019	AU 2003-239294	20030127	
NZ 534136	A	20070831	NZ 2003-534136	20030127	
ZA 2004005239	A	20050617	ZA 2004-5239	20040701	
US 20040249154	A1	20041209	US 2004-891357	20040714	
IN 2004CN01635	A	20060224	IN 2004-CN1635	20040723	
MX 2004PA07308	A	20041029	MX 2004-PA7308	20040728	
NO 2004003586	A	20041007	NO 2004-3586	20040827	
AU 2006225205	A1	20061026	AU 2006-225205	20061003	
AU 2006225206	A1	20061026	AU 2006-225206	20061003	

PRIORITY APPLN. INFO.:	US 2002-352316P	P	20020128
	US 2002-383188P	P	20020524
	US 2003-350615	A3	20030124
	WO 2003-EP804	W	20030127

OTHER SOURCE(S): CASREACT 139:164712; MARPAT 139:164712
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for the preparation of I [R1 = (un)substituted (cyclo)alkyl, aralkyl; R2-7 = H, halo, OH, (un)substituted (cyclo)alkyl, aryl, aralkyl, etc.] and

analogs is disclosed. The process involves the Ti(OPr-i)4/(S)-BINOL mediated addition of II [R1 = as above; R, R' = alkyl] to III [R2-7 = as above]. For instance, II [R1 = Et; R, R' = Me] (preparation given) is reacted with III [R2 = F; R3-7 = H] (THF, 4Å mol. sieves, (S)-BINOL/Ti(OPr-i)4, 19°, 2 days) to give I [R1 = Et; R2 = F; R3-7 = H] in 81.6% yield (after purification) and the amount of undesired enantiomer was below the limit of detection. Addnl. examples demonstrated sidechain manipulation (to the δ(S)-β(R)-ester) and subsequent conversion to pitavastatin (calcium salt) via the intermediacy of the 2H-pyranone. Exptl. details regarding mol. sieve preparation and their use in a fixed bed reactor are given.

PI WO 2003064382 A2 20030807

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003064382	A2	20030807	WO 2003-EP804	20030127	<--
	WO 2003064382	A3	20031211			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR					
	US 20030208072	A1	20031106	US 2003-350615	20030124	<--
	US 6835838	B2	20041228			
	CA 2472340	A1	20030807	CA 2003-2472340	20030127	<--
	EP 1472227	A2	20041103	EP 2003-734696	20030127	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	BR 2003007236	A	20041207	BR 2003-7236	20030127	
	JP 2005516064	T	20050602	JP 2003-564005	20030127	
	CN 1625550	A	20050608	CN 2003-802877	20030127	
	AU 2003239294	B2	20061019	AU 2003-239294	20030127	
	NZ 534136	A	20070831	NZ 2003-534136	20030127	
	ZA 2004005239	A	20050617	ZA 2004-5239	20040701	
	US 20040249154	A1	20041209	US 2004-891357	20040714	
	IN 2004CN01635	A	20060224	IN 2004-CN1635	20040723	
	MX 2004PA07308	A	20041029	MX 2004-PA7308	20040728	
	NO 2004003586	A	20041007	NO 2004-3586	20040827	
	AU 2006225205	A1	20061026	AU 2006-225205	20061003	
	AU 2006225206	A1	20061026	AU 2006-225206	20061003	

AB . . . enantiomer was below the limit of detection. Addnl. examples demonstrated sidechain manipulation (to the δ(S)-β(R)-ester) and subsequent conversion to pitavastatin (calcium salt) via the intermediacy of the 2H-pyranone. Exptl. details regarding mol. sieve preparation and their use in a fixed bed. . .

IT 13257-83-5P, 3-((Trimethylsilanyl)oxy)but-2-enoic acid ethyl ester
89186-81-2P, 1-Ethoxy-1,3-bis(trimethylsilanyloxy)butan-1,3-diene
141750-63-2P 167073-19-0P 254452-91-0P 574705-92-3P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. titanium mediated disilyloxydiene/aldehyde addition process for preparation of δ-hydroxy-β-ketoesters)

IT 147526-32-7P 562099-39-2P 562099-40-5P 562099-41-6P
562099-43-8P 573649-74-8P 573649-75-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)
(asym. titanium mediated disilyloxydiene/aldehyde addition process for preparation of δ-hydroxy-β-ketoesters)

L9 ANSWER 15 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:164542 CA
TITLE: Preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions
INVENTOR(S): Lloyd, John; Jeon, Yoon T.; Finlay, Heather; Yan, Lin; Gross, Michael F.; Beaudoin, Serge
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Icagen, Inc.
SOURCE: PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063797	A2	20030807	WO 2003-US3170	20030131 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474451	A1	20030807	CA 2003-2474451	20030131 <--
US 20040072880	A1	20040415	US 2003-356158	20030131
EP 1507504	A1	20050223	EP 2003-735126	20030131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1732146	A	20060208	CN 2003-807570	20030131
JP 2006508016	T	20060309	JP 2003-563493	20030131
BR 2003007329	A	20060411	BR 2003-7329	20030131
NZ 534098	A	20070427	NZ 2003-534098	20030131
IN 2004DN02052	A	20050401	IN 2004-DN2052	20040716
MX 2004PA07365	A	20050331	MX 2004-PA7365	20040729
NO 2004003645	A	20040831	NO 2004-3645	20040831
US 20050234106	A1	20051020	US 2004-997734	20041124
US 7202253	B2	20070410		
ZA 2004005905	A	20060531	ZA 2004-5905	20060313
US 20070142333	A1	20070621	US 2007-670482	20070202

PRIORITY APPLN. INFO.:	US 2002-353884P	P	20020201
	US 2003-356158	B1	20030131
	WO 2003-US3170	W	20030131
	US 2004-997734	A3	20041124

OTHER SOURCE(S): MARPAT 139:164542
GI



AB Claimed are novel cycloalkyl compds. (shown as I; variables defined below; e.g. cis- and trans-N-(4-hydroxy-1-thiophen-2-ylcyclohexylmethyl)-2-methoxybenzamide and trans-N-[[4-[N'-cyano-N''-ethyl-N-(furan-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide) useful as inhibitors of K channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which was linked to the ultra-rapidly activating delayed rectifier K+ current IKur; no data), methods of using such compds. in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compns. containing such compds. For I: dashed line = an optional double bond, provided that R1a is absent when a double bond is present; m and p = 0-3; R1 = H, NR8C(:W)NR6R7 (W = NR8a2, NCO2R8a2, NC(O)R8a2, NCN, NSO2R8a2), NR8SO2NR6R7, etc.; R1a = H, RX; or R1 and R1a together form oxo; or R1 and R1a together with the C atom to which they are attached combine to form an (un)substituted spiro-fused heterocyclo group; or R1 and R1a together combine to form :CR8R9. R2 is heteroaryl, (heteroaryl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, alkyl, alkenyl or cycloalkyl; J is a bond, C1-4 alkylene or C1-4 alkenylene; R3 = R5 (R5 = NR6aR7a, heteroaryl, (heteroaryl)alkyl, aryl, arylalkyl, alkyl, etc.), OR5, C(:Z1)R5, OC(:Z1)R5, C(:Z1)OR5, NR8a1C(:Z1)R5, etc.; RX is one or more optional substituents, attached to any available ring carbon atom; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, >600 example prepns. are included.

PI WO 2003063797 A2 20030807

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003063797	A2	20030807	WO 2003-US3170	20030131 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2474451	A1	20030807	CA 2003-2474451	20030131 <--
US 20040072880	A1	20040415	US 2003-356158	20030131
EP 1507504	A1	20050223	EP 2003-735126	20030131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1732146	A	20060208	CN 2003-807570	20030131
JP 2006508016	T	20060309	JP 2003-563493	20030131
BR 2003007329	A	20060411	BR 2003-7329	20030131

NZ 534098	A	20070427	NZ 2003-534098	20030131
IN 2004DN02052	A	20050401	IN 2004-DN2052	20040716
MX 2004PA07365	A	20050331	MX 2004-PA7365	20040729
NO 2004003645	A	20040831	NO 2004-3645	20040831
US 20050234106	A1	20051020	US 2004-997734	20041124
US 7202253	B2	20070410		
ZA 2004005905	A	20060531	ZA 2004-5905	20060313
US 20070142333	A1	20070621	US 2007-670482	20070202

IT Angiotensin receptor antagonists
Anticoagulants
Antihypertensives
Calcium channel blockers
Platelet aggregation inhibitors
β-Adrenoceptor antagonists
(combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 50-78-2, Aspirin 52-01-7, Spironolactone 52-53-9, Verapamil 56-03-1D, Biguanide, derivs. 81-81-2, Warfarin 630-60-4, Ouabain 3930-20-9, Sotalol 9005-49-6D, Heparin, derivs. 10238-21-8D, Glyburide, combinations with biguanide 42399-41-7, Diltiazem 62571-86-2, Captopril 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81872-10-8, Zofenopril 82924-03-6, Pentopril 83435-66-9, Delapril 85441-61-8, Quinapril 87333-19-5, Ramipril 88768-40-5, Cilazapril 98048-97-6, Fosinopril 107724-20-9, Eplerenone 111223-26-8 113665-84-2, Clopidogrel 115256-11-6, Dofetilide 134523-00-5, Atorvastatin 143443-90-7, Ifetroban 147511-69-1 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat 171870-23-8, Lanoteplase 191588-94-0, Tenecteplase 287714-41-4, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

L9 ANSWER 16 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:149536 CA
TITLE: Preparation of an asymmetric β,δ-dihydroxycarboxylic acid side chain used for the manufacture of a HMG-CoA reductase inhibitors
INVENTOR(S): Acemoglu, Murat; Riss, Bernhard
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064392	A1	20030807	WO 2003-EP954	20030130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,				

	SK, TR				
CA 2472776	A1	20030807	CA 2003-2472776		20030130 <--
EP 1472228	A1	20041103	EP 2003-734716		20030130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003007303	A	20050111	BR 2003-7303		20030130
CN 1622937	A	20050601	CN 2003-802740		20030130
JP 2005520814	T	20050714	JP 2003-564015		20030130
NZ 534232	A	20060331	NZ 2003-534232		20030130
AU 2003226971	B2	20061130	AU 2003-226971		20030130
RU 2299196	C2	20070520	RU 2004-126442		20030130
ZA 2004005322	A	20050617	ZA 2004-5322		20040705
US 20050070605	A1	20050331	US 2004-502177		20040721
US 7371865	B2	20080513			
IN 2004CN01647	A	20060512	IN 2004-CN1647		20040726
MX 2004PA07396	A	20041011	MX 2004-PA7396		20040730
NO 2004003611	A	20040830	NO 2004-3611		20040830
US 20080182873	A1	20080731	US 2008-54193		20080324
PRIORITY APPLN. INFO.:			US 2002-353787P	P	20020131
			WO 2003-EP954	W	20030130
			US 2004-502177	A1	20040721

OTHER SOURCE(S): MARPAT 139:149536

GI





AB A process for the stereoselective preparation of a β,δ-dihydroxycarboxylic acid I [R = cyclic residue] is disclosed. For instance, glutaric acid diamide analog II (preparation given) is reacted with methanephosphonic acid di-Et ester (THF, n-BuLi, -78°) and the resulting phosphonate condensed with [2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]carboxaldehyde (i-PrOH, Cs2CO3) to give the

corresponding E-olefin. This intermediate is deprotected and reduced (THF, NaBH4, Me2BOMe, -78°, 30 min) to give III. Addnl. examples demonstrate the conversion of III (optionally via the intermediacy of a 2H-pyran intermediate) to pitavastatin (calcium salt).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2003064392 A1 20030807

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003064392	A1	20030807	WO 2003-EP954	20030130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
CA 2472776	A1	20030807	CA 2003-2472776	20030130 <--
EP 1472228	A1	20041103	EP 2003-734716	20030130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007303	A	20050111	BR 2003-7303	20030130
CN 1622937	A	20050601	CN 2003-802740	20030130
JP 2005520814	T	20050714	JP 2003-564015	20030130
NZ 534232	A	20060331	NZ 2003-534232	20030130
AU 2003226971	B2	20061130	AU 2003-226971	20030130
RU 2299196	C2	20070520	RU 2004-126442	20030130
ZA 2004005322	A	20050617	ZA 2004-5322	20040705
US 20050070605	A1	20050331	US 2004-502177	20040721
US 7371865	B2	20080513		
IN 2004CN01647	A	20060512	IN 2004-CN1647	20040726
MX 2004PA07396	A	20041011	MX 2004-PA7396	20040730
NO 2004003611	A	20040830	NO 2004-3611	20040830
US 20080182873	A1	20080731	US 2008-54193	20080324

AB . . . to give III. Addnl. examples demonstrate the conversion of III (optionally via the intermediacy of a 2H-pyran intermediate) to pitavastatin (calcium salt).

IT 94061-80-0P 147526-32-7P, Pitavastatin hemicalcium
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of an asym. β,δ-dihydroxycarboxylic acid side chain used for manufacture of a HMG-CoA reductase inhibitors)

L9 ANSWER 17 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 139:90459 CA
TITLE: Use of an immediate-release powder in pharmaceutical and nutraceutical compositions
INVENTOR(S): Besse, Jerome; Besse, Laurence
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030124191	A1	20030703	US 2002-106923	20020325 <--
FR 2834212	A1	20030704	FR 2001-16934	20011227 <--
FR 2834212	B1	20040709		
CA 2471903	A1	20030710	CA 2002-2471903	20021227 <--
WO 2003055464	A1	20030710	WO 2002-FR4575	20021227 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364489	A1	20030715	AU 2002-364489	20021227 <--
EP 1458356	A1	20040922	EP 2002-799854	20021227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015380	A	20041207	BR 2002-15380	20021227
JP 2005520799	T	20050714	JP 2003-556042	20021227
HU 2005000509	A2	20050928	HU 2005-509	20021227
RU 2302232	C2	20070710	RU 2004-122919	20021227
MX 2004PA06181	A	20050419	MX 2004-PA6181	20040622
NO 2004003172	A	20040914	NO 2004-3172	20040726
US 20050118272	A1	20050602	US 2005-500213	20050204
PRIORITY APPLN. INFO.:			FR 2001-16934 A	20011227
			WO 2002-FR4575 W	20021227

AB The present invention relates to the use of a powder comprising at least one active substance, at least one surfactant, at least one wetting agent and at least one diluent, for preparing a pharmaceutical or nutraceutical composition, this composition allowing rapid and immediate release of the active substance. Granules containing phloroglucinol 10, sorbitol 89, and propylene glycol 1% were prepared

PI US 20030124191 A1 20030703

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030124191	A1	20030703	US 2002-106923	20020325 <--
FR 2834212	A1	20030704	FR 2001-16934	20011227 <--
FR 2834212	B1	20040709		
CA 2471903	A1	20030710	CA 2002-2471903	20021227 <--
WO 2003055464	A1	20030710	WO 2002-FR4575	20021227 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364489	A1	20030715	AU 2002-364489	20021227 <--
EP 1458356	A1	20040922	EP 2002-799854	20021227

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR	2002015380	A	20041207	BR 2002-15380	20021227
JP	2005520799	T	20050714	JP 2003-556042	20021227
HU	2005000509	A2	20050928	HU 2005-509	20021227
RU	2302232	C2	20070710	RU 2004-122919	20021227
MX	2004PA06181	A	20050419	MX 2004-PA6181	20040622
NO	2004003172	A	20040914	NO 2004-3172	20040726
US	20050118272	A1	20050602	US 2005-500213	20050204

IT 50-03-3, Hydrocortisone acetate 50-23-7, Hydrocortisone 50-28-2, Oestradiol, biological studies 50-28-2D, Oestradiol, derivs. 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 51-34-3, Scopolamine 51-98-9, Norethisterone acetate 54-11-5, Nicotine 54-21-7, Sodium salicylate 55-63-0, Trinitrin 56-81-5, Glycerol, biological studies 57-09-0, Cetrimonium bromide 57-13-6, Urea, biological studies 57-47-6, Physostigmine 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 57-63-6, Ethinyl oestradiol 57-83-0, Progesterone, biological studies 58-08-2, Caffeine, biological studies 58-22-0, Testosterone 59-66-5, Acetazolamide 60-40-2, Mecamylamine 63-42-3, Lactose 64-17-5, Ethanol, biological studies 67-73-2, Fluocinolone acetonide 69-65-8, Mannitol 71-52-3, Bicarbonate, biological studies 81-13-0, Dexpanthenol 87-33-2, Isosorbide dinitrate 87-99-0, Xylitol 89-78-1, Menthol) 94-36-0, Benzoyl peroxide, biological studies 97-53-0, Eugenol 101-20-2, Triclocarban 106-24-1, Geraniol 106-25-2, Nerol 106-60-5, 5-Aminolevulinic acid 108-73-6, Phloroglucinol 110-27-0, Isopropyl myristate 112-62-9, Methyl oleate 112-80-1, Oleic acid, biological studies 113-45-1, Methyl phenidate 114-07-8, Erythromycin 123-03-5, Cetylpyridinium chloride 124-94-7, Triamcinolone 137-58-6, Lidocaine 139-33-3 143-07-7, Lauric acid, biological studies 144-80-9, Sulphacetamide 145-42-6, Sodium taurocholate 147-24-0, Diphenhydramine hydrochloride 151-21-3, Sodium lauryl sulphate, biological studies 152-97-6, Fluocortolone 302-79-4, Tretinoin 303-40-2, Fluocortolone hexanoate 356-12-7, Fluocinolide 437-38-7, Fentanyl 443-48-1, Metronidazole 470-82-6, Eucalyptol 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 521-18-6, Dihydrotestosterone 585-86-4, Lactitol 611-53-0, Ibacitabine 638-94-8, Desonide 645-92-1 745-65-3, Alprostadil 797-63-7, Levonorgestrel 863-57-0, Sodium glycocholate 1180-95-6, Sodium taurodeoxycholate 2002-29-1, Flumetasone pivalate 2152-44-5, Betamethasone valerate 2438-72-4, Bufexamac 3764-87-2 4205-90-7, Clonidine 4394-00-7, Nifluminic acid 4759-48-2, Isotretinoin 4985-25-5, Pyrazinobutazone 5104-49-4, Flurbiprofen 5593-20-4, Betamethasone dipropionate 5633-20-5, Oxybutynin 5716-20-1, Bamethan sulfate 6805-41-0, Escin 7757-93-9, Dibasic calcium phosphate 7758-87-4, Tribasic calcium phosphate 7759-35-5, Nestorone 7778-18-9, Calcium sulphate 9000-30-0, Guar gum 9002-72-6, Growth hormone 9003-39-8, Povidone 9004-10-8, Insulin, biological studies 9004-32-4, Sodium carboxymethylcellulose 9004-53-9, Dextrins 9004-57-3, Ethylcellulose 9004-65-3, Hydroxypropylmethylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-63-4D, Polyoxyethylene sorbitan, esters with fatty acids 9005-65-6, Polysorbate 80 9042-14-2, Dextran sulphate 9087-70-1, Aprotinin 12619-70-4, Cyclodextrins 12794-10-4, Benzodiazepine 14611-51-9, Selegiline 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 16409-34-0, Sodium

glycodeoxycholate 18559-94-9, Salbutamol 19216-56-9, Prazosin 22071-15-4, Ketoprofen 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23674-86-4, Difluprednate 24169-02-6, Econazole nitrate 25122-46-7, Clobetasol propionate 25322-68-3, Polyethylene glycol 25655-41-8, Povidone Iodine 25717-80-0, Molsidomine 28981-97-7, Alprozolam 29205-06-9, Fluocortolone pivalate 29679-58-1, Fenoprofen 29984-33-6, Vidarabine monophosphate 34580-13-7, Ketotifen 36322-90-4, Piroxicam 36505-84-7, Buspirone 38304-91-5, Minoxidil 39219-28-8, Promestriene 39404-33-6, Dextrates 39809-25-1, Penciclovir 41570-61-0, Tulobuterol 51022-69-6, Amcinonide 52485-79-7, Buprenorphine 53016-31-2, Norelgestromin 59198-70-8, Diflucortolone Valerate 59227-89-3, Azone 59277-89-3, Acyclovir 60282-87-3, Gestodene 65277-42-1, Ketoconazole 66104-22-1, Pergolide 66734-13-2, Alclometasone dipropionate 72522-13-5, Eptazocine 74103-06-3, Ketorolac 80214-83-1, Roxithromycin 99011-02-6, Imiquimod 99755-59-6, Rotigotine 106685-40-9, Adapalene 113775-47-6, Dexmedetomidine 118292-40-3, Tazarotene 119141-88-7, Esomeprazole 122852-42-0, Alosetron 129722-12-9, Aripiprazole 133099-04-4, Darifenacin 137234-62-9, Voriconazole 141563-69-1, Orzel 143322-58-1, Eletriptan 145158-71-0, Tegaserod 145209-50-3, Thiatolserine 145375-43-5, Mitiglinide 147511-69-1, Pitavastatin 147657-22-5, Calcipotriol monohydrate 153259-65-5, Cilomilast 154189-24-9, Viozan 159776-70-2, Melagatran 163222-33-1 167305-00-2, Omapatrilat 178979-85-6, Capravirine 179463-17-3, Caspofungin acetate 181695-72-7, Valdecoxib 198470-84-7, Parecoxib 202409-33-4, Etoricoxib 287714-41-4, Rosuvastatin 552881-25-1, Crilanomer

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of immediate-release powder in pharmaceutical and nutraceutical compns.)

L9 ANSWER 18 OF 38 CA COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 138:343864 CA
TITLE: In vivo delivery methods and compositions
INVENTOR(S): Kensey, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030078517	A1	20030424	US 2001-839785	20010420 <--
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,

MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

HU	2001000201	A2	20010528	HU 2001-201	19980826 <--
HU	2001000201	A3	20040329		
NZ	502905	A	20010831	NZ 1998-502905	19980826 <--
JP	2001514384	T	20010911	JP 2000-507994	19980826 <--
US	6322524	B1	20011127	US 1999-439795	19991112 <--
US	6322525	B1	20011127	US 2000-501856	20000210 <--
NO	2000000944	A	20000225	NO 2000-944	20000225 <--
MX	200002073	A	20010821	MX 2000-2073	20000228 <--
US	6428488	B1	20020806	US 2000-615340	20000712 <--
WO	2002009583	A2	20020207	WO 2001-US23696	20010730 <--
WO	2002009583	A3	20020425		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO	2002043806	A2	20020606	WO 2001-US44352	20011127 <--
WO	2002043806	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2002026986	A	20020611	AU 2002-26986	20011127 <--
US	20020088953	A1	20020711	US 2001-33841	20011227 <--
US	6624435	B2	20030923		
WO	2002079778	A2	20021010	WO 2002-US3984	20020207 <--
WO	2002079778	A3	20030710		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20020184941	A1	20021212	US 2002-156165	20020528 <--
US	6571608	B2	20030603		

PRIORITY APPLN. INFO.:

US 1997-919906	A2	19970828
US 1999-439795	A2	19991112
US 2000-501856	A2	20000210
US 2000-628401	A2	20000801
US 2000-727950	B2	20001201
US 2001-819924	A2	20010328
US 1997-966076	A	19971107
WO 1998-US17657	W	19980826

US 2000-615340	A3	20000712
US 2000-228612P	P	20000828
US 2001-789350	B2	20010221
US 2001-828761	A	20010409
US 2001-839785	A	20010420
US 2001-841389	A	20010424
US 2001-897164	A3	20010702
WO 2001-US44352	W	20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least 1 drug. Agents effective to regulate at least 1 of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

PI US 20030078517 A1 20030424

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20030078517	A1	20030424	US 2001-839785	20010420	<--
	US 6019735	A	20000201	US 1997-919906	19970828	<--
	CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
	WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	HU 2001000201	A2	20010528	HU 2001-201	19980826	<--
	HU 2001000201	A3	20040329			
	NZ 502905	A	20010831	NZ 1998-502905	19980826	<--
	JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
	US 6322524	B1	20011127	US 1999-439795	19991112	<--
	US 6322525	B1	20011127	US 2000-501856	20000210	<--
	NO 2000000944	A	20000225	NO 2000-944	20000225	<--
	MX 200002073	A	20010821	MX 2000-2073	20000228	<--
	US 6428488	B1	20020806	US 2000-615340	20000712	<--
	WO 2002009583	A2	20020207	WO 2001-US23696	20010730	<--
	WO 2002009583	A3	20020425			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	WO 2002043806	A2	20020606	WO 2001-US44352	20011127	<--
	WO 2002043806	A3	20030327			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,					

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002026986 A 20020611 AU 2002-26986 20011127 <--
US 20020088953 A1 20020711 US 2001-33841 20011227 <--
US 6624435 B2 20030923
WO 2002079778 A2 20021010 WO 2002-US3984 20020207 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

US 20020184941 A1 20021212 US 2002-156165 20020528 <--
US 6571608 B2 20030603

IT Adrenoceptor antagonists
Agglutination
Animal tissue
Antiarrhythmics
Anticholesteremic agents
Anticoagulants
Antidiabetic agents
Antihypertensives
Antiobesity agents
Appetite depressants
Artery, disease
Blood
Blood coagulation
Calcium channel blockers
Dietary supplements
Electrolytes
Erythrocyte
Heart
Human
Hypolipemic agents
Lubricants
Organ, animal
Platelet aggregation
Platelet aggregation inhibitors
Shear
Shear stress
Surfactants
Thixotropy
Thrombus
Tobacco products
Vasodilators

Viscosity
β-Adrenoceptor antagonists
(in vivo delivery methods and compns.)

IT 50-28-2, Estradiol, biological studies 50-78-2, Aspirin 52-01-7, Spironolactone 52-53-9, Verapamil 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol 57-83-0, Progestin, biological studies 58-32-2, Dipyridamole 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-66-5, Acetazolamide 68-22-4, Norethindrone 69-65-8, Mannitol 70-51-9 72-33-3, Mestranol 81-81-2, Warfarin 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate 94-20-2, Chlorpropamide 122-09-8, Phentermine 396-01-0, Triamterene 520-85-4, Medroxyprogesterone 525-66-6, Propranolol 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin 797-63-7, Levonorgestrel 1156-19-0, Tolazamide 1231-93-2, Ethynodiol 2098-66-0, Cyproterone 3056-17-5, Stavudine 3930-20-9, Sotalol 4291-63-8, Cladribine 6533-00-2, Norgestrel 7631-86-9, Silicon dioxide, biological studies 8001-27-2, Hirudin 9000-69-5, Pectin 9000-94-6, Antithrombin III 9002-01-1, Streptokinase 9002-18-0, Agar 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-67-5, Methylcellulose 9005-27-0, Hetastarch 9007-12-9, Calcitonin 9039-53-6, Urokinase 10238-21-8, Glyburide 11041-12-6, Cholestyramine 12650-69-0, Mupirocin 13523-86-9, Pindolol 14808-79-8, Sulfate, biological studies 15291-77-7, Ginkgolide B 15307-86-5, Diclofenac 16051-77-7, Isosorbide mononitrate 17560-51-9, Metolazone 18559-94-9, Salbutamol 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 24967-94-0, Dermatan sulfate 25322-68-3, Polyethylene glycol 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 26839-75-8, Timolol 28395-03-1, Bumetanide 28523-86-6, Sevoflurane 28721-07-5, Oxcarbazepine 29094-61-9, Glipizide 29122-68-7, Atenolol 29457-07-6, Ticarcillin disodium 30516-87-1, Zidovudine 32222-06-3, Calcitriol 34391-04-3, Levosalbutamol 34580-13-7, Ketotifen 34911-55-2, Bupropion 35189-28-7, Norgestimate 38304-91-5, Minoxidil 39562-70-4, Nitrendipine 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 47141-42-4, Levobunolol 49562-28-9, Fenofibrate 50925-79-6, Colestipol 51333-22-3, Budesonide 51384-51-1, Metoprolol 54024-22-5, Desogestrel 55142-85-3, Ticlopidine 55985-32-5, Nicardipine 56180-94-0, Acarbose 56211-40-6, Torsemide 56420-45-2, Epirubicin 59122-46-2, Misoprostol 60282-87-3, Gestodene 62571-86-2, Captopril 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64706-54-3, Bepridil 66085-59-4, Nimodipine 66722-44-9, Bisoprolol 67227-56-9, Fenoldopam 68252-19-7, Pirmenol 68291-97-4, Zonisamide 69655-05-6, Didanosine 71119-11-4, Bucindolol 71486-22-1, Vinorelbine 72509-76-3, Felodipine 72956-09-3, Carvedilol 73573-87-2, Formoterol 73963-72-1, Cilostazol 74191-85-8, Doxazosin 74863-84-6, Argatroban 75330-75-5, Lovastatin 75695-93-1, Isradipine 75847-73-3, Enalapril 76547-98-3, Lisinopril 77191-36-7, Nefiracetam 78415-72-2, Milrinone 79350-37-1, Cefixime 79902-63-9, Simvastatin 80474-14-2, FLuticasone propionate 81732-65-2, Bambuterol 82410-32-0, Ganciclovir 83869-56-1, GM-CSF 84057-84-1, Lamotrigine 84057-95-4, Ropivacaine 84449-90-1, Raloxifene 84625-59-2, Dotarizine 85441-61-8, Quinapril 86541-75-5, Benazepril 86780-90-7, Aranidipine 87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6, Trandolapril 88150-42-9, Amlodipine 89565-68-4, Tropisetron 90729-41-2, Oxodipine 92665-29-7, Cefprozil 93221-48-8, Levobetaxolol 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 94535-50-9, Lemakalim 94739-29-4, Lemildipine 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96125-53-0, Clentiazem

96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 97682-44-5, Irinotecan 98048-97-6, Fosinopril 99522-79-9, Pranidipine 100427-26-7, Lercanidipine 100986-85-4, Levofloxacin 101526-83-4, Sematilide 103577-45-3, Lansoprazole 103745-39-7, Fasudil 103890-78-4, Lacidipine 104713-75-9, Barnidipine 105816-04-4, Nateglinide 105857-23-6, Alteplase 105979-17-7, Benidipine 106650-56-0, Sibutramine 107452-89-1, Ziconotide 109889-09-0, Granisetron 111025-46-8, Pioglitazone 112809-51-5, Letrozole 113665-84-2, Clopidogrel 113806-05-6, Olopatadine 114432-13-2, Fantofarone 114798-26-4, Losartan 114870-03-0, Fondaparinux sodium 115103-54-3, Tiagabine 115256-11-6, Dofetilide 116308-55-5, Watanidipine 117279-73-9, Israpafant 118457-14-0, Nebivolol 119684-05-8, Mesoglycan 120511-73-1, Anastrozole 120993-53-5, Desirudin 121181-53-1, Filgrastim 121679-13-8, Naratriptan 122647-31-8, Ibutilide 123524-52-7, Azelnidipine 123774-72-1, Sargramostim 123948-87-8, Topotecan 124750-99-8, Losartan potassium 124832-26-4, Valacyclovir 124937-51-5, Tolterodine 128270-60-0, Bivalirudin 128470-16-6, Arbutamine 129618-40-2, Nevirapine 130209-82-4, Latanoprost 130636-43-0, Nifekalant 131179-95-8, RSR 13 132579-32-9, Rocepafant 132875-61-7, Remifentanil 133040-01-4, Eprosartan 133242-30-5, Landiolol 133652-38-7, Reteplase 134308-13-7, Tolcapone 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 134865-37-5, Meluadrine tartrate 135062-02-1, Repaglinide 136468-36-5, Foropafant 137862-53-4, Valsartan 138068-37-8, Lepirudin 138402-11-6, Irbesartan 138661-03-7, Furnidipine 143653-53-6, Abciximab 144494-65-5, Tirofiban 144689-24-7, Olmesartan 144701-48-4, Telmisartan 145040-37-5, Candesartan cilexetil 145375-43-5, Mitiglinide 145599-86-6, Cerivastatin 147059-72-1, Trovafloxacin 147511-69-1, Pitavastatin 148883-56-1, Tifacogin 149908-53-2, Azimilide 150332-35-7, Pamaqueside 154189-24-9, ARC 68397AA 158876-82-5, Rupatadine 159776-70-2, Melagatran 170902-47-3, Roxifiban 173324-94-2, Temiverine 187523-35-9, BMS 204352 187741-48-6, CHF 1521 188627-80-7, Eptifibatide 192939-46-1, H376/95 210101-16-9, Conivaptan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo delivery methods and compns.)

L9 ANSWER 19 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:281598 CA
TITLE: Androstane compounds as androgen receptor (AR) modulators for the treatment of AR-related diseases
INVENTOR(S): Wang, Jiabing
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026568	A2	20030403	WO 2002-US29436	20020917 <--
WO 2003026568	A3	20040226		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2459943	A1	20030403	CA 2002-2459943	20020917	<--
AU 2002330031	A1	20030407	AU 2002-330031	20020917	<--
AU 2002330031	B2	20070705			
EP 1429779	A2	20040623	EP 2002-766288	20020917	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005507886	T	20050324	JP 2003-530207	20020917	
US 20040235808	A1	20041125	US 2004-489072	20040308	
PRIORITY APPLN. INFO.:			US 2001-324124P	P 20010921	
			WO 2002-US29436	W 20020917	

OTHER SOURCE(S): MARPAT 138:281598

GI



I

AB Compds. of structural formula (I) as herein defined are claimed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compds. are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, inflammatory arthritis and joint repair, alone or in combination with other active agents. Methods for the co-administration of those compds. with bone-strengthening agents are also claimed.

PI WO 2003026568 A2 20030403

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2003026568	A2	20030403	WO 2002-US29436	20020917 <--
	WO 2003026568	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2459943	A1	20030403	CA 2002-2459943	20020917 <--
	AU 2002330031	A1	20030407	AU 2002-330031	20020917 <--
	AU 2002330031	B2	20070705		
	EP 1429779	A2	20040623	EP 2002-766288	20020917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005507886	T	20050324	JP 2003-530207	20020917
	US 20040235808	A1	20041125	US 2004-489072	20040308

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium, antagonists; androstane compds. as androgen receptor (AR) modulators in conjunction with bone-strengthening agents for treatment of AR-related diseases)

IT 50-28-2, 17β-Estradiol, biological studies 53-16-7, Estrone, biological studies 57-83-0, Progestin, biological studies 57-83-0D, Progestin, derivs. 64-96-0, U 11555A 67-96-9, Dihydrotachysterol 67-98-1, Mer-25 68-22-4, Norethindrone 71-58-9, Medroxyprogesterone acetate 436-52-2, U 11555A 471-34-1, Calcium carbonate, biological studies 911-45-5, Clomiphene 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, derivs. 1845-11-0, Nafoxidine 2809-21-4 4717-38-8, 17β-Ethynyl estradiol 5863-35-4, CI-628 7440-70-2, Calcium, biological studies 7440-70-2D, Calcium, salts 7681-49-4, Sodium fluoride, biological studies 7693-13-2, Calcium citrate 9002-64-6, Parathyroid hormone 9002-64-6D, Parathyroid hormone, analogs 9007-12-9, Calcitonin 10540-29-1, Tamoxifen 10596-23-3 12001-79-5, Vitamin K 12001-79-5D, Vitamin K, derivs. 15690-55-8, Zuclomiphene 15690-57-0, Enclomiphene 16984-48-8D, Fluoride, salts 19356-17-3 20859-36-3, Monosodium fluorophosphate 32222-06-3 35212-22-7, Ipriflavone 40391-99-9 41294-56-8 47931-85-1, Salmon calcitonin 52232-67-4, Human parathormone 1-34 54573-75-0 56287-31-1, CI-680 57333-95-6 57333-96-7 61912-98-9, Insulin-like growth factor 62031-54-3, Fibroblast growth factor 63132-39-8 66376-36-1 67763-96-6, IGF I 67763-97-7, IGF II 68893-82-3, Human parathormone 1-84 75330-75-5, Lovastatin 75755-07-6 78994-23-7, Levormeloxifene 79778-41-9 79902-63-9, Simvastatin 81093-37-0, Pravastatin 82413-20-5, Droloxifene 83805-11-2 84449-90-1, Raloxifene 89778-26-7, Toremifene 89987-06-4 93957-54-1, Fluvastatin 103909-75-7, 22-Oxacalcitriol 104121-92-8, ED71 105462-24-6 106096-92-8, Acidic Fibroblast Growth Factor 106096-93-9, Basic fibroblast growth factor 112965-21-6, Calcipotriol 114084-78-5 116057-75-1, Idoxifene 118072-93-8 118694-43-2, Ro 23-7553 121009-77-6 121268-17-5, Alendronate monosodium trihydrate 124351-85-5 125946-91-0 130447-37-9 131875-08-6, KH1060 134404-52-7, EB1089 134523-00-5, Atorvastatin

134523-84-5 141750-63-2, Nisvastatin 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 180064-38-4 180916-16-9, Lasofoxifene 182167-02-8, EM-652 182167-03-9, EM-800 187483-31-4, U-100A 193830-08-9, GDF5 198481-33-3, TSE 424 287714-41-4, Rosuvastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androstane compds. as androgen receptor (AR) modulators in conjunction with bone-strengthening agents for treatment of AR-related diseases)

L9 ANSWER 20 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:231777 CA
TITLE: Use of statins to inhibit formation of osteoclasts
INVENTOR(S): Baragi, Vijaykumar M.; Devalaraja, Radhika; Peters, Brandon R.; Renkiewicz, Richard Raymond
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
EP 1291017	A2	20030312	EP 2002-19026	20020827	<--
EP 1291017	A3	20030702			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CN 1403081	A	20030319	CN 2002-132146	20020903	<--
NZ 521188	A	20040625	NZ 2002-521188	20020904	
TW 226238	B	20050111	TW 2002-91120188	20020904	
CA 2401319	A1	20030310	CA 2002-2401319	20020905	<--
AU 2002300900	A1	20030612	AU 2002-300900	20020906	<--
BR 2002003656	A	20030603	BR 2002-3656	20020909	<--
HU 2002002969	A2	20030728	HU 2002-2969	20020909	<--
HU 2002002969	A3	20040830			
ZA 2002007233	A	20040309	ZA 2002-7233	20020909	
US 20030055101	A1	20030320	US 2002-238266	20020910	<--
JP 2003104883	A	20030409	JP 2002-264412	20020910	<--

PRIORITY APPLN. INFO.: US 2001-318450P P 20010910

AB A method for inhibiting the formation of osteoclasts comprising administering a therapeutically effective amount of a statin to a mammal in need thereof as well as pharmaceutical compns., kits for containing such compns. comprising a statin or a method of treating or preventing a disease state selected from the group consisting of: osteoporosis, Paget's disease, osteolysis, hypercalcemia of malignancy, osteogenesis imperfecta, osteoarthritis, alveolar bone loss, side effects of immunosuppressive therapy, and side effects of chronic glucocorticoid use by inhibiting the formation of osteoclasts comprising administering a therapeutically effective amount of a statin to a mammal in need thereof.

PI EP 1291017 A2 20030312

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI EP 1291017	A2	20030312	EP 2002-19026	20020827	<--
EP 1291017	A3	20030702			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,					

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

CN 1403081	A	20030319	CN 2002-132146	20020903	<--
NZ 521188	A	20040625	NZ 2002-521188	20020904	
TW 226238	B	20050111	TW 2002-91120188	20020904	
CA 2401319	A1	20030310	CA 2002-2401319	20020905	<--
AU 2002300900	A1	20030612	AU 2002-300900	20020906	<--
BR 2002003656	A	20030603	BR 2002-3656	20020909	<--
HU 2002002969	A2	20030728	HU 2002-2969	20020909	<--
HU 2002002969	A3	20040830			
ZA 2002007233	A	20040309	ZA 2002-7233	20020909	
US 20030055101	A1	20030320	US 2002-238266	20020910	<--
JP 2003104883	A	20030409	JP 2002-264412	20020910	<--

IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia; use of statins to inhibit formation of osteoclasts)

IT 73573-88-3, Mevastatin 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin calcium 145599-86-6, Cerivastatin 147511-69-1 287714-41-4, Rosuvastatin 501121-34-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of statins to inhibit formation of osteoclasts)

L9 ANSWER 21 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:204870 CA
TITLE: Processes for preparing calcium salt forms of statins
INVENTOR(S): Niddam-Hildesheim, Valerie; Lifshitz-Liron, Revital; Lidor-Hadas, Rami
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2003016317	A1	20030227	WO 2002-US26012	20020816	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20020099224	A1	20020725	US 2001-37412	20011024	<--
US 6528661	B2	20030304			
CA 2450820	A1	20030227	CA 2002-2450820	20020816	<--
AU 2002324715	A1	20030303	AU 2002-324715	20020816	<--
US 20030114685	A1	20030619	US 2002-222556	20020816	<--

US 6777552	B2	20040817			
EP 1425287	A1	20040609	EP 2002-759374		20020816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
TR 200302281	T2	20040921	TR 2003-2281		20020816
CN 1543468	A	20041103	CN 2002-815999		20020816
JP 2005500382	T	20050106	JP 2003-521239		20020816
NZ 529913	A	20050324	NZ 2002-529913		20020816
HU 2005000616	A2	20051128	HU 2005-616		20020816
ZA 2003009373	A	20041202	ZA 2003-9373		20031202
IN 2003MN01112	A	20050429	IN 2003-MN1112		20031205
MX 2004PA01451	A	20050217	MX 2004-PA1451		20040213
NO 2004001082	A	20040315	NO 2004-1082		20040315
US 20040176615	A1	20040909	US 2004-803414		20040318
US 20050197501	A1	20050908	US 2005-120567		20050502
AU 2007205725	A1	20070830	AU 2007-205725		20070809
PRIORITY APPLN. INFO.:			US 2001-312812P	P	20010816
			US 2001-37412	A	20011024
			US 2000-249319P	P	20001116
			US 2001-312144P	P	20010813
			US 2001-326529P	P	20011001
			AU 2002-17927	T0	20011129
			AU 2002-217927	A3	20011129
			US 2002-222556	A3	20020816
			WO 2002-US26012	W	20020816
			US 2004-803414	A1	20040318

OTHER SOURCE(S): MARPAT 138:204870

GI



I

AB Processes for preparing hemicalcium salts of a statins RCH(OH)CH2CH(OH)CH2CO2H (R = statin organic radical selected from pravastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin, pitavastatin, simvastatin, or lovastatin) from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected satin ester derivative, the protecting group is hydrolyzed during salt formation by contact with

calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide. Thus, diol-protected atorvastatin ester I (R = CMe3, R3R5 = CMe2) was treated with an 80% aqueous soln of AcOH at rt for 20 h to form the deprotected ester I (R = CMe3, R3 = R5 = H) which was in turn dissolved in EtOH, treated with a saturated soln of Ca(OH)2 containing Bu4N+Br- and stirred at 45° for 24 h to give atorvastatin hemicalcium salt I (R = 1/2Ca, R3 = R5 = H) in 77% yield for the two steps.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Processes for preparing calcium salt forms of statins

PI WO 2003016317 A1 20030227

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003016317	A1	20030227	WO 2002-US26012	20020816 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020099224	A1	20020725	US 2001-37412	20011024 <--
US 6528661	B2	20030304		
CA 2450820	A1	20030227	CA 2002-2450820	20020816 <--
AU 2002324715	A1	20030303	AU 2002-324715	20020816 <--
US 20030114685	A1	20030619	US 2002-222556	20020816 <--
US 6777552	B2	20040817		
EP 1425287	A1	20040609	EP 2002-759374	20020816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
TR 200302281	T2	20040921	TR 2003-2281	20020816
CN 1543468	A	20041103	CN 2002-815999	20020816
JP 2005500382	T	20050106	JP 2003-521239	20020816
NZ 529913	A	20050324	NZ 2002-529913	20020816
HU 2005000616	A2	20051128	HU 2005-616	20020816
ZA 2003009373	A	20041202	ZA 2003-9373	20031202
IN 2003MN01112	A	20050429	IN 2003-MN1112	20031205
MX 2004PA01451	A	20050217	MX 2004-PA1451	20040213
NO 2004001082	A	20040315	NO 2004-1082	20040315
US 20040176615	A1	20040909	US 2004-803414	20040318
US 20050197501	A1	20050908	US 2005-120567	20050502
AU 2007205725	A1	20070830	AU 2007-205725	20070809

AB . . . cerivastatin, atorvastatin, rosuvastatin, pitavastatin, simvastatin, or lovastatin) from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected satin ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide. Thus, diol-protected atorvastatin ester I (R =

CMe3, R3R5 = CMe2) was treated with an 80% aqueous soln of. . . = CMe3, R3 = R5 = H) which was in turn dissolved in EtOH, treated with a saturated soln of Ca(OH)2 containing Bu4N+Br- and stirred at 45° for 24 h to give atorvastatin hemicalcium salt I (R = 1/2Ca, R3 =. . .

ST statin calcium salt prepn; rosuvastatin hemicalcium salt prepn; pitavastatin hemicalcium salt prepn; atorvastatin hemicalcium salt prepn; simvastatin hemicalcium salt prepn; lovastatin hemicalcium. . .

IT 134395-00-9P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(processes for preparing calcium salt forms of statins)

IT 77550-72-2P, Lovastatin hemicalcium 125995-03-1P, Atorvastatin lactone 134523-00-5P, Atorvastatin 134523-03-8P, Atorvastatin hemicalcium 141750-63-2P, Pitavastatin lactone 147098-20-2P, Rosuvastatin hemicalcium 147526-32-7P, Pitavastatin hemicalcium 151006-06-3P, Pravastatin hemicalcium 151006-18-7P, Simvastatin hemicalcium 500103-16-2P, Fluvastatin hemicalcium 500103-17-3P, Cerivastatin hemicalcium
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(processes for preparing calcium salt forms of statins)

IT 125971-95-1 147118-40-9 167073-19-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(processes for preparing calcium salt forms of statins)

IT 1305-62-0, Calcium hydroxide, reactions
RL: RGT (Reagent); RACT (Reactant or reagent)
(processes for preparing calcium salt forms of statins)

L9 ANSWER 22 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:14048 CA
TITLE: Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T.; Jeon, Yoon; Wang, Wei
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523 <--
WO 2002096357	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030092697 A1 20030515 US 2002-153342 20020522 <--

US 7105556	B2	20060912			
CA 2449006	A1	20021205	CA 2002-2449006	20020523	<--
AU 2002310141	A1	20021209	AU 2002-310141	20020523	<--
EP 1401433	A2	20040331	EP 2002-737192	20020523	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005506954	T	20050310	JP 2002-592870	20020523	
HU 2006000226	A2	20061128	HU 2006-226	20020523	
US 20060189598	A1	20060824	US 2006-406799	20060419	
PRIORITY APPLN. INFO.:			US 2001-294505P	P 20010530	
			US 2002-153342	A3 20020522	
			WO 2002-US16628	W 20020523	

OTHER SOURCE(S): MARPAT 138:14048

GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, with an alkenyl or alkynyl bond in the chain, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; provided that ≥1 of x2 and x3 ≠ 0; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that ≥1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = (CH2)x4, (CH2)x5, (CH2)x6O(CH2)x7; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepared as antidiabetic and antiobesity agents (no data). Thus, the title compound (II) was prepared in 6 steps.

PI WO 2002096357 A2 20021205

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2002096357	A2	20021205	WO 2002-US16628	20020523 <--
	WO 2002096357	A3	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20030092697	A1	20030515	US 2002-153342	20020522 <--
	US 7105556	B2	20060912		
	CA 2449006	A1	20021205	CA 2002-2449006	20020523 <--
	AU 2002310141	A1	20021209	AU 2002-310141	20020523 <--
	EP 1401433	A2	20040331	EP 2002-737192	20020523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005506954	T	20050310	JP 2002-592870	20020523
	HU 2006000226	A2	20061128	HU 2006-226	20020523
	US 20060189598	A1	20060824	US 2006-406799	20060419

IT Angiotensin receptor antagonists
Antiosteoporotic agents
Appetite depressants
Calcium channel blockers
Platelet aggregation inhibitors
β-Adrenoceptor antagonists
β3-Adrenoceptor agonists
RL: BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 58-32-2, Dipyridamole 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 4205-91-8, Clonidine hydrochloride 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol 49562-28-9, Fenofibrate 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS 962 145599-86-6, Cerivastatin 147511-69-1 152755-31-2, LY 295427 159183-92-3, L 750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 166518-60-1,

Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS 30440 170861-63-9, JTT 501 176435-10-2, LY 315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4, GI 262570 199113-98-9, NN 2344 199914-96-0, YM 440 213252-19-8, KRP 297 244081-42-3, AJ 9677 251565-85-2, AR-H 039242 251572-86-8, P 32/98 258345-41-4, GW 409544 282526-98-1, ATL 962 287714-41-4 335149-08-1, L 895645 335149-14-9, R 119702 335149-15-0, KAD 1129 335149-23-0, NVP-DPP 728A 335149-25-2, CP 331648 430433-17-3, Glipyride 444069-80-1, Axokine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)

L9 ANSWER 23 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:337790 CA
TITLE: Preparation of 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid as remedial agent for glomerular disease
INVENTOR(S): Nakagawa, Takashi; Suda, Makoto; Yamauchi, Youichi
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085363	A1	20021031	WO 2002-JP3870	20020418 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002251483	A1	20021105	AU 2002-251483	20020418 <--
EP 1386608	A1	20040204	EP 2002-720493	20020418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040116468	A1	20040617	US 2003-474194	20031016
PRIORITY APPLN. INFO.:			JP 2001-121058	A 20010419
			JP 2001-361257	A 20011127
			WO 2002-JP3870	W 20020418

GI



I

AB Disclosed is a preventive or remedy for glomerular diseases which contains as the active ingredient the compound represented by the following formula (I) or a salt of the compound The preventive or remedy is useful as a preventive or remedy for various glomerular diseases including IgA kidney disease, glomerulosclerosis, membranous nephropathy, membranous proliferative nephritis, and chronic glomerulonephritis. The compound I is known to possess excellent HMG-CoA reductase inhibitory activity (no data). Thus, calcium bis[(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate] (II) was prepared via conversion of 2-amino-4'-fluorobenzophenone into Me 3-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate by the known procedures. II showed IC50 of 22.4 μM for inhibiting the production of phosphatidylinositol 4-phosphate (PIP) stimulated by TGF-β1 in human glomerular interstitial cell CryoNHMC (mesangium cell).

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2002085363 A1 20021031

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002085363	A1	20021031	WO 2002-JP3870	20020418	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	AU 2002251483	A1	20021105	AU 2002-251483	20020418	<--
	EP 1386608	A1	20040204	EP 2002-720493	20020418	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	US 20040116468	A1	20040617	US 2003-474194	20031016	

AB . . . proliferative nephritis, and chronic glomerulonephritis. The compound I is known to possess excellent HMG-CoA reductase inhibitory activity (no data). Thus, calcium bis[(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate] (II) was prepared via conversion of 2-amino-4'-fluorobenzophenone into Me 3-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate by the known procedures. II showed IC50 of 22.4. . .

IT 121659-03-8P, 7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid 147511-69-1P, (+)-(3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid 147526-32-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [cyclopropyl(fluorophenyl)quinolyl]hydroxyheptenoic acid as remedial agent for glomerular diseases)

L9 ANSWER 24 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:299919 CA
TITLE: Stable pharmaceutical composition containing NK-104
INVENTOR(S): Muramatsu, Toyojiro; Mashita, Katsumi; Shinoda, Yasuo; Sassa, Hironori; Kawashima, Hiroyuki; Tanizawa, Yoshio; Takeuchi, Hideatsu
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 894,279, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6465477	B1	20021015	US 1999-436789	19991108 <--
PRIORITY APPLN. INFO.:			JP 1995-354654 A	19951222
			US 1997-894279 B2	19970818

AB A pharmaceutical composition comprises (E)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2'-cyclopropylquinolin-3'-yl]-6-heptenoic acid (NK-104) or its salt or ester, of which the aqueous solution or dispersion has a pH of 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long. Tablets contained calcium salt of NK-104 1.0, lactose 101.4, low substituted hydroxypropyl cellulose 12.0, hydroxypropyl Me cellulose-2910 2.0, Mg aluminometasilicate 2.4, and Mg stearate 1.2 mg/tablet.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
PI US 6465477 B1 20021015

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6465477	B1	20021015	US 1999-436789	19991108 <--

AB . . . has good time-dependent stability and has no change in its outward appearance even after having been stored long. Tablets contained calcium salt of NK-104 1.0, lactose 101.4, low substituted hydroxypropyl cellulose 12.0, hydroxypropyl Me cellulose-2910 2.0, Mg aluminometasilicate 2.4, and Mg. . .
IT 147511-69-1, NK 104 468064-55-3
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable pharmaceutical composition containing NK-104)

L9 ANSWER 25 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:118852 CA

TITLE: Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor
AUTHOR(S): Isley, William L.
CORPORATE SOURCE: Saint Luke's Lipid and Diabetes Research Center, University of Missouri, Kansas City, MO, 64111, USA
SOURCE: Drugs of Today (2001), 37(9), 587-594
CODEN: MDACAP; ISSN: 0025-7656
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Pitavastatin calcium (NK-104) is a new synthetic hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statin). Animal studies suggest that, in addition to reducing low-d. lipoprotein (LDL) cholesterol, the drug may produce marked redns. in triglyceride-rich particles (very-low-d. [VLDL] and intermediate-d. lipoproteins [IDL]). It is not metabolized by the common cytochrome P 450 3A4 enzyme, possibly reducing the risk for drug interactions. Early studies suggest that it may be quite useful for treating common dyslipidemias (isolated elevations of LDL cholesterol and combined disorders with elevations of LDL cholesterol and triglycerides). Such improvements in lipid profiles are proven to have pos. effects on cardiovascular risk. Human studies are under way to further elucidate the effects of the drug and procure approval by various regulatory bodies.
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
SO Drugs of Today (2001), 37(9), 587-594
CODEN: MDACAP; ISSN: 0025-7656
AB A review. Pitavastatin calcium (NK-104) is a new synthetic hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statin). Animal studies suggest that, in addition to reducing low-d. lipoprotein. . .
IT 147526-32-7, NK-104
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pitavastatin is a new HMG-CoA reductase inhibitor)

L9 ANSWER 26 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:109267 CA
TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20020094977	A1	20020718	US 2001-7407		20011204	<--
US 6627636	B2	20030930				
US 20020013334	A1	20020131	US 2001-875155		20010606	<--
PRIORITY APPLN. INFO.:			US 2000-211595P	P	20000615	
			US 2001-875155	A2	20010606	

OTHER SOURCE(S): MARPAT 137:109267

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO2, NR7; Z = HOCHCH2CH(OH)CH2CO2R3, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H, alkyl, metal ion; R4 = H, halo, CF3, etc.; R7 = H, alkyl, aryl, alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis (no data). A multistep synthesis of II is reported.

PI US 20020094977 A1 20020718

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20020094977	A1	20020718	US 2001-7407	20011204	<--
US 6627636	B2	20030930			
US 20020013334	A1	20020131	US 2001-875155	20010606	<--

IT Calcium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(T-type, blockers, coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium, antagonists, coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT 5-HT reuptake inhibitors
Angiotensin receptor antagonists
Anti-Alzheimer's agents
Anti-infective agents
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antiarthritics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antioxidants
Antitumor agents
Appetite depressants
Calcium channel blockers
Cardiovascular agents
Diuretics
Hormone replacement therapy
Hypolipemic agents
Immunomodulators
α-Adrenoceptor antagonists
β-Adrenoceptor antagonists

β3-Adrenoceptor agonists
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-01-7, Spironolactone 52-53-9, Verapamil 54-31-9, Furosemide 58-32-2, Dipyridamole 58-93-5, Hydrochlorothiazide 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 564-25-0, Doxycycline 637-07-0, Clofibrate 657-24-9, Metformin 1684-40-8, Tacrine hydrochloride 3416-24-8, Glucosamine 4205-91-8, Clonidine hydrochloride 9004-61-9, Hyaluronic acid 9007-28-7, Chondroitin sulfate 10118-90-8, Minocycline 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 29094-61-9, Glipizide 29122-68-7, Atenolol 42200-33-9, Nadolol 49562-28-9, Fenofibrate 55142-85-3, Ticlopidine 56180-94-0, Acarbose 56211-40-6, Torasemide 62571-86-2, Captopril 68475-42-3, Anagrelide 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89750-14-1, Glucagon-like peptide I 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 113665-84-2, Clopidogrel 114798-26-4, Losartan 120014-06-4, Donepezil 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC 2993 143443-90-7, Ifetroban 143653-53-6, Abciximab 144288-97-1, TS 962 144494-65-5, Tirofiban 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 152755-31-2, LY 295427 159183-92-3, L 750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 162011-90-7, Vioxx 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS 30440 169590-42-5, Celebrex 170861-63-9, JTT 501 176435-10-2, LY 315902 178759-95-0, MD 700 182815-44-7, Cholestagel 188627-80-7, Eptifibatide 196808-45-4, GI 262570 199113-98-9, NN 2344 199914-96-0, YM 440 213252-19-8, KRP 297 244081-42-3, AJ 9677 246852-12-0, Amlodipine mesylate 251572-86-8, P 32/98 258345-41-4, GW 409544 282526-98-1, ATL 962 287714-41-4, Rosuvastatin 335149-08-1, L 895645 335149-14-9, R 119702 335149-15-0, KAD 1129 335149-17-2, ARHO 39242 335149-23-0, NVP-DPP 728A 335149-25-2, CP 331648 430433-17-3, Glipyride 430433-43-5, CP 644673 444069-80-1, Axokine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

L9 ANSWER 27 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:24314 CA
TITLE: Methods and apparatus for determining and utilizing the viscosity of circulating blood over a range of shear rates for diagnostics and treatment
INVENTOR(S): Kensey, Kenneth; Hokanson, Charles

PATENT ASSIGNEE(S): Visco Technologies, Inc., USA; Rheologics, Inc.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043806	A2	20020606	WO 2001-US44352	20011127 <--
WO 2002043806	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
NO 2000000944	A	20000225	NO 2000-944	20000225 <--
US 20020061835	A1	20020523	US 2001-828761	20010409 <--
US 20030078517	A1	20030424	US 2001-839785	20010420 <--
AU 2002026986	A	20020611	AU 2002-26986	20011127 <--

PRIORITY APPLN. INFO.:

US 1997-966076	A	19971107
US 2000-727950	A	20001201
US 2001-819924	A	20010328
US 2001-828761	A	20010409
US 2001-839785	A	20010420
US 1997-919906	A	19970828
WO 1998-US17657	W	19980826
US 1999-439795	A2	19991112
US 2000-501856	A2	20000210
US 2000-628401	A2	20000801
WO 2001-US44352	W	20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for

explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

PI WO 2002043806 A2 20020606

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002043806	A2	20020606	WO 2001-US44352	20011127	<--
	WO 2002043806	A3	20030327			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
	WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	HU 2001000201	A2	20010528	HU 2001-201	19980826	<--
	HU 2001000201	A3	20040329			
	NZ 502905	A	20010831	NZ 1998-502905	19980826	<--
	JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
	NO 2000000944	A	20000225	NO 2000-944	20000225	<--
	US 20020061835	A1	20020523	US 2001-828761	20010409	<--
	US 20030078517	A1	20030424	US 2001-839785	20010420	<--
	AU 2002026986	A	20020611	AU 2002-26986	20011127	<--

IT Adrenoceptor antagonists
Antiarrhythmics
Anticholesteremic agents
Anticoagulants
Antidiabetic agents
Antihypertensives
Antiobesity agents
Appetite depressants
  Calcium channel blockers
Circulation
Diuretics
Electrolytes
Hypolipemic agents
Platelet aggregation inhibitors
Vasodilators

(methods and apparatus for determining and utilizing the viscosity of circulating
blood over a range of shear rates for diagnostics and treatment)
IT 50-28-2, Estradiol, biological studies 50-78-2, Aspirin 52-01-7, Spironolactone 52-53-9, Verapamil 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinylestradiol 58-32-2, Dipyridamole 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-66-5, Acetazolamide 68-22-4, Norethindrone 69-65-8, D-Mannitol 70-51-9 72-33-3, Mestranol 81-81-2, Warfarin 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate 94-20-2, Chlorpropamide 122-09-8, Phentermine 396-01-0, Triamterene 520-85-4, Medroxyprogesterone 525-66-6, Propranolol 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin 797-63-7, Levonorgestrel 1156-19-0, Tolazamide 1231-93-2, Ethynodiol 2098-66-0, Cyproterone 3056-17-5, Stavudine 3930-20-9, Sotalol 4291-63-8, Cladribine 6533-00-2, Norgestrel 8001-27-2, Hirudin 9000-94-6, Antithrombin 9002-01-1, Streptokinase 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-54-0, Dextran, biological studies 9005-27-0, Hetastarch 9007-12-9, Calcitonin 9039-53-6, Urokinase 10238-21-8, Glyburide 11041-12-6, Cholestyramine 12650-69-0, Mupirocin 13523-86-9, Pindolol 15291-77-7, Ginkgolide b 15307-86-5, Diclofenac 16051-77-7, Isosorbide mononitrate 17560-51-9, Metolazone 18559-94-9, Salbutamol 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 26839-75-8, Timolol 28395-03-1, Bumetanide 28523-86-6, Sevoflurane 28721-07-5, Oxcarbazepine 29094-61-9, Glipizide 29122-68-7, Atenolol 29457-07-6, Ticarcillin disodium 30516-87-1, Zidovudine 32222-06-3, Calcitriol 34391-04-3, Levosalbutamol 34580-13-7, Ketotifen 34911-55-2, Bupropion 35189-28-7, Norgestimate 38304-91-5, Minoxidil 39562-70-4, Nitrendipine 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 47141-42-4, Levobunolol 49562-28-9, Fenofibrate 50925-79-6, Colestipol 51384-51-1, Metoprolol 54024-22-5, Desogestrel 55142-85-3, Ticlopidine 55985-32-5, Nicardipine 56180-94-0, Acarbose 56211-40-6, Torsemide 56420-45-2, Epirubicin 59122-46-2, Misoprostol 60202-16-6, Blood-coagulation factor XIV 60282-87-3, Gestodene 62571-86-2, Captopril 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64706-54-3, Bepridil 66085-59-4, Nimodipine 66722-44-9, Bisoprolol 67227-56-9, Fenoldopam 68252-19-7, Pirmenol 68291-97-4, Zonisamide 69655-05-6, Didanosine 71119-11-4, Bucindolol 71486-22-1, Vinorelbine 72509-76-3, Felodipine 72956-09-3, Carvedilol 73573-87-2, Formoterol 73963-72-1, Cilostazol 74191-85-8, Doxazosin 74863-84-6, Argatroban 75330-75-5, Lovastatin 75695-93-1, Isradipine 75847-73-3, Enalapril 76547-98-3, Lisinopril 77191-36-7, Nefiracetam 78415-72-2, Milrinone 79350-37-1, Cefixime 79902-63-9, Simvastatin 80474-14-2, Fluticasone propionate 81732-65-2, Bambuterol 82410-32-0, Ganciclovir 83869-56-1, GM-CSF 84057-84-1, Lamotrigine 84057-95-4, Ropivacaine 84449-90-1, Raloxifene 84625-59-2, Dotarizine 85441-61-8, Quinapril 86541-75-5, Benazepril 86780-90-7, Aranidipine 87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6, Trandolapril 88150-42-9, Amlodipine 89365-50-4, Salmeterol 89565-68-4, Tropisetron 90729-41-2, Oxodipine 92665-29-7, Cefprozil 93221-48-8, Levobetaxolol 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 94535-50-9, Lemakalim 94739-29-4, Lemildipine 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96125-53-0, Clentiazem 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 97682-44-5, Irinotecan 98048-97-6, Fosinopril 99522-79-9, Pranidipine 100427-26-7, Lercanidipine 100986-85-4,

Levofloxacin 101526-83-4, Sematilide 102786-52-7, Blood-coagulation factor VII (human clone λHVII2463 protein moiety) 103577-45-3, Lansoprazole 103745-39-7, Fasudil 103890-78-4, Lacidipine 104713-75-9, Barnidipine 105816-04-4, Nateglinide 105857-23-6, Alteplase 105979-17-7, Benidipine 106650-56-0, Sibutramine 107452-89-1, Ziconotide 109889-09-0, Granisetron 111025-46-8, Pioglitazone 112809-51-5, Letrozole 113665-84-2, Clopidogrel 113806-05-6, Olopatadine 114432-13-2, Fantofarone 114798-26-4, Losartan 114870-03-0, Fondaparinux sodium 115103-54-3, Tiagabine 115256-11-6, Dofetilide 116308-55-5, Watanidipine 117279-73-9, Israpafant 118457-14-0, Nebivolol 119684-05-8, Mesoglycan 120511-73-1, Anastrozole 120993-53-5, Desirudin 121181-53-1, Filgrastim 121679-13-8, Naratriptan 122647-31-8, Ibutilide 123524-52-7, Azelnidipine 123774-72-1, Leukine 123948-87-8, Topotecan 124750-99-8, Losartan potassium 124832-26-4, Valacyclovir 124937-51-5, Tolterodine 128270-60-0, Bivalirudin 128470-16-6, Arbutamine 129618-40-2, Nevirapine 130209-82-4, Latanoprost 130636-43-0, Nifekalant 131179-95-8, RSR 13 132579-32-9, Rocepafant 132875-61-7, Remifentanil 133040-01-4, Eprosartan 133242-30-5, Landiolol 133652-38-7, Reteplase 134308-13-7, Tolcapone 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 134865-37-5, Meluadrine tartrate 135062-02-1, Repaglinide 136468-36-5, Foropafant 137862-53-4, Valsartan 138068-37-8, Lepirudin 138402-11-6, Irbesartan 138661-03-7, Furnidipine 143653-53-6, Abciximab 144494-65-5, Tirofiban 144689-63-4, Olmesartan medoxomil 144701-48-4, Telmisartan 145040-37-5, Candesartan cilexetil 145375-43-5, Mitiglinide 145599-86-6, Cerivastatin 147059-72-1, Trovafloxacin 147511-69-1, Pitavastatin 148883-56-1, Tifacogin 149908-53-2, Azimilide 150332-35-7, Pamaqueside 154189-24-9, ARC68397aa 158876-82-5, Rupatadine 159776-70-2, Melagatran 170902-47-3, Roxifiban 173324-94-2, Temiverine 187523-35-9, BMS204352 188627-80-7, Eptifibatide 210101-16-9, Conivaptan 679809-58-6, Enoxaparin sodium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and apparatus for determining and utilizing the viscosity of circulating
blood over a range of shear rates for diagnostics and treatment)

L9 ANSWER 28 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:11000 CA
TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction
INVENTOR(S): Sahota, Pritam Singh
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043807	A2	20020606	WO 2001-EP13976	20011129 <--
WO 2002043807	A3	20030814		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

CA 2430924	A1	20020606	CA 2001-2430924	20011129	<--
AU 2002026365	A5	20020611	AU 2002-26365	20011129	<--
EP 1353727	A2	20031022	EP 2001-995680	20011129	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004514703	T	20040520	JP 2002-545776	20011129	
US 20020107236	A1	20020808	US 2001-8445	20011203	<--
US 20040087484	A1	20040506	US 2003-433189	20030624	

PRIORITY APPLN. INFO.: US 2000-250540P P 20001201
WO 2001-EP13976 W 20011129

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

PI WO 2002043807 A2 20020606

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2002043807	A2	20020606	WO 2001-EP13976	20011129	<--
WO 2002043807	A3	20030814			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

CA 2430924	A1	20020606	CA 2001-2430924	20011129	<--
AU 2002026365	A5	20020611	AU 2002-26365	20011129	<--
EP 1353727	A2	20031022	EP 2001-995680	20011129	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004514703	T	20040520	JP 2002-545776	20011129	
US 20020107236	A1	20020808	US 2001-8445	20011203	<--
US 20040087484	A1	20040506	US 2003-433189	20030624	

IT Angiotensin receptor antagonists
Antihypertensives
Calcium channel blockers
Diabetes mellitus
Diuretics
Sexual disorders
α-Adrenoceptor antagonists
β-Adrenoceptor agonists
β-Adrenoceptor antagonists
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)

IT 52-53-9, Verapamil 55-63-0, Nitroglycerin 58-93-5, Hydrochlorothiazide 58-94-6D, Thiazide, derivs. 87-33-2, Isosorbide dinitrate 525-66-6 16051-77-7, Isosorbide mononitrate 16662-47-8, Gallopamil 21829-25-4, Nifedipine 22609-73-0, Niludipine 39562-70-4, Nitrendipine

42399-41-7, Diltiazem 51384-51-1, Metoprolol 55985-32-5, Nicardipine 57010-31-8, Tiapamil 62571-86-2, Captopril 63675-72-9, Nisoldipine 66085-59-4, Nimodipine 66722-44-9, Bisoprolol 72509-76-3, Felodipine 74258-86-9, Alacepril 75330-75-5, LovastatIN 75695-93-1, Isradipine 75847-73-3, Enalapril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 79902-63-9, SimvastaTIN 81093-37-0, PRAVASTATin 82834-16-0, Perindopril 83435-66-9, Delapril 83647-97-6, Spirapril 85441-61-8, Quinapril 85856-54-8, Moveltipril 86541-74-4, Benazepril hydrochloride 86541-75-5, Benazepril 86541-78-8, Benazeprilat 87333-19-5, Ramipril 87679-37-6, Trandolapril 88150-42-9, Amlodipine 88768-40-5, Cilazapril 89371-37-9, Imidapril 89964-00-1, Ryosidine 93957-55-2, Fluvastatin sodium 98048-97-6, Fosinopril 103336-05-6, Ditekiren 111223-26-8, Ceronapril 111470-99-6, AMlodipine besylate 111902-57-9, Temocapril 113165-32-5, Niguldipine 114798-26-4, Losartan 119625-78-4, Terlakiren 133040-01-4, Eprosartan 134523-00-5, Atorvastatin 135015-84-8, Zd 8731 137862-53-4, Valsartan 138402-11-6, Irbesartan 138742-43-5, Zankiren 139481-59-7, Candesartan 144701-48-4, Telmisartan 145216-43-9, Sc-52458 145599-86-6, Cerivastatin 145733-36-4, Tasosartan 146623-69-0, Saprisartan 147511-69-1, PITaVASTATIN 173334-57-1, Aliskiren
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)

L9 ANSWER 29 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:406945 CA
TITLE: Methods for in vivo drug delivery based on monitoring blood flow parameters
INVENTOR(S): Kensey, Kenneth R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 727,950.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020061835	A1	20020523	US 2001-828761	20010409 <--
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--

JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
US 6322524	B1	20011127	US 1999-439795	19991112	<--
US 6322525	B1	20011127	US 2000-501856	20000210	<--
NO 2000000944	A	20000225	NO 2000-944	20000225	<--
MX 200002073	A	20010821	MX 2000-2073	20000228	<--
US 6428488	B1	20020806	US 2000-615340	20000712	<--
WO 2002009583	A2	20020207	WO 2001-US23696	20010730	<--
WO 2002009583	A3	20020425			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2002043806	A2	20020606	WO 2001-US44352	20011127	<--
WO 2002043806	A3	20030327			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002026986	A	20020611	AU 2002-26986	20011127	<--
US 20020088953	A1	20020711	US 2001-33841	20011227	<--
US 6624435	B2	20030923			
WO 2002079778	A2	20021010	WO 2002-US3984	20020207	<--
WO 2002079778	A3	20030710			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20020184941	A1	20021212	US 2002-156165	20020528	<--
US 6571608	B2	20030603			

PRIORITY APPLN. INFO.:

US 1997-919906	A2	19970828
US 1999-439795	A2	19991112
US 2000-501856	A2	20000210
US 2000-628401	A2	20000801
US 2000-727950	A2	20001201
US 1997-966076	A	19971107
WO 1998-US17657	W	19980826
US 2000-615340	A3	20000712
US 2000-228612P	P	20000828
US 2001-789350	B2	20010221
US 2001-819924	A	20010328
US 2001-828761	A	20010409
US 2001-839785	A	20010420

US 2001-841389 A 20010424
US 2001-897164 A3 20010702
WO 2001-US44352 W 20011127

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

PI US 20020061835 A1 20020523

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 20020061835	A1	20020523	US 2001-828761	20010409	<--
	US 6019735	A	20000201	US 1997-919906	19970828	<--
	CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
	WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	HU 2001000201	A2	20010528	HU 2001-201	19980826	<--
	HU 2001000201	A3	20040329			
	NZ 502905	A	20010831	NZ 1998-502905	19980826	<--
	JP 2001514384	T	20010911	JP 2000-507994	19980826	<--
	US 6322524	B1	20011127	US 1999-439795	19991112	<--
	US 6322525	B1	20011127	US 2000-501856	20000210	<--
	NO 2000000944	A	20000225	NO 2000-944	20000225	<--
	MX 200002073	A	20010821	MX 2000-2073	20000228	<--
	US 6428488	B1	20020806	US 2000-615340	20000712	<--
	WO 2002009583	A2	20020207	WO 2001-US23696	20010730	<--
	WO 2002009583	A3	20020425			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	WO 2002043806	A2	20020606	WO 2001-US44352	20011127	<--
	WO 2002043806	A3	20030327			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,					

UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002026986	A	20020611	AU 2002-26986	20011127	<--
US 20020088953	A1	20020711	US 2001-33841	20011227	<--
US 6624435	B2	20030923			
WO 2002079778	A2	20021010	WO 2002-US3984	20020207	<--
WO 2002079778	A3	20030710			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20020184941	A1	20021212	US 2002-156165	20020528	<--
US 6571608	B2	20030603			

IT Adrenoceptor antagonists
Agglutination
Antiarrhythmics
Anticholesteremic agents
Anticoagulants
Antidiabetic agents
Antihypertensives
Antiobesity agents
Appetite depressants
Blood coagulation
Calcium channel blockers
Cardiac contraction
Circulation
Diagnostic agents
Dietary supplements
Drug delivery systems
Drug dependence
Electrolytes, biological
Human
Hypolipemic agents
Platelet aggregation
Platelet aggregation
Platelet aggregation inhibitors
Psychotropics
Surfactants
Thixotropy
Vasodilators
β-Adrenoceptor antagonists
(methods for in vivo drug delivery based on monitoring blood flow parameters)

IT 50-28-2, Estradiol, biological studies 50-78-2, Aspirin 52-01-7, Spironolactone 52-53-9, Verapamil 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol 58-32-2, Dipyridamole 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-66-5, Acetazolamide

68-22-4, Norethindrone 69-65-8, D-Mannitol 70-51-9 72-33-3, Mestranol 81-81-2, Warfarin 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate 94-20-2, Chlorpropamide 122-09-8, Phentermine 396-01-0, Triamterene 520-85-4, Medroxyprogesterone 525-66-6, Propranolol 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin 797-63-7, Levonorgestrel 1156-19-0, Tolazamide 1231-93-2, Ethynodiol 2098-66-0, Cyproterone 3056-17-5, Stavudine 3930-20-9, Sotalol 4291-63-8, Cladribine 6533-00-2, Norgestrel 8001-27-2, Hirudin 9000-94-6, Antithrombin III 9002-01-1, Streptokinase 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-54-0, Dextran, biological studies 9005-27-0, Hetastarch 9007-12-9, Calcitonin 9039-53-6, Urokinase 9041-08-1, OP 2000 10238-21-8, Glyburide 11041-12-6, Cholestyramine 12650-69-0, Mupirocin 13523-86-9, Pindolol 15291-77-7, Ginkgolide B 15307-86-5, Diclofenac 16051-77-7, Isosorbide mononitrate 17560-51-9, Metolazone 18559-94-9, Salbutamol 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 24967-94-0, Dermatan sulfate 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 26839-75-8, Timolol 28395-03-1, Bumetanide 28523-86-6, Sevoflurane 28721-07-5, Oxcarbazepine 29094-61-9, Glipizide 29122-68-7, Atenolol 29457-07-6, Ticarcillin disodium 30516-87-1, Zidovudine 32222-06-3, Calcitriol 34391-04-3, Levosalbutamol 34580-13-7, Ketotifen 34911-55-2, Bupropion 35189-28-7, Norgestimate 38304-91-5, Minoxidil 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 47141-42-4, Levobunolol 49562-28-9, Fenofibrate 50925-79-6, Colestipol 51333-22-3, Budesonide 51384-51-1, Metoprolol 54024-22-5, Desogestrel 55142-85-3, Ticlopidine 55985-32-5, Nicardipine 56180-94-0, Acarbose 56211-40-6, Torsemide 56420-45-2, Epirubicin 59122-46-2, Misoprostol 60282-87-3, Gestodene 62571-86-2, Captopril 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64706-54-3, Bepridil 66085-59-4, Nimodipine 66722-44-9, Bisoprolol 67227-56-9, Fenoldopam 68252-19-7, Pirmenol 68291-97-4, Zonisamide 69655-05-6, Didanosine 71119-11-4, Bucindolol 71486-22-1, Vinorelbine 72509-76-3, Felodipine 72956-09-3, Carvedilol 73573-87-2, Formoterol 73963-72-1, Cilostazol 74191-85-8, Doxazosin 74863-84-6, Argatroban 75330-75-5, Lovastatin 75695-93-1, Isradipine 75847-73-3, Enalapril 76547-98-3, Lisinopril 77191-36-7, Nefiracetam 78415-72-2, Milrinone 79350-37-1, Cefixime 79902-63-9, Simvastatin 80474-14-2, Fluticasone propionate 81732-65-2, Bambuterol 82410-32-0, Ganciclovir 83869-56-1, Granulocyte-macrophage colony-stimulating factor 84057-84-1, Lamotrigine 84057-95-4, Ropivacaine 84449-90-1, Raloxifene 84625-59-2, Dotarizine 85441-61-8, Quinapril 86541-75-5, Benazepril 86780-90-7, Aranidipine 87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6, Trandolapril 88150-42-9, Amlodipine 89365-50-4, Salmeterol 89565-68-4, Tropisetron 90729-41-2, Oxodipine 92665-29-7, Cefprozil 93221-48-8, Levobetaxolol 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 94535-50-9, Lemakalim 94739-29-4, Lemildipine 95058-81-4, Gemcitabine 96036-03-2, Meropenem 96125-53-0, Clentiazem 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 97682-44-5, Irinotecan 98048-97-6, Fosinopril 99522-79-9, Pranidipine 100427-26-7, Lercanidipine 100986-85-4, Levofloxacin 101526-83-4, Sematilide 102786-52-7, Blood-coagulation factor VII (human clone AHVII2463 protein moiety) 103577-45-3, Lansoprazole 103745-39-7, Fasudil 103890-78-4, Lacidipine 104713-75-9, Barnidipine 105816-04-4, Nateglinide 105857-23-6, Alteplase 105979-17-7, Benidipine 106650-56-0, Sibutramine 107452-89-1, Ziconotide 109889-09-0, Granisetron 111025-46-8, Pioglitazone 112809-51-5,

Letrozole 113665-84-2, Clopidogrel 113806-05-6, Olopatadine 114432-13-2, Fantofarone 114798-26-4, Losartan 114870-03-0, Fondaparinux sodium 115103-54-3, Tiagabine 115256-11-6, Dofetilide 116308-55-5 117279-73-9, Israpafant 118457-14-0, Nebivolol 119684-05-8, Mesoglycan 120511-73-1, Anastrozole 120993-53-5, Desirudin 121181-53-1, Filgrastim 121679-13-8, Naratriptan 122647-31-8, Ibutilide 123524-52-7, Azelnidipine 123774-72-1, Leukine 123948-87-8, Topotecan 124750-99-8, Losartan potassium 124832-26-4, Valacyclovir 124937-51-5, Tolterodine 125670-52-2 128270-60-0, Bivalirudin 128470-16-6, Arbutamine 129618-40-2, Nevirapine 130209-82-4, Latanoprost 130636-43-0, Nifekalant 131179-95-8, RSR13 132579-32-9, Rocepafant 132875-61-7, Remifentanil 133040-01-4, Eprosartan 133242-30-5, Landiolol 133652-38-7, Reteplase 134308-13-7, Tolcapone 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 134865-37-5, Meluadrine tartrate 135062-02-1, Repaglinide 136468-36-5, Foropafant 137862-53-4, Valsartan 138068-37-8, Lepirudin 138402-11-6, Irbesartan 138661-03-7, Furnidipine 143653-53-6, Abciximab 144494-65-5, Tirofiban 144689-63-4, Olmesartan 144701-48-4, Telmisartan 145040-37-5, Candesartan cilexetil 145375-43-5, Mitiglinide 145599-86-6, Cerivastatin 147059-72-1, Trovafloxacin 147511-69-1, Pitavastatin 148883-56-1, Tifacogin 149908-53-2, Azimilide 150332-35-7, Pamaqueside 154189-24-9, ARC68397AA 158876-82-5, Rupatadine 159776-70-2, Melagatran 170902-47-3, Roxifiban 173324-94-2, Temiverine 186615-83-8 187523-35-9, BMS204352 187741-48-6, CHF 1521 188627-80-7, Eptifibatide 210101-16-9, Conivaptan 679809-58-6, Enoxaparin sodium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for in vivo drug delivery based on monitoring blood flow parameters)

L9 ANSWER 30 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:401651 CA
TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors
INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20020061901	A1	20020523	US 2001-8154		20011204 <--
US 6620821	B2	20030916			
US 20020028826	A1	20020307	US 2001-875218		20010606 <--
US 20040024216	A1	20040205	US 2003-602753		20030624
PRIORITY APPLN. INFO.:			US 2000-211594P	P	20000615
			US 2001-875218	A2	20010606
			US 2001-8154	A3	20011204

OTHER SOURCE(S): MARPAT 136:401651
GI



I II

AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH2CR7(OH)CH2CO2R3 or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R1, R2 = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R3 = H or lower alkyl; R4 = H, halo, CF3, OH, alkyl, alkoxy, CO2H, (un)substituted NH2, cyano, (un)substituted CONH2, etc.; R7 = H, alkyl]. The compds. are HMG-CoA reductase inhibitors, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Prepns. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as inhibitors of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

PI US 20020061901 A1 20020523

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020061901	A1	20020523	US 2001-8154	20011204 <--
	US 6620821	B2	20030916		
	US 20020028826	A1	20020307	US 2001-875218	20010606 <--
	US 20040024216	A1	20040205	US 2003-602753	20030624

IT Calcium channel blockers
(T-channel, therapeutic compns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

IT Calcium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(T-type, blockers, therapeutic compns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

IT Receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium, agonists, therapeutic compns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

IT 5-HT reuptake inhibitors
Angiotensin receptor antagonists
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antioxidants
Appetite depressants
Calcium channel blockers
Diuretics
Immunomodulators
Immunosuppressants
α-Adrenoceptor antagonists
β-Adrenoceptor antagonists
β3-Adrenoceptor agonists
(therapeutic compns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-01-7, Spironolactone 52-53-9, Verapamil 54-31-9, Furosemide 58-32-2, Dipyridamole 58-93-5, Hydrochlorothiazide 59-67-6, Nicotinic acid, biological studies 59-67-6D, Nicotinic acid, derivs. 94-20-2, Chlorpropamide 122-09-8, Phentermine 303-98-0, Coenzyme Q10 525-66-6, Propranolol 564-25-0, Doxycycline 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 1684-40-8, Tacrine hydrochloride 3416-24-8, Glucosamine 4205-91-8, Clonidine hydrochloride 9002-64-6, Parathyroid hormone 9004-10-8, Insulin, biological studies 9004-61-9, Hyaluronic acid 9007-28-7, Chondroitin sulfate 10118-90-8, Minocycline 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 29094-61-9, Glipizide 29122-68-7, Atenolol 42200-33-9, Nadolol 49562-28-9, Fenofibrate 55142-85-3, Ticlopidine 56180-94-0, Acarbose 56211-40-6, Torasemide 62571-86-2, Captopril 66376-36-1, Alendronate 68475-42-3, Anagrelide 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89750-14-1, Glucagon-like peptide I 89750-14-1D, Glucagon-like peptide I, mimetics 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 120014-06-4, Donepezil 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC2993 143443-90-7, Ifetroban 143653-53-6, Abciximab 144288-97-1, TS 962 144494-65-5, Tirofiban 145599-86-6, Cerivastatin 147511-69-1, Pitavastatin 152755-31-2, LY295427 159183-92-3, L750355 160135-92-2, Gemopatrilat 161600-01-7 162011-90-7, Vioxx 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS 30440 169590-42-5, Celebrex 170861-63-9, JTT-501 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 188627-80-7, Eptifibatide 196808-45-4 199113-98-9, NN-2344 199914-96-0, YM-440 213252-19-8, KRP297

244081-42-3, AJ9677 251572-86-8, P32/98 258345-41-4, GW-409544
282526-98-1, ATL-962 287714-41-4, Rosuvastatin 335149-08-1, L895645
335149-14-9, R-119702 335149-15-0, KAD1129 335149-17-2, AR-H039242
335149-23-0, NVP-DPP-728A 335149-25-2, CP331648 430433-17-3, Glipyride
430433-43-5, CP 644673 444069-80-1, Axokine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic comprns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

L9 ANSWER 31 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:252567 CA
TITLE: Methods for drug administration and distribution based on monitoring blood viscosity and other parameters for diagnostics and treatment
INVENTOR(S): Kensey, Kenneth
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 819,924.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020032149	A1	20020314	US 2001-841389	20010424 <--
US 6019735	A	20000201	US 1997-919906	19970828 <--
CA 2301161	A1	19990304	CA 1998-2301161	19980826 <--
WO 9910724	A2	19990304	WO 1998-US17657	19980826 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
HU 2001000201	A2	20010528	HU 2001-201	19980826 <--
HU 2001000201	A3	20040329		
NZ 502905	A	20010831	NZ 1998-502905	19980826 <--
JP 2001514384	T	20010911	JP 2000-507994	19980826 <--
US 6322524	B1	20011127	US 1999-439795	19991112 <--
US 6322525	B1	20011127	US 2000-501856	20000210 <--
NO 2000000944	A	20000225	NO 2000-944	20000225 <--
MX 200002073	A	20010821	MX 2000-2073	20000228 <--
US 6428488	B1	20020806	US 2000-615340	20000712 <--
WO 2002009583	A2	20020207	WO 2001-US23696	20010730 <--
WO 2002009583	A3	20020425		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 20020088953	A1	20020711	US 2001-33841	20011227 <--	
US 6624435	B2	20030923			
WO 2002079778	A2	20021010	WO 2002-US3984	20020207 <--	
WO 2002079778	A3	20030710			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20020184941	A1	20021212	US 2002-156165	20020528 <--	
US 6571608	B2	20030603			

PRIORITY APPLN. INFO.:

US 1997-919906	A2 19970828
US 1999-439795	A2 19991112
US 2000-501856	A2 20000210
US 2000-628401	A2 20000801
US 2000-727950	A2 20001201
US 2001-819924	A2 20010328
US 1997-966076	A 19971107
WO 1998-US17657	W 19980826
US 2000-615340	A3 20000712
US 2000-228612P	P 20000828
US 2001-789350	B2 20010221
US 2001-828761	A 20010409
US 2001-839785	A 20010420
US 2001-841389	A 20010424
US 2001-897164	A3 20010702

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being, i.e., a human, over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream. For example, when blood viscosity is a blood flow parameter monitored, an agent is selected from i.v. diluents, red blood cell deformability agents, antiurea agents, oral contraceptives, antidiabetic agents, antiarrhythmics, antihypertensives, antihyperlipidemics, antiplatelet agents, appetite suppressants, antiobesity agents, blood modifiers, smoking deterrent agents, and nutritional supplements.

PI US 20020032149 A1 20020314

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 20020032149	A1	20020314	US 2001-841389	20010424	<--
US 6019735	A	20000201	US 1997-919906	19970828	<--
CA 2301161	A1	19990304	CA 1998-2301161	19980826	<--
WO 9910724	A2	19990304	WO 1998-US17657	19980826	<--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

HU	2001000201	A2	20010528	HU 2001-201	19980826 <--
HU	2001000201	A3	20040329		
NZ	502905	A	20010831	NZ 1998-502905	19980826 <--
JP	2001514384	T	20010911	JP 2000-507994	19980826 <--
US	6322524	B1	20011127	US 1999-439795	19991112 <--
US	6322525	B1	20011127	US 2000-501856	20000210 <--
NO	2000000944	A	20000225	NO 2000-944	20000225 <--
MX	200002073	A	20010821	MX 2000-2073	20000228 <--
US	6428488	B1	20020806	US 2000-615340	20000712 <--
WO	2002009583	A2	20020207	WO 2001-US23696	20010730 <--
WO	2002009583	A3	20020425		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20020088953	A1	20020711	US 2001-33841	20011227 <--
US	6624435	B2	20030923		
WO	2002079778	A2	20021010	WO 2002-US3984	20020207 <--
WO	2002079778	A3	20030710		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20020184941	A1	20021212	US 2002-156165	20020528 <--
US	6571608	B2	20030603		

IT Adrenoceptor antagonists
Agglutination
Antiarrhythmics
Anticholesteremic agents
Anticoagulants
Antidiabetic agents
Antihypertensives
Antiobesity agents
Appetite depressants
Blood analysis
Blood coagulation
  Calcium channel blockers
Cardiac contraction
Circulation

Diagnosis
Dietary supplements
Drug delivery systems
Drug delivery systems
Drug dependence
Electrolytes, biological
Human
Hypolipemic agents
Platelet aggregation
Platelet aggregation
Platelet aggregation inhibitors
Sedimentation (separation)
Surfactants
Therapy
Thixotropy
Tobacco products
Vasodilators
β-Adrenoceptor antagonists
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)

IT 50-28-2, Estradiol, biological studies 50-78-2, Aspirin 52-01-7, Spironolactone 52-53-9, Verapamil 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-63-6, Ethinyl estradiol 58-32-2, Dipyridamole 58-54-8, Ethacrynic acid 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-66-5, Acetazolamide 68-22-4, Norethindrone 69-65-8, Mannitol 70-51-9 72-33-3, Mestranol 81-81-2, Warfarin 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate 94-20-2, Chlorpropamide 122-09-8, Phentermine 396-01-0, Triamterene 520-85-4, Medroxyprogesterone 525-66-6, Propranolol 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin 797-63-7, Levonorgestrel 1156-19-0, Tolazamide 1231-93-2, Ethynodiol 2098-66-0, Cyproterone 3056-17-5, Stavudine 3930-20-9, Sotalol 4291-63-8, Cladribine 6533-00-2, Norgestrel 8001-27-2, Hirudin 9000-69-5, Pectin 9000-94-6, Antithrombin III 9002-01-1, Streptokinase 9002-18-0, Agar 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-54-0, Dextran, biological studies 9004-67-5, Methyl cellulose 9005-27-0, Hetastarch 9007-12-9, Calcitonin 9039-53-6, Urokinase 9041-08-1, OP 2000 10238-21-8, Glyburide 11041-12-6, Cholestyramine 12650-69-0, Mupirocin 13523-86-9, Pindolol 15291-77-7, Ginkgolide B 15307-86-5, Diclofenac 16051-77-7, Isosorbide mononitrate 17560-51-9, Metolazone 18559-94-9, Salbutamol 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 24967-94-0, Dermatan sulfate 25322-68-3, Polyethylene glycol 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26807-65-8, Indapamide 26839-75-8, Timolol 28395-03-1, Bumetanide 28523-86-6, Sevoflurane 28721-07-5, Oxcarbazepine 29094-61-9, Glipizide 29122-68-7, Atenolol 29457-07-6, Ticarcillin disodium 30516-87-1, Zidovudine 32222-06-3, Calcitriol 34391-04-3, Levosalbutamol 34580-13-7, Ketotifen 34911-55-2, Bupropion 35189-28-7, Norgestimate 38304-91-5, Minoxidil 39562-70-4, Nitrendipine 42200-33-9, Nadolol 42399-41-7, Diltiazem 42924-53-8, Nabumetone 47141-42-4, Levobunolol 49562-28-9, Fenofibrate 50925-79-6, Colestipol 51333-22-3, Budesonide 51384-51-1, Metoprolol 54024-22-5, Desogestrel 55142-85-3, Ticlopidine 55985-32-5, Nicardipine 56180-94-0, Acarbose 56211-40-6, Torsemide 56420-45-2, Epirubicin 59122-46-2, Misoprostol 60202-16-6, Blood-coagulation factor XIV 60282-87-3, Gestodene 62571-86-2, Captopril 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 64221-86-9, Imipenem 64544-07-6,

Cefuroxime axetil 64706-54-3, Bepridil 66085-59-4, Nimodipine
66722-44-9, Bisoprolol 67227-56-9, Fenoldopam 68252-19-7, Pirmenol
68291-97-4, Zonisamide 69655-05-6, Didanosine 71119-11-4, Bucindolol
71486-22-1, Vinorelbine 72509-76-3, Felodipine 72956-09-3, Carvedilol
73573-87-2, Formoterol 73963-72-1, Cilostazol 74191-85-8, Doxazosin
74863-84-6, Argatroban 75330-75-5, Lovastatin 75695-93-1, Isradipine
75847-73-3, Enalapril 76547-98-3, Lisinopril 77191-36-7, Nefiracetam
78415-72-2, Milrinone 79350-37-1, Cefixime 79902-63-9, Simvastatin
80474-14-2, Fluticasone propionate 81732-65-2, Bambuterol 82410-32-0,
Ganciclovir 82834-16-0, Perindopril 83869-56-1, Granulocyte-macrophage
colony-stimulating factor 84057-84-1, Lamotrigine 84057-95-4,
Ropivacaine 84449-90-1, Raloxifene 84625-59-2, Dotarizine
85441-61-8, Quinapril 86541-75-5, Benazepril 86780-90-7, Aranidipine
87239-81-4, Cefpodoxime proxetil 87333-19-5, Ramipril 87679-37-6,
Trandolapril 88150-42-9, Amlodipine 89565-68-4, Tropisetron
90729-41-2, Oxodipine 91161-71-6, Terbinafine 92665-29-7, Cefprozil
93221-48-8, Levobetaxolol 93479-97-1, Glimepiride 93957-54-1,
Fluvastatin 94535-50-9, Lemakalim 94739-29-4, Lemildipine
95058-81-4, Gemcitabine 96036-03-2, Meropenem 96125-53-0, Clentiazem
96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone
97682-44-5, Irinotecan 98048-97-6, Fosinopril 99522-79-9, Pranidipine
100427-26-7, Lercanidipine 100986-85-4, Levofloxacin 101526-83-4,
Sematilide 102786-61-8, Blood-coagulation factor VIIa (human clone
λHVII2463 protein moiety) 103577-45-3, Lansoprazole
103628-46-2, Sumatriptan 103745-39-7, Fasudil 103890-78-4, Lacidipine
104713-75-9, Barnidipine 105816-04-4, Nateglinide 105857-23-6,
Alteplase 105979-17-7, Benidipine 106650-56-0, Sibutramine
107452-89-1, Ziconotide 109889-09-0, Granisetron 111025-46-8,
Pioglitazone 112809-51-5, Letrozole 113665-84-2, Clopidogrel
113806-05-6, Olopatadine 114432-13-2, Fantofarone 114798-26-4,
Losartan 114870-03-0, Fondaparinux sodium 115103-54-3, Tiagabine
115256-11-6, Dofetilide 116308-55-5, Watanidipine 117279-73-9,
Israpafant 118457-14-0, Nebivolol 119684-05-8, Mesoglycan
120511-73-1, Anastrozole 120993-53-5, Desirudin 121181-53-1,
Filgrastim 121679-13-8, Naratriptan 122647-31-8, Ibutilide
123524-52-7, Azelnidipine 123774-72-1, Sargramostim 123948-87-8,
Topotecan 124750-99-8, Losartan potassium 124832-26-4, Valacyclovir
124937-51-5, Tolterodine 128270-60-0, Bivalirudin 128470-16-6,
Arbutamine 129618-40-2, Nevirapine 130209-82-4, Latanoprost
130636-43-0, Nifekalant 131179-95-8, RSR 13 132579-32-9, Rocepafant
132875-61-7, Remifentanil 133040-01-4, Eprosartan 133242-30-5,
Landiolol 133652-38-7, Reteplase 134308-13-7, Tolcapone 134523-00-5,
Atorvastatin 134678-17-4, Lamivudine 134865-37-5, Meluadrine tartrate
135062-02-1, Repaglinide 136468-36-5, Foropafant 137862-53-4,
Valsartan 138068-37-8, Lepirudin 138402-11-6, Irbesartan
138661-03-7, Furnidipine 143653-53-6, Abciximab 144494-65-5, Tirofiban
144689-63-4, Olmesartan medoxomil 144701-48-4, Telmisartan
145040-37-5, Candesartan cilexetil 145375-43-5, Mitiglinide
145599-86-6, Cerivastatin 147059-72-1, Trovafloxacin 147511-69-1
, Pitavastatin 148883-56-1, Tifacogin 149908-53-2, Azimilide
150332-35-7, Pamaqueside 154189-24-9, ARC68397AA 158876-82-5,
Rupatadine 159776-70-2, Melagatran 170902-47-3, Roxifiban
173324-94-2, Temiverine 187523-35-9, BMS204352
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apparatus and methods for monitoring blood viscosity and other parameters
in drug delivery for diagnostics and treatment)

L9 ANSWER 32 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:205466 CA
TITLE: Medicinal compositions containing HMG-CoA reductase inhibitors and angiotensin II receptor antagonists for preventing or treating heart failure
INVENTOR(S): Lee, Tsung Ming; Lee, Bai-Ching; Su, Shen-Fang; Hsiao, Chia-Ling; Chu, Chia-Wei
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002017913	A1	20020307	WO 2001-JP7437	20010829	<--
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
AU 2001084413	A	20020313	AU 2001-84413	20010829	<--
JP 2002145770	A	20020522	JP 2001-259399	20010829	<--
CA 2420844	A1	20030228	CA 2001-2420844	20010829	<--
EP 1314425	A1	20030528	EP 2001-963398	20010829	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
US 20030181500	A1	20030925	US 2003-374171	20030226	<--
US 20050059720	A1	20050317	US 2004-977645	20041029	

PRIORITY APPLN. INFO.: JP 2000-260949 A 20000830
WO 2001-JP7437 W 20010829
US 2003-374171 A3 20030226

AB Disclosed are medicinal compns. comprising an HMG-CoA reductase inhibitor selected from the group consisting of pravastatin, simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of pravastatin 10, losartan 50, and amlodipine 5 mg/day for 6 mo on left ventricle hypertrophy in patients was examined

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

PI WO 2002017913 A1 20020307

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002017913	A1	20020307	WO 2001-JP7437	20010829	<--
	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, ZA					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR					
	AU 2001084413	A	20020313	AU 2001-84413	20010829	<--
	JP 2002145770	A	20020522	JP 2001-259399	20010829	<--
	CA 2420844	A1	20030228	CA 2001-2420844	20010829	<--
	EP 1314425	A1	20030528	EP 2001-963398	20010829	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
	US 20030181500	A1	20030925	US 2003-374171	20030226	<--

US 20050059720 A1 20050317 US 2004-977645 20041029
AB . . . the group consisting of pravastatin, simvastatin, lovastatin, pitavastatin and ZD-4522, and an angiotensin II receptor antagonist optionally together with a calcium channel blocker. The preventive effect of administration of pravastatin 10, losartan 50, and amlodipine 5 mg/day for 6 mo on. . .
IT Calcium channel blockers
(medicinal compns. containing HMG-CoA reductase inhibitors, angiotensin II receptor antagonists, and calcium blockers for preventing or treating heart failure)
IT 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81131-70-6, Pravastatin sodium salt 147098-20-2, ZD-4522 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing HMG-CoA reductase inhibitors and angiotensin II receptor antagonists for preventing or treating heart failure)
IT 88150-42-9, Amlodipine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing HMG-CoA reductase inhibitors, angiotensin II receptor antagonists, and calcium blockers for preventing or treating heart failure)

L9 ANSWER 33 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:112193 CA
TITLE: Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors
AUTHOR(S): Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Kitahara, M.; Sakashita, M.; Sakoda, R.
CORPORATE SOURCE: Central Research Laboratories, Nissan Chemical Industries, Ltd., Funabashi, Chiba, 274-8507, Japan
SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(10), 2727-2743
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:112193
AB A series of quinoline-based 3,5-dihydroxyheptenoic acid derivs. were synthesized from quinolinecarboxylic acid esters by homologation, aldol condensation with Et acetoacetate dianion, and reduction of 3-hydroxyketone to evaluate their ability to inhibit the enzyme HMG-CoA reductase in vitro. In agreement with previous literature, a strict structural requirement exists on the external ring, and 4-fluorophenyl is the most active in this system. For the central ring, substitution on positions 6, 7, and 8 of the central quinoline nucleus moderately affected the potency, whereas the alkyl side chain on the 2-position had a more pronounced influence on activity. Among the derivs., NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and improvement in potency at inhibiting HMG-CoA reductase was obtained by having the optimal substituents flanking the desmethylmevalonic acid portion, i.e., 4-fluorophenyl and cyclopropyl, instead of the usual iso-Pr group.
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
SO Bioorganic & Medicinal Chemistry (2001), 9(10), 2727-2743
CODEN: BMECEP; ISSN: 0968-0896
AB . . . whereas the alkyl side chain on the 2-position had a more

pronounced influence on activity. Among the derivs., NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and. . .

IT 118175-21-6P 118175-23-8P 130048-17-8P 207976-70-3P
391681-56-4P 391681-57-5P 391681-58-6P 391681-59-7P
391681-60-0P 391681-61-1P 391681-62-2P 391681-63-3P 391681-64-4P
391681-65-5P 391681-66-6P 391681-67-7P 391681-68-8P 391681-69-9P
391681-70-2P 391681-71-3P 391681-72-4P 391681-73-5P 391681-74-6P
391681-75-7P 391681-76-8P 391681-77-9P 391681-78-0P 391681-79-1P
391681-80-4P 391681-81-5P 391681-82-6P 391681-83-7P 391681-84-8P
391681-85-9P 391681-86-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. evaluations of quinoline-based HMG-CoA reductase inhibitors)

IT 147526-32-7, NK-104
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis and biol. evaluations of quinoline-based HMG-CoA reductase inhibitors)

IT 121659-86-7P 121660-11-5P 121660-37-5P 130048-08-7P 130048-09-8P
130048-10-1P 130048-11-2P 130954-99-3P 147008-20-6P
148516-11-4P 148901-68-2P 148901-69-3P 256431-72-8P 391681-87-1P
391681-88-2P 391681-89-3P 391681-90-6P 391681-91-7P 391681-92-8P
391681-93-9P 391681-94-0P 391681-95-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. evaluations of quinoline-based HMG-CoA reductase inhibitors)

L9 ANSWER 34 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 136:96068 CA
TITLE: SREBP-2 gene expression promoters as hypolipidemics
INVENTOR(S): Kodama, Tatsuhiko; Hamakubo, Takao; Murakami, Takeshi; Saito, Yasushi; Morikawa, Shigeru; Kitahara, Masaki; Tamaki, Taro
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002003374	A	20020109	JP 2000-189161	20000623 <--

PRIORITY APPLN. INFO.: JP 2000-189161 20000623
OTHER SOURCE(S): MARPAT 136:96068
AB SREBP-2 (sterol regulatory element-binding protein) gene expression promoters RXCH(OH)CH2CH(OH)CH2CO2M (I; R = organic base; X = -CH2CH2-, -CH=CH-; M = H, alkyl, physiol. acceptable cation), including (+)-bis[(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid] calcium, are claimed as hypolipidemics.

PI JP 2002003374 A 20020109

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002003374	A	20020109	JP 2000-189161	20000623 <--

AB . . . RXCH(OH)CH2CH(OH)CH2CO2M (I; R = organic base; X = -CH2CH2-, -CH=CH-; M = H, alkyl, physiol. acceptable cation), including (+)-bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid} calcium, are claimed as hypolipidemics.

IT 147526-32-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SREBP-2 (sterol regulatory element-binding protein) gene expression promoters as hypolipidemics)

L9 ANSWER 35 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 135:10035 CA
TITLE: HMG-CoA reductase inhibitors for ameliorating abnormal bone states
INVENTOR(S): Bagi, Cedo M.
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037876	A2	20010531	WO 2000-EP11466	20001117 <--
WO 2001037876	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-167267P P 19991124

AB This application relates to methods of using HMG-CoA reductase inhibitors for the prevention and for the treatment of abnormal conditions ameliorated by concurrent decrease in bone resorption and stimulation of bone formation. This invention also relates to methods of using HMG-CoA reductase inhibitors for the prevention and for the treatment of conditions ameliorated by a decrease in plasma calcium levels. Thus, tablets contained cerivastatin 25, microcryst. cellulose 200, colloidal SiO2 10, and stearic acid 5 mg/tablet.

PI WO 2001037876 A2 20010531

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037876	A2	20010531	WO 2000-EP11466	20001117 <--
WO 2001037876	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AB . . . of using HMG-CoA reductase inhibitors for the prevention and for the treatment of conditions ameliorated by a decrease in plasma calcium levels. Thus, tablets contained cerivastatin 25, microcryst. cellulose 200, colloidal SiO2 10, and stearic acid 5 mg/tablet.

IT 75330-75-5, Lovastatin 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 145599-86-6, Cerivastatin 147511-69-1, Itavastatin 287714-41-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitors for ameliorating abnormal bone states)

IT 7440-70-2, Calcium, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(hypercalcemia, inhibitors; HMG-CoA reductase inhibitors for ameliorating abnormal bone states)

L9 ANSWER 36 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 134:311218 CA
TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors
INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 221 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002 <--
WO 2001027107	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6887870	B1	20050503	US 2000-669298	20000925
CA 2388813	A1	20010419	CA 2000-2388813	20001002 <--
EP 1224183	A2	20020724	EP 2000-968723	20001002 <--
EP 1224183	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

BR 2000014725	A	20030617	BR 2000-14725	20001002	<--
HU 2003000195	A2	20030728	HU 2003-195	20001002	<--
HU 2003000195	A3	20030929			
JP 2003527331	T	20030916	JP 2001-530325	20001002	<--
NZ 517668	A	20040924	NZ 2000-517668	20001002	
AT 314364	T	20060115	AT 2000-968723	20001002	
ES 2254236	T3	20060616	ES 2000-968723	20001002	
IN 2002MN00354	A	20050318	IN 2002-MN354	20020322	
ZA 2002002479	A	20040727	ZA 2002-2479	20020327	
MX 2002PA03626	A	20030922	MX 2002-PA3626	20020410	<--
NO 2002001717	A	20020610	NO 2002-1717	20020411	<--
US 2005013716	A1	20050623	US 2005-46993	20050131	
US 7326705	B2	20080205			

PRIORITY APPLN. INFO.:

US 1999-158755P	P	19991012
US 2000-669298	A3	20000925
WO 2000-US27461	W	20001002

OTHER SOURCE(S): MARPAT 134:311218

GI



AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α-chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β-adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

PI WO 2001027107 A2 20010419

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2001027107	A2	20010419	WO 2000-US27461	20001002	<--
WO 2001027107	A3	20020124			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6887870	B1	20050503	US 2000-669298	20000925	
CA 2388813	A1	20010419	CA 2000-2388813	20001002	<--
EP 1224183	A2	20020724	EP 2000-968723	20001002	<--
EP 1224183	B1	20051228			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014725	A	20030617	BR 2000-14725	20001002	<--
HU 2003000195	A2	20030728	HU 2003-195	20001002	<--
HU 2003000195	A3	20030929			
JP 2003527331	T	20030916	JP 2001-530325	20001002	<--
NZ 517668	A	20040924	NZ 2000-517668	20001002	
AT 314364	T	20060115	AT 2000-968723	20001002	
ES 2254236	T3	20060616	ES 2000-968723	20001002	
IN 2002MN00354	A	20050318	IN 2002-MN354	20020322	
ZA 2002002479	A	20040727	ZA 2002-2479	20020327	
MX 2002PA03626	A	20030922	MX 2002-PA3626	20020410	<--
NO 2002001717	A	20020610	NO 2002-1717	20020411	<--
US 20050137216	A1	20050623	US 2005-46993	20050131	
US 7326705	B2	20080205			

IT Ion channel blockers
(calcium, pharmaceuticals containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

IT 50-02-2, Dexamethasone 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 56-03-1D, Biguanide, derivs. 58-32-2, Dipyridamole 58-55-9, Theophylline, biological studies 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 124-94-7, Triamcinolone 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 3385-03-3, Flunisolide 4205-91-8, Clonidine hydrochloride 4419-39-0, Beclomethasone 9002-01-1, Streptokinase 9039-53-6, Urokinase 10238-21-8, Glyburide 13392-18-2, Fenoterol 14838-15-4, Phenylpropanolamine 16110-51-3, Cromolyn 18559-94-9, Albuterol 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 23031-25-6, Terbutaline 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 30392-40-6, Bitolterol 37250-24-1, HMG CoA reductase 38677-81-5, Pirbuterol 42200-33-9, Nadolol 49562-28-9, Fenofibrate 51333-22-3, Budesonide 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 69049-73-6, Nedocromil 72432-03-2, Miglitol 72956-09-3, Carvedilol 73573-87-2, Formoterol 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89365-50-4, Salmeterol 89750-14-1, Glucagon-like peptide I 90566-53-3, Fluticasone 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103177-37-3, Pranlukast 103775-10-6, Moexipril 105816-04-4, Nateglinide 105857-23-6, Activase 105913-11-9D, Plasminogen activator, complex 106650-56-0, Sibutramine 107753-78-6, Zafirlukast 111025-46-8, Pioglitazone 111406-87-2, Zileuton 111470-99-6, Amlodipine besylate

113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 133652-38-7, Reteplase 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 139639-23-9, Tissue plasminogen activator 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS 962 145599-86-6, Cerivastatin 147511-69-1, Itavastatin 150322-43-3, CS 747 152755-31-2, LY 295427 158966-92-8, Montelukast 159183-92-3, L 750355 160135-92-2 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS 30440 170861-63-9, JTT 501 171870-23-8, Lanoteplase 176435-10-2, LY 315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4, GI 262570 199113-98-9, NN 2344 199914-96-0 213252-19-8, KRP 297 244081-42-3, AJ 9677 251572-86-8 258345-41-4, GW 409544 335149-05-8, AZ 4522 335149-08-1, L 895645 335149-14-9, R 119702 335149-15-0, KAD 1129 335149-17-2, ARHO 39242 335149-23-0, NVP-DPP 728A 335149-25-2, CP 331648
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)

L9 ANSWER 37 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 127:113387 CA
ORIGINAL REFERENCE NO.: 127:21777a,21780a
TITLE: Pharmaceutical composition containing quinolinheptenoic acid derivatives stabilized with a basic agent
INVENTOR(S): Muramatsu, Toyojiro; Mashita, Katsumi; Shinoda, Yasuo; Sassa, Hironori; Kawashima, Hiroyuki; Tanizawa, Yoshio; Takeuchi, Hideatsu
PATENT ASSIGNEE(S): Kowa Company, Ltd., Japan; Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723200	A1	19970703	WO 1996-JP3722	19961220 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2213608	A1	19970703	CA 1996-2213608	19961220 <--
CA 2213608	C	20030708		
ZA 9610792	A	19970709	ZA 1996-10792	19961220 <--
AU 9711715	A	19970717	AU 1997-11715	19961220 <--
AU 725622	B2	20001019		
EP 814782	A1	19980107	EP 1996-942588	19961220 <--
EP 814782	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, FI, RO

CN 1189098	A	19980729	CN 1996-192065	19961220	<--
JP 11503763	T	19990330	JP 1997-523500	19961220	<--
JP 3276962	B2	20020422			
RU 2142790	C1	19991220	RU 1997-114095	19961220	<--
HU 9903536	A2	20000328	HU 1999-3536	19961220	<--
HU 9903536	A3	20010628			
CZ 288545	B6	20010711	CZ 1997-2681	19961220	<--
IL 121565	A	20020210	IL 1996-121565	19961220	<--
AT 228354	T	20021215	AT 1996-942588	19961220	<--
SK 282991	B6	20030109	SK 1997-1160	19961220	<--
ES 2183023	T3	20030316	ES 1996-942588	19961220	<--
PT 814782	T	20030430	PT 1996-942588	19961220	<--
PL 186907	B1	20040331	PL 1996-321868	19961220	
TW 436294	B	20010528	TW 1996-85115860	19961221	<--
NO 9703814	A	19971013	NO 1997-3814	19970819	<--
NO 316724	B1	20040419			

PRIORITY APPLN. INFO.:	JP 1995-354654	A	19951222
	WO 1996-JP3722	W	19961220

AB Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4'-4''-fluorophenyl-2'-cyclopropyl-quinolin-3'-yl]-6-heptenoic acid (NK-104), or its salt or ester, of which the aqueous solution or dispersion has a pH of from 7 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long. A pharmaceutical tablet contained calcium salt of NK-104 1.0, lactose 101.4, low substituted hydroxypropyl cellulose 12.0, hydroxypropylmethyl cellulose 2.0, magnesium metasilicate aluminate 2.4, and magnesium stearate 1.2 mg.

PI WO 9723200 A1 19970703

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 9723200	A1	19970703	WO 1996-JP3722	19961220	<--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2213608	A1	19970703	CA 1996-2213608	19961220	<--
CA 2213608	C	20030708			
ZA 9610792	A	19970709	ZA 1996-10792	19961220	<--
AU 9711715	A	19970717	AU 1997-11715	19961220	<--
AU 725622	B2	20001019			
EP 814782	A1	19980107	EP 1996-942588	19961220	<--
EP 814782	B1	20021127			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
CN 1189098	A	19980729	CN 1996-192065	19961220	<--
JP 11503763	T	19990330	JP 1997-523500	19961220	<--
JP 3276962	B2	20020422			
RU 2142790	C1	19991220	RU 1997-114095	19961220	<--
HU 9903536	A2	20000328	HU 1999-3536	19961220	<--
HU 9903536	A3	20010628			
CZ 288545	B6	20010711	CZ 1997-2681	19961220	<--
IL 121565	A	20020210	IL 1996-121565	19961220	<--
AT 228354	T	20021215	AT 1996-942588	19961220	<--

SK 282991	B6	20030109	SK 1997-1160	19961220	<--
ES 2183023	T3	20030316	ES 1996-942588	19961220	<--
PT 814782	T	20030430	PT 1996-942588	19961220	<--
PL 186907	B1	20040331	PL 1996-321868	19961220	
TW 436294	B	20010528	TW 1996-85115860	19961221	<--
NO 9703814	A	19971013	NO 1997-3814	19970819	<--
NO 316724	B1	20040419			

AB . . . . time-dependent stability and has no change in its outward appearance even after having been stored long. A pharmaceutical tablet contained calcium salt of NK-104 1.0, lactose 101.4, low substituted hydroxypropyl cellulose 12.0, hydroxypropylmethyl cellulose 2.0, magnesium metasilicate aluminate 2.4, and magnesium. . .

IT 147511-69-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing quinolinheptenoic acid derivs. stabilized with basic agent)

IT 74-79-3, L-Arginine, biological studies 7758-11-4, Dipotassium hydrogen phosphate 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropylmethyl cellulose 15551-62-9, Aluminum magnesium metasilicate 147526-32-7 192565-91-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing quinolinheptenoic acid derivs. stabilized with basic agent)

L9 ANSWER 38 OF 38 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 122:38847 CA
ORIGINAL REFERENCE NO.: 122:7395a,7398a
TITLE: Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound
INVENTOR(S): Kabadi, Mohan B.; Vivilecchia, Richard V.
PATENT ASSIGNEE(S): Sandoz Ltd., Switz.
SOURCE: U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 805,667, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5356896	A	19941018	US 1992-995252	19921222	<--
HU 63328	A2	19930830	HU 1992-3780	19921130	<--
HU 217629	B	20000328			
HU 221849	B1	20030228	HU 2000-790	19921130	<--
DE 4240430	A1	19930617	DE 1992-4240430	19921202	<--
DE 4240430	B4	20071227			
CH 684309	A5	19940831	CH 1992-3751	19921207	<--
GB 2262229	A	19930616	GB 1992-25659	19921208	<--
GB 2262229	B	19951101			
ES 2142819	T3	20000501	ES 1992-810962	19921208	<--
PT 547000	T	20000630	PT 1992-810962	19921208	<--
CA 2085037	A1	19930613	CA 1992-2085037	19921210	<--

CA 2085037	C	20001128			
NO 9204768	A	19930614	NO 1992-4768	19921210	<--
NO 302099	B1	19980126			
AU 9230069	A	19930617	AU 1992-30069	19921210	<--
AU 661075	B2	19950713			
JP 05246844	A	19930924	JP 1992-352222	19921210	<--
RO 111542	B1	19961129	RO 1992-1545	19921210	<--
IL 104041	A	19981227	IL 1992-104041	19921210	<--
CZ 287776	B6	20010117	CZ 1992-3633	19921210	<--
SK 281710	B6	20010710	SK 1992-3633	19921210	<--
FI 114284	B1	20040930	FI 1992-5615	19921210	
ZA 9209642	A	19940613	ZA 1992-9642	19921211	<--
AT 9202449	A	19960515	AT 1992-2449	19921211	<--
AT 401870	B	19961227			
RU 2121835	C1	19981120	RU 1992-4564	19921211	<--
FR 2684876	A1	19930618	FR 1992-15142	19921214	<--
FR 2684876	B1	19950505			
CN 1091634	A	19940907	CN 1993-100650	19930130	<--
CN 1041794	C	19990127			
AT 9501905	A	19960515	AT 1995-1905	19951123	<--
AT 401872	B	19961227			
GR 3032929	T3	20000731	GR 2000-400625	20000310	<--
PRIORITY APPLN. INFO.:			US 1991-805667	B2 19911212	
			DE 1992-4245089	A 19921202	
			CS 1992-3633	A 19921210	
			AT 1992-2449	A 19921211	
			US 1992-995252	19921222	

OTHER SOURCE(S): MARPAT 122:38847

AB A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition

PI US 5356896 A 19941018

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5356896	A	19941018	US 1992-995252	19921222	<--
	HU 63328	A2	19930830	HU 1992-3780	19921130	<--
	HU 217629	B	20000328			
	HU 221849	B1	20030228	HU 2000-790	19921130	<--
	DE 4240430	A1	19930617	DE 1992-4240430	19921202	<--
	DE 4240430	B4	20071227			
	CH 684309	A5	19940831	CH 1992-3751	19921207	<--
	GB 2262229	A	19930616	GB 1992-25659	19921208	<--
	GB 2262229	B	19951101			
	ES 2142819	T3	20000501	ES 1992-810962	19921208	<--
	PT 547000	T	20000630	PT 1992-810962	19921208	<--
	CA 2085037	A1	19930613	CA 1992-2085037	19921210	<--
	CA 2085037	C	20001128			
	NO 9204768	A	19930614	NO 1992-4768	19921210	<--
	NO 302099	B1	19980126			
	AU 9230069	A	19930617	AU 1992-30069	19921210	<--
	AU 661075	B2	19950713			
	JP 05246844	A	19930924	JP 1992-352222	19921210	<--
	RO 111542	B1	19961129	RO 1992-1545	19921210	<--
	IL 104041	A	19981227	IL 1992-104041	19921210	<--
	CZ 287776	B6	20010117	CZ 1992-3633	19921210	<--

SK 281710	B6	20010710	SK 1992-3633	19921210	<--
FI 114284	B1	20040930	FI 1992-5615	19921210	
ZA 9209642	A	19940613	ZA 1992-9642	19921211	<--
AT 9202449	A	19960515	AT 1992-2449	19921211	<--
AT 401870	B	19961227			
RU 2121835	C1	19981120	RU 1992-4564	19921211	<--
FR 2684876	A1	19930618	FR 1992-15142	19921214	<--
FR 2684876	B1	19950505			
CN 1091634	A	19940907	CN 1993-100650	19930130	<--
CN 1041794	C	19990127			
AT 9501905	A	19960515	AT 1995-1905	19951123	<--
AT 401872	B	19961227			
GR 3032929	T3	20000731	GR 2000-400625	20000310	<--

IT 144-55-8, Sodium bicarbonate, biological studies 471-34-1, Calcium carbonate, biological studies 93957-55-2, Fluvastatin sodium 94061-80-0 118312-81-5 145599-86-6 147008-21-7 159736-87-5 159736-89-7 159768-15-7 159813-76-0 159813-77-1 159813-78-2 159839-30-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized pharmaceutical compns. containing an HMG-CoA reductase inhibitor)

=> d fhitstr 1-38

L9 ANSWER 1 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate fibrate formulations)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 2 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bile prepns. for colorectal disorders)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 3 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual controlled-release osmotic device comprising two different active agents)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 4 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(orally administered small peptides synergize statin activity, and therapeutic uses)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 5 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 6 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release pitavastatin compns. containing enteric layers)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 7 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical goods comprising a heparin-based hemocompatible coating)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 8 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 9 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in addition to SARMs treatment; synthesis and uses of 4-azasteroid derivs. as selective androgen receptor modulators (SARMs) in the treatment of androgen deficiency-related diseases)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 10 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147526-32-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedies for glomerular diseases containing antiplatelet agents and HMG-CoA reductase inhibitors)
RN 147526-32-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L9 ANSWER 11 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of fluorinated 4-aza-androstan-3-one-17β-carboxamide derivs. as

androgen receptor modulators and their therapeutic uses)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 12 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 586966-54-3P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivs.)
RN 586966-54-3 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, 1,1-dimethylethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 13 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid-lowering drug; cyclooxygenase-1 inhibitor for treating or preventing cardiovascular conditions)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 14 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 167073-19-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. titanium mediated disilyloxydiene/aldehyde addition process for preparation of δ-hydroxy-β-ketoesters)
RN 167073-19-0 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L9 ANSWER 15 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 16 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147526-32-7P, Pitavastatin hemicalcium
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of an asym. β,δ-dihydroxycarboxylic acid side chain used for manufacture of a HMG-CoA reductase inhibitors)
RN 147526-32-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L9 ANSWER 17 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of immediate-release powder in pharmaceutical and nutraceutical compns.)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 18 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vivo delivery methods and compns.)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-

dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 19 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androstane compds. as androgen receptor (AR) modulators in conjunction with bone-strengthening agents for treatment of AR-related diseases)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 20 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of statins to inhibit formation of osteoclasts)

RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 21 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147526-32-7P, Pitavastatin hemicalcium
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(processes for preparing calcium salt forms of statins)
RN 147526-32-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L9 ANSWER 22 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 23 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 121659-03-8P, 7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [cyclopropyl(fluorophenyl)quinolyl]hydroxyheptenoic acid as remedial agent for glomerular diseases)
RN 121659-03-8 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy- (CA INDEX NAME)



L9 ANSWER 24 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, NK 104

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable pharmaceutical composition containing NK-104)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 25 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147526-32-7, NK-104
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pitavastatin is a new HMG-CoA reductase inhibitor)
RN 147526-32-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L9 ANSWER 26 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 27 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and apparatus for determining and utilizing the viscosity of circulating
blood over a range of shear rates for diagnostics and treatment)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 28 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, PITaVASTATIN
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 29 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for in vivo drug delivery based on monitoring blood flow parameters)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 30 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. containing; preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 31 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 32 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Pitavastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing HMG-CoA reductase inhibitors and angiotensin II receptor antagonists for preventing or treating heart failure)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 33 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 391681-56-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and biol. evaluations of quinoline-based HMG-CoA reductase inhibitors)
RN 391681-56-4 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, sodium salt (1:1), (3R,5S,6E)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



● Na

L9 ANSWER 34 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147526-32-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SREBP-2 (sterol regulatory element-binding protein) gene expression promoters as hypolipidemics)
RN 147526-32-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



●1/2 Ca

L9 ANSWER 35 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Itavastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitors for ameliorating abnormal bone states)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 36 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1, Itavastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 37 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147511-69-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition containing quinolinheptenoic acid derivs. stabilized
with basic agent)
RN 147511-69-1 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



L9 ANSWER 38 OF 38 CA COPYRIGHT 2008 ACS on STN
IT 147008-21-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized pharmaceutical compns. containing an HMG-CoA reductase inhibitor)
RN 147008-21-7 CA
CN 6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, (3R,5S,6E)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



=> d his

(FILE 'HOME' ENTERED AT 10:48:00 ON 08 SEP 2008)

FILE 'REGISTRY' ENTERED AT 10:48:22 ON 08 SEP 2008

FILE 'REGISTRY' ENTERED AT 10:48:39 ON 08 SEP 2008
L1 STRUCTURE UPLOADED
L2 5 S L1 SAM
L3 73 S L1 FULL

FILE 'CA' ENTERED AT 10:50:20 ON 08 SEP 2008
L4 720 S L3
L5 8 S CRYSTAL AND L4
L6 215 S L4 AND PY<2004
L7 6 S L6 AND (SOLID OR CRYST?)
L8 209 S L6 NOT L7
L9 38 S L8 AND (CA OR CALCIUM)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 10:54:03 ON 08 SEP 2008